Aztreonam is a synthetic monobactam antibiotic. It is effective against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa, and is often used to treat infections in patients who are allergic to penicillin. The compound was first synthesized in the 1970s and its structure is based on the monocyclic beta-lactam ring system. It inhibits the synthesis of bacterial cell walls by binding to and inactivating transpeptidases, which are enzymes essential for the formation of peptidoglycans, the main structural component of bacterial cell walls. Aztreonam is not metabolized by bacterial enzymes and is therefore resistant to inactivation by bacterial beta-lactamases. It is given intravenously or intramuscularly and is typically used to treat serious infections such as pneumonia, urinary tract infections, and septicemia. Aztreonam is studied because it has a low incidence of adverse effects and is effective against a broad range of gram-negative bacteria, including those resistant to other antibiotics. It is also studied because it is not metabolized by the liver and is excreted unchanged in the urine, making it a suitable treatment option for patients with impaired liver function.'
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 5742832 |
| CHEMBL ID | 158 |
| MeSH ID | M0002090 |
| PubMed CID | 2274 |
| MeSH ID | M0002090 |
| PubMed CID | 5459211 |
| CHEMBL ID | 410081 |
| CHEBI ID | 94511 |
| SCHEMBL ID | 37512 |
| SCHEMBL ID | 13616074 |
| MeSH ID | M0002090 |
| Synonym |
|---|
| AC-4330 |
| BIDD:GT0765 |
| BRD-K62607865-001-03-0 |
| AKOS015840157 |
| sq-26776 |
| PRESTWICK2_000185 |
| 2-({[(1z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid |
| PRESTWICK3_000185 |
| nsc-646279 |
| PRESTWICK_914 |
| BPBIO1_000121 |
| BSPBIO_000109 |
| NCGC00179656-01 |
| 2-[(z)-[1-(2-aminothiazol-4-yl)-2-[[(2s,3s)-2-methyl-4-oxo-1-sulfo-azetidin-3-yl]amino]-2-oxo-ethylidene]amino]oxy-2-methyl-propanoic acid |
| NSC646279 , |
| [2s-[2alpha,3beta(z)]]-2-[[[1-(2-amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid |
| primbactam |
| az-threonam |
| (z)-2-((((2-amino-4-thiazolyl)(((2s,3s)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)carbamoyl)methylene)amino)oxy)-2-methylpropionic acid |
| sq 26776 |
| HMS2090K09 |
| azetreonam |
| (2s,3s)-3-({(2z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]ethanoyl}amino)-2-methyl-4-oxoazetidine-1-sulfonate(aztreonam) |
| 2-[1-(2-amino-thiazol-4-yl)-1-((2s,3s)-2-methyl-4-oxo-1-sulfo-azetidin-3-ylcarbamoyl)-meth-(z)-ylideneaminooxy]-2-methyl-propionic acid |
| bdbm50240480 |
| (2s,3s)-3-({(2z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]ethanoyl}amino)-2-methyl-4-oxoazetidine-1-sulfonate |
| nsc-758913 |
| CHEMBL158 , |
| nebactam |
| so 26776 |
| azonam |
| aztreon |
| azthreonam |
| az threonam |
| 2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid |
| HMS1568F11 |
| HMS2095F11 |
| g2b4ve5gh8 , |
| BCP9000372 |
| dtxsid0022640 , |
| squibb 26776 |
| AKOS015961777 |
| BCPP000356 |
| MLS003915628 |
| smr002204030 |
| (z)-2-[[[(2-amino-4-thiazolyl)[[(2s,3s)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]carbamoyl]methylene]amino]oxy]-2-methylpropionic acid |
| aztreonam [jan] |
| aztreonam [usan] |
| aztreonam [vandf] |
| aztreonam [who-dd] |
| aztreonam [mart.] |
| aztreonam [orange book] |
| aztreonam [usp-rs] |
| aztreonam [usp monograph] |
| aztreonam [mi] |
| aztreonam [inn] |
| propanoic acid, 2-(((1-(2-amino-4-thiazolyl)-2-((2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-, (2s-(2.alpha.,3.beta.(z)))- |
| CCG-220185 |
| HY-B0129 |
| CS-1902 |
| smr004703537 |
| MLS006011974 |
| propanoic acid, 2-[[(z)-[1-(2-amino-4-thiazolyl)-2-[[(2s,3s)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methyl- |
| aztreonam, analytical standard |
| SR-01000841814-3 |
| sr-01000841814 |
| SR-01000841814-2 |
| aztreonam, united states pharmacopeia (usp) reference standard |
| aztreonam, pharmaceutical secondary standard; certified reference material |
| 80951-91-3 |
| HMS3712F11 |
| rel-aztreonam |
| 149496-40-2 |
| 2-((((e)-1-(2-aminothiazol-4-yl)-2-(((2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid |
| S1505 |
| AS-13760 |
| 2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid |
| Q27262730 |
| 2-aminothiazol-4-yl)-2-((2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-ylamino)-2-oxoethylideneaminooxy)-2-methylpropanoic acid |
| aztreonamum (latin) |
| aztreonam (mart.) |
| j01df01 |
| aztreonam (usp monograph) |
| aztreonam (usp-rs) |
| aztreonam (usan:usp:inn:ban:jan) |
| 2-((z)-(2-aminothiazol-4-yl)-((2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-ylcarbamoyl)methyleneaminooxy)-2-methyl-1-propanoic acid |
| 2-((((1z)-1-(2-amino-1,3-thiazol-4-yl) -2- (((2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino) -2- oxoethylidene)amino)oxy)-2-methylpropanoic acid |
| (2s,3s)-3-((2z)-2-(2-ammonio-1,3-thiazol-4-yl)-2-((2-carboxypropan-2-yloxy)imino)acetamido)-2-methyl-4-oxoazetidine-1-sulfonate |
| EN300-22411481 |
| 2-{[(z)-[(2-amino-1,3-thiazol-4-yl)({[(2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]carbamoyl})methylidene]amino]oxy}-2-methylpropanoic acid |
| 78110-38-0 |
| aztreonam |
| 2-[({1-(2-amino-1,3-thiazol-4-yl)-2-[(2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino]-2-oxoethylidene}amino)oxy]-2-methylpropanoic acid |
| 2-[[1-(2-amino-1,3-thiazol-4-yl)-2-[(2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid |
| 85506-30-5 |
| FT-0602574 |
| HMS3373D13 |
| mfcd00072145 |
| HMS3654F18 |
| SY129274 |
| BCP01737 |
| HMS3748K17 |
| DTXSID10861003 |
| cas-78110-38-0 |
| NCGC00016936-01 |
| BSPBIO_002512 |
| sq-26,776 |
| SPECTRUM1505122 |
| NCGC00016936-02 |
| 2-({[(1e)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid |
| STL011049 |
| 2-[(e)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino]-2-oxoethylidene]amino]oxy-2-methylpropanoic acid |
| 2-[[(z)-[1-(2-amino-4-thiazolyl)-2-[[(2s,3s)-2-methyl-4-oxo-1-sulfo-3-azetidinyl]amino]-2-oxoethylidene]amino]oxy]-2-methylpropionic acid |
| A839338 |
| aztreonam e-isomer |
| CHEMBL410081 |
| pharmakon1600-01505122 |
| nsc758913 |
| tox21_110692 |
| dtxcid602640 |
| AKOS015969724 |
| unii-5q55m3d9ua |
| propanoic acid, 2-(((e)-(1-(2-amino-4-thiazolyl)-2-(((2s,3s)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-2-methyl- |
| 99341-02-3 |
| sq-28429 |
| (e)-2-((((2-amino-4-thiazolyl)(((2s,3s)-2-methyl-4-oxo-1-sulfo-3-azetidinyl)carbamoyl(methylene)amino(oxy)-2-methylpropionic acid |
| propanoic acid, 2-(((1-(2-amino-4-thiazolyl)-2-((2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-, (2s-(2alpha,3beta(e)))- |
| 5q55m3d9ua , |
| sq 28429 |
| CCG-213342 |
| SCHEMBL37512 |
| tox21_110692_1 |
| NCGC00016936-04 |
| aztreonam e-isomer [usp-rs] |
| propanoic acid, 2-(((1-(2-amino-4-thiazolyl)-2-((2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-, (2s-(2.alpha.,3.beta.(e)))- |
| SCHEMBL13616074 |
| aztreonam, antibiotic for culture media use only |
| A-9950 |
| AB01563305_01 |
| DTXSID20244045 |
| 2-((((z)-1-(2-aminothiazol-4-yl)-2-(((2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid |
| CHEBI:94511 |
| SBI-0206775.P001 |
| Z1511483977 |
| 2-[[(2-amino-1,3-thiazol-4-yl)-[[(2s,3s)-2-methyl-4-oxo-1-sulfo-azetidin-3-yl]carbamoyl]methylidene]amino]oxy-2-methylpropanoic acid |
| Q418546 |
| cid 5362041 |
| AKOS034796899 |
| 2-(((2-amino-1,3-thiazol-4-yl)-(((2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl)carbamoyl)methylidene)amino)oxy-2-methylpropanoic acid |
| BRD-K36547807-001-02-4 |
| gtpl10763 |
| sq26776 |
| 2-{[(e)-[(2-amino-1,3-thiazol-4-yl)({[(2s,3s)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]carbamoyl})methylidene]amino]oxy}-2-methylpropanoic acid |
| EN300-21900097 |
Aztreonam is a Gram-negative bacteria-targeting synthetic monobactam antibiotic. It is an important option against Enterobacterales producing metallo-β-lactamases (MBLs)
Atreonam has a newly developed and synthetic structure belonging to the group of monobactams. It possesses excellent antibacterial activity against a broad range of Gram-negative bacteria (including the beta-lactamase producing strains)
Atreonam is a newly developed and synthetic structure belonging to the group of monobactams. It possesses excellent antibacterial activity against a broad range of Gram-negative bacteria (including the beta-lactamase producing strains). AztreonAm has been effective in eradicating pseudomonal infections in most patients.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Aztreonam has a high affinity for the protein-binding protein 3 (PBP-3) of aerobic gram-negative bacteria." | ( How and why aztreonam works. Rittenbury, MS, 1990) | 1.38 |
| "Aztreonam has a directed spectrum of activity covering gram-negative bacilli usually associated with UTIs." | ( UTIs and two new antibiotics in the elderly. Jones, SR; Kimbrough, R, 1988) | 1 |
| "Aztreonam (AZT), which has a newly developed and synthetic structure belonging to the group of monobactams, possesses excellent antibacterial activity against a broad range of Gram-negative bacteria (including the beta-lactamase producing strains). " | ( [Susceptibility of clinical isolates to aztreonam]. Asari, S; Hayashi, C; Horikawa, M; Kouda, K; Miyai, K; Tsukamoto, H, 1987) | 1.98 |
| "Aztreonam lysinate has been shown to ameliorate pulmonary function in cystic fibrosis patients with chronic airway Pseudomonas infection and this is paralleled by a reduction in bacterial density in the lungs." | ( Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. Assael, BM, 2011) | 2.53 |
| "Aztreonam lysine has been used for treatment of patients with CF with chronic P. " | ( Desensitization to inhaled aztreonam lysine in an allergic patient with cystic fibrosis using a novel approach. Abdulhamid, I; Ditouras, J; Guglani, L; Montejo, J, 2012) | 2.12 |
| "Aztreonam has been commonly used in various combinations to enhance antimicrobial spectrum of co-drugs and produce potential synergistic activity. " | ( Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli. Huynh, HK; Jones, RN; Sader, HS, 2003) | 2.03 |
| "Aztreonam has been used in a wide array of infections of the urinary tract and respiratory tract, blood, intra-abdominal and gynecologic infections and infections of the skin, bones and joints." | ( Aztreonam. Scheld, WM; Tunkel, AR, 1990) | 2.44 |
| "Aztreonam has a high affinity for the protein-binding protein 3 (PBP-3) of aerobic gram-negative bacteria." | ( How and why aztreonam works. Rittenbury, MS, 1990) | 1.38 |
| "Aztreonam also has been found to be well-tolerated by highly penicillin-allergic patients." | ( Immunogenicity and cross-allergenicity of aztreonam. Adkinson, NF, 1990) | 1.26 |
| "Aztreonam has no renal toxicity, which is an advantage to take into account in patients with altered renal function." | ( Therapeutic efficacy of the combination of aztreonam with cefotaxime in the treatment of severe nosocomial pneumonia. Comparative study against amikacin combined with cefotaxime. Agusti Vidal, A; Almela, M; de Celis, R; Deulofeu, R; Marco, F; Rabinad, E; Rodriguez-Roisin, R; Torres, A, 1989) | 1.26 |
| "Aztreonam has been compared both in vitro and in clinical trials to aminoglycosides in its activity against aerobic gram-negative bacteria. " | ( Comparison of the inhibitory and bactericidal activity of aztreonam and amikacin against gram negative aerobic bacilli. Fung-Tomc, JC; Kessler, RE; Lincourt, W; Thater, C, ) | 1.82 |
| "Aztreonam has proven to be effective, safe therapy for serious and life-threatening infections caused by multiresistant aerobic gram negative bacteria." | ( Aztreonam: the first monobactam. Neu, HC, 1988) | 2.44 |
| "Aztreonam has a directed spectrum of activity covering gram-negative bacilli usually associated with UTIs." | ( UTIs and two new antibiotics in the elderly. Jones, SR; Kimbrough, R, 1988) | 1 |
| "Aztreonam (AZT), which has a newly developed and synthetic structure belonging to the group of monobactams, possesses excellent antibacterial activity against a broad range of Gram-negative bacteria (including the beta-lactamase producing strains). " | ( [Susceptibility of clinical isolates to aztreonam]. Asari, S; Hayashi, C; Horikawa, M; Kouda, K; Miyai, K; Tsukamoto, H, 1987) | 1.98 |
| "Aztreonam has been effective in eradicating pseudomonal infections in most patients (except in patients with cystic fibrosis), but the inevitably limited number of pseudomonal infections available for study prevents any conclusions as to the relative efficacy of aztreonam compared with other appropriate regimens against these infections." | ( Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Brogden, RN; Heel, RC, 1986) | 2.44 |
| "Aztreonam has shown the highest activity against all the tested strains, with a geometrical mean of MICs (MG) of 0.37 and a MIC 90 of 8 micrograms/ml." | ( [Evaluation of the in vitro activity of aztreonam on 1990 gram-negative bacterial strains recently isolated in Campania hospitals]. Amato, G; Anzivino, D; Bolletti-Censi, M; Covelli, I; Fortunato, A; Guarino, A; Gulletta, E; Lavitola, A; Nani, E; Spagnoletti, G, 1986) | 1.26 |
| "Aztreonam has excellent activity against P." | ( Aztreonam--an overview. Hopefl, AW, 1985) | 2.43 |
| "Aztreonam has undoubtedly high clinical and bacteriological efficacy in the therapy of nosocomial infections in patients with impaired host defenses." | ( Aztreonam in the therapy of nosocomial infections in patients with impaired host defenses. Cristiano, P; Iovene, MR; Paradisi, F, 1985) | 2.43 |
| "Aztreonam has no useful activity against gram-positive or anaerobic microorganisms." | ( Aztreonam, a new monobactam antimicrobial. Guay, DR; Koskoletos, C, ) | 2.3 |
Treatment with aztreonam reduced the incidence of mice infected with Proteus mirabilis (p < 0.01), but it showed no efficacy on Streptococcus faecalis. Treatment with az treonam did not result in IgG or IgE antibody responses in vitro.
Aztreonam was not toxic to the albino rabbit retina up to a total injected dose of 2. Adverse events were similar, with increased nausea and vomiting in the tigecycline group and increased rash and elevated hepatic aminotransferase levels in the vancomycin-aztreonAm group.
The pharmacokinetic interaction of the monobactam antibiotic aztreonam with cephradine, clindamycin, gentamicin, metronidazole, and nafcillin was investigated in five separate studies in 48 healthy male volunteers. The aim of this study was to evaluate whether the addition of avibactam could reduce or close the mutant selection window (MSW) for Escherichia coli and Klebsiella pneumoniae harbouring MBLs.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data." | ( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. Jolivette, LJ; Ward, KW, 2005) | 0.33 |
| " Pharmacokinetic data in eight CF patients and healthy subjects that were matched for age, gender, weight, and height were obtained and analyzed by using the nonparametric adaptive grid algorithm." | ( Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. Heijerman, HG; Mathôt, RA; Mouton, JW; van Rossem, RN; Vinks, AA, 2007) | 0.34 |
| "Using an in vitro pharmacodynamic model, a multidrug-resistant strain of Acinetobacter baumannii was exposed to colistin methanesulfonate alone and in combination with ceftazidime." | ( Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Hovde, LB; Kroeger, LA; Mitropoulos, IF; Rotschafer, JC; Schafer, J, 2007) | 0.34 |
| " pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data." | ( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008) | 0.35 |
| " In this thesis pharmacodynamic parameters have been studied after brief exposure of gram-positive bacteria to daptomycin, imipenem or vancomycin and after short exposure of gram-negative bacteria to amikacin, ampicillin, aztreonam, cefepime, cefotaxime, ceftazidime, ceftriaxone, cefuroxime, imipenem, mecillinam, or piperacillin." | ( Pharmacodynamic effects of antibiotics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time. Hanberger, H, 1992) | 0.47 |
| " In order to evaluate the difficulties, a pharmacokinetic analysis of aztreonam (AZT), which is a monocyclic beta-lactam antimicrobial agent, was undertaken in 2 groups consisting of 5 children of ages 1-6 and 5 older children of 7-15." | ( [Dose calibration of aztreonam in pediatric patients by means of pharmacokinetic analysis]. Kawasaki, H, 1991) | 0.83 |
| " No significant differences in any pharmacokinetic parameters between first dose and steady state were observed." | ( Aztreonam pharmacokinetics in burn patients. Brundage, DM; Friedrich, LV; Kays, MB; White, RL; Yarbrough, D, 1991) | 1.72 |
| " Pharmacokinetic study (1) Upon one-shot intravenous injection of AZT 1 g before delivery, maternal serum concentration of AZT was 89." | ( [Pharmacokinetics and clinical evaluations on aztreonam in perinatal infections in obstetrics and gynecology. A study of aztreonam in the perinatal co-research group]. Haga, H; Hirayama, H; Inoue, R; Matsuda, S; Mizoguchi, H; Oh, K; Sengoku, K; Shimizu, T; Tori-i, Y; Yamazaki, T, 1990) | 0.54 |
| " Umbilical cord blood concentration showed a lower peak, which was reached with a slight delay to the Tmax for maternal blood concentration, then decreased." | ( [Pharmacokinetic study of aztreonam transfer from mother to fetus]. Hayashi, S; Imakawa, N; Obata, I; Yamato, T, 1990) | 0.58 |
| "Clinical and pharmacokinetic studies on aztreonam (AZT) were performed in neonates." | ( [Clinical and pharmacokinetic studies on aztreonam in neonates]. Abe, T; Fujii, R; Hashira, S; Meguro, H; Tajima, T, 1990) | 0.81 |
| " The steady-state pharmacokinetic parameters and plasma concentration-time profiles of carumonam when adjusted for dose were similar for the three regimens." | ( Multiple intravenous dose pharmacokinetic study of carumonam in healthy subjects. Banken, L; Patel, IH; Portmann, R; Soni, PP; Suter, K; Weidekamm, E, 1989) | 0.28 |
| " Using serum levels of the drug obtained in blood samples, pharmacokinetic parameters were calculated and a simulation curve of serum levels was drawn automatically using a micro-computer." | ( [Pharmacokinetic evaluations and analysis of aztreonam in children]. Kawasaki, H, 1989) | 0.54 |
| " Because of the large variation in the degree of renal insufficiency, calculations of the mean values for the pharmacokinetic parameters in the patient group were not generally justified with the exception of the volume of distribution (Vdss = 14." | ( Pharmacokinetics and dose recommendations of carumonam in renal failure. Höffler, D; Koeppe, P; Strobel, K, 1987) | 0.27 |
| " The pharmacokinetic study in nine elderly patients showed a prolonged plasma half life of aztreonam (2." | ( Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections. Dette, GA; Grobecker, H; Kees, F; Knothe, H; Naber, KG, 1986) | 0.72 |
| "The pharmacokinetic properties of carumonam (AMA-1080, Ro 17-2301) were studied in mice, rats, rabbits, dogs, and cynomolgus monkeys and compared with those of aztreonam." | ( Comparative pharmacokinetics of carumonam and aztreonam in mice, rats, rabbits, dogs, and cynomolgus monkeys. Fugono, T; Imada, A; Kita, Y, 1986) | 0.73 |
| " Aztreonam pharmacokinetic parameters were determined by model-independent methods." | ( Single-dose pharmacokinetics of aztreonam in children with cystic fibrosis. Aronoff, SC; Blumer, JL; Friedhoff, LT; Myers, CM; Reed, MD; Stern, RC; Yamashita, TS, ) | 1.33 |
| " A single pharmacokinetic study was performed over one dosing interval after steady-state conditions were achieved." | ( Pharmacokinetics and extravascular penetration of aztreonam in patients with abdominal sepsis. Schentag, JJ; Simons, GW; Smith, IL; Swanson, DJ; Vigano, A; Wels, PB; Winslade, NE, ) | 0.38 |
| " The pharmacokinetic parameters for aztreonam were calculated on the basis of a 2-compartment open model." | ( Pharmacokinetics of aztreonam in patients with chronic renal failure. Baudoin, C; Fillastre, JP; Godin, M; Humbert, G; Leroy, A; Swabb, EA; Vertucci, C, ) | 0.73 |
| "The pharmacokinetic interaction of the monobactam antibiotic aztreonam with cephradine, clindamycin, gentamicin, metronidazole, and nafcillin was investigated in five separate studies in 48 healthy male volunteers." | ( Pharmacokinetic interaction of aztreonam with other antibiotics. Adamovics, J; Creasey, WA; Dhruv, R; Platt, TB; Sugerman, AA, 1984) | 0.79 |
| " The elimination half-life varied inversely, and the clearance from serum varied directly, with age." | ( Single-dose pharmacokinetics of aztreonam in pediatric patients. Marks, MI; Stutman, HR; Swabb, EA, 1984) | 0.55 |
| " The mean of beta elimination phase half-life ranged from 2 h in normal subjects to 6 h in anephric patients." | ( Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction. Bolton, ND; Bolton, WK; Mihindu, JC; Scheld, WM; Spyker, DA; Swabb, EA, 1983) | 0.59 |
| "Interspecies correlations of pharmacokinetic parameters obtained in animals were used to predict human pharmacokinetics in order to design the first clinical study of an investigational drug." | ( Prediction of aztreonam pharmacokinetics in humans based on data from animals. Bonner, DP; Swabb, EA, 1983) | 0.63 |
| "To describe the pharmacokinetic profile of aztreonam and vancomycin hydrochloride in a clinically relevant experimental model of hemorrhagic shock and trauma." | ( Antibiotic pharmacokinetics following fluid resuscitation from traumatic shock. Boucher, BA; Croce, MA; Fabian, TC; McKindley, DS; Proctor, KG, 1995) | 0.55 |
| "To assess the impact of degradation of aztreonam, a beta-lactam antibiotic, during HPLC analysis on pharmacokinetic parameter estimates." | ( Drug degradation during HPLC analysis of aztreonam: effect on pharmacokinetic parameter estimation. Burgess, DS; Friedrich, LV; Kays, MB; White, RL, 1994) | 0.82 |
| "The baseline (B) serum concentration-time data from a published pharmacokinetic study of aztreonam were degraded using first-order equations and a degradation rate constant (0." | ( Drug degradation during HPLC analysis of aztreonam: effect on pharmacokinetic parameter estimation. Burgess, DS; Friedrich, LV; Kays, MB; White, RL, 1994) | 0.78 |
| "Aztreonam degradation resulted in increased variability in pharmacokinetic parameter estimates." | ( Drug degradation during HPLC analysis of aztreonam: effect on pharmacokinetic parameter estimation. Burgess, DS; Friedrich, LV; Kays, MB; White, RL, 1994) | 2 |
| " Although the mean peak serum concentrations of aztreonam for the two groups were similar, there were differences in other pharmacokinetic parameters." | ( Pharmacokinetics of aztreonam in healthy elderly and young adult volunteers. Bournazos, C; Hirschman, SZ; Mendelson, MH; Meyers, BR; Tejero, C; Wilkinson, P, 1993) | 0.87 |
| " Teicoplanin is an alternative treatment to vancomycin in these patients but few pharmacokinetic studies of teicoplanin in children have been conducted and optimal dosages have not been well-established." | ( Teicoplanin pharmacokinetics in pediatric patients. Dufort, G; Olivé, T; Ortega, JJ; Ventura, C, 1996) | 0.29 |
| "To evaluate the pharmacokinetic profiles of aztreonam and imipenem in critically ill trauma patients with pneumonia." | ( Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia. Boucher, BA; Croce, MA; Fabian, TC; Hess, MM; McKindley, DS, ) | 0.72 |
| " Pharmacokinetic data demonstrate that coadministration of linezolid and aztreonam does not alter the disposition of either agent under single-dose conditions." | ( A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. Hopkins, NK; Jungbluth, GL; Sisson, TL, 1999) | 0.76 |
| "The pharmacodynamic parameter that appears to correlate best with a successful therapeutic outcome with beta-lactam antibiotics is the length of time the serum antibiotic concentration remains above the minimum inhibitory concentration (MIC) for the infecting pathogen." | ( Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion. Burgess, DS; Hardin, TC; Summers, KK, 1999) | 0.57 |
| " Pharmacokinetic parameters for each antibiotic were determined using population modeling, and variables potentially related to outcomes were evaluated using tree-based modeling, logistic regression, and nonlinear regression methods." | ( Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Ballow, CH; Booker, BM; Forrest, A; Schentag, JJ; Smith, PF, 2001) | 0.58 |
| "The common usage of extended spectrum beta-lactams co-administered with amikacin in everyday clinical practice for infections by multidrug-resistant isolates has created the need to search for pharmacokinetic interaction." | ( Pharmacokinetic interactions of ceftazidime, imipenem and aztreonam with amikacin in healthy volunteers. Adamis, G; Gargalianos, P; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kosmidis, J; Papaioannou, MG, 2004) | 0.57 |
| " Pharmacokinetic data in eight CF patients and healthy subjects that were matched for age, gender, weight, and height were obtained and analyzed by using the nonparametric adaptive grid algorithm." | ( Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. Heijerman, HG; Mathôt, RA; Mouton, JW; van Rossem, RN; Vinks, AA, 2007) | 0.66 |
| "This randomized crossover study in healthy participants assessed pharmacokinetic interactions between telavancin, aztreonam, and piperacillin/tazobactam." | ( Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. Barriere, SL; Goldberg, MR; Kinzig, M; Kitt, MM; Sörgel, F; Wong, SL, 2009) | 0.78 |
| "In an in vitro pharmacodynamic model, linezolid attenuated the activity of aztreonam and ceftazidime against Escherichia coli." | ( Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model. LaPlante, KL; Sakoulas, G, 2009) | 0.97 |
| "Our objectives were to compare the pharmacokinetics (PK) of carumonam, a monobactam, between cystic fibrosis (CF) patients and healthy volunteers and assess its pharmacodynamic profile." | ( Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers. Bulitta, JB; Drusano, GL; Duffull, SB; Holzgrabe, U; Kinzig, M; Landersdorfer, CB; Sörgel, F; Stephan, U, 2009) | 0.35 |
| " Pharmacokinetic (PK)/pharmacodynamic (PD) understanding of this combination is critical for optimal clinical dose selection." | ( Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. Bradford, PA; Eakin, AE; Harris, JJ; Kim, A; McLaughlin, RE; O'Donnell, JP; Patey, S; Singh, R; Tanudra, MA, 2015) | 0.63 |
| " Of particular interest are the pharmacokinetic and pharmacodynamic properties of aztreonam alone and in combination with β-lactamase inhibitors." | ( A review of the pharmacokinetics and pharmacodynamics of aztreonam. MacGowan, AP; Ramsey, C, 2016) | 0.91 |
| " Despite the long history of clinical use, population pharmacokinetic modeling of aztreonam in renally impaired patients is not yet available." | ( Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis. Al-Huniti, N; Li, J; Xu, H; Zhou, D; Zhou, W, 2017) | 1.04 |
| " push administration on the pharmacodynamic exposures of meropenem, cefepime, and aztreonam were evaluated." | ( Effects of i.v. push administration on β-lactam pharmacodynamics. Burgner, K; Butterfield-Cowper, JM, 2017) | 0.68 |
| "Pharmacokinetic and pharmacodynamic analyses were conducted using previously published pharmacokinetic data for meropenem, cefepime, and aztreonam." | ( Effects of i.v. push administration on β-lactam pharmacodynamics. Burgner, K; Butterfield-Cowper, JM, 2017) | 0.66 |
| " push over 5 minutes indicated that there would be minimal or no effect on pharmacodynamic exposures compared with the effect when administered by 30-minute infusions." | ( Effects of i.v. push administration on β-lactam pharmacodynamics. Burgner, K; Butterfield-Cowper, JM, 2017) | 0.46 |
| "Checkerboard experiments followed by fractional inhibitory concentration (FIC) index determinations are commonly used to assess in vitro pharmacodynamic interactions between combined antibiotics, but FIC index cannot be determined in case of antibiotic/non-active compound combinations." | ( Pharmacodynamic modelling of β-lactam/β-lactamase inhibitor checkerboard data: illustration with aztreonam-avibactam. Buyck, J; Chauzy, A; Couet, W; de Jonge, BLM; Grégoire, N; Marchand, S, 2019) | 0.73 |
| "The aim of this study was to build and verify a preliminary physiologically based pharmacokinetic (PBPK) model of Chinese pregnant women." | ( Preliminary physiologically based pharmacokinetic modeling of renally cleared drugs in Chinese pregnant women. Li, X; Liu, D; Liu, X; Song, L; Xu, Y; Yu, Z; Zhou, T, 2020) | 0.56 |
| " The aim of this study was to evaluate whether the addition of avibactam could reduce or close the mutant selection window (MSW) of aztreonam in Escherichia coli and Klebsiella pneumoniae harbouring MBLs; MSW is a pharmacodynamic (PD) parameter for the selection of emergent resistant mutants." | ( Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases. Dong, D; Feng, K; Gong, H; Jia, N; Liu, Y; Lv, Z; Martins, FS; Sy, S; Sy, SKB; Yu, M; Zhang, J; Zhu, P; Zhu, S; Zhu, Y, 2021) | 2.27 |
Aztreonam is a synthetic monobactam antimicrobial agent specifically active against aerobic, gram-negative microorganisms. It was studied in combination with extended-spectrum penicillins azlocillin and piperacillin against 46 strains of Pseudomonas aeruginosa.
| Excerpt | Reference | Relevance |
|---|---|---|
| " An investigation was therefore carried out to determine whether aztreonam, a synthetic monocyclic beta-lactam antibiotic, can safely be combined with cyclosporin." | ( Aztreonam can safely be used in combination with cyclosporin without aggravating nephrotoxicity. Hoitsma, AJ; Koene, RA; Rietbroek, RC, 1989) | 1.96 |
| "The in vitro activity of aztreonam combined with tobramycin and with gentamicin was assessed in 78 clinical isolates of Pseudomonas aeruginosa and 11 clinical isolates of Pseudomonas cepacia from patients with cystic fibrosis." | ( In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. Bosso, JA; Matsen, JM; Saxon, BA, 1987) | 0.9 |
| "Aztreonam, a synthetic monobactam antimicrobial agent specifically active against aerobic, gram-negative microorganisms, was studied in combination with the extended-spectrum penicillins azlocillin and piperacillin against 46 strains of Pseudomonas aeruginosa." | ( Effect of aztreonam in combination with azlocillin or piperacillin on Pseudomonas aeruginosa. Baltch, AL; Conley, PE; Smith, RP; Wu, DH, 1984) | 2.11 |
| "The activities of ticarcillin, cefsulodin, ceftazidime, aztreonam, and imipenem, formerly known as N-formimidoyl thienamycin, were evaluated alone and in combination with aminoglycosides against 56 clinical isolates of Pseudomonas aeruginosa, which were characterized by aminoglycoside susceptibility and content of aminoglycoside-modifying enzymatic activities." | ( Effect of highly potent antipseudomonal beta-lactam agents alone and in combination with aminoglycosides against Pseudomonas aeruginosa. Berndt, KD; Boisvert, WE; Dudek, EJ; Lerner, SA, ) | 0.38 |
| "The in vitro synergistic activity of aztreonam in combination with piperacillin, moxalactam, cefotaxime, cefoperazone, and amikacin was examined against multiply resistant isolates of the family Enterobacteriaceae and Pseudomonas aeruginosa." | ( In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli. Buesing, MA; Jorgensen, JH, 1984) | 0.86 |
| "The in-vitro activities of various antibiotics, either alone or in combination with amikacin were assessed in clinical isolates of Pseudomonas aeruginosa." | ( In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. Gerçeker, AA; Gürler, B, 1995) | 0.29 |
| "The synergistic potential of levofloxacin, ofloxacin and ciprofloxacin combined with aztreonam, ceftazidime, or piperacillin was compared using 24 strains of Pseudomonas aeruginosa with varying susceptibility profiles." | ( In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa. Jung, R; Messick, CR; Pendland, SL, 2002) | 0.76 |
| " Aztreonam was combined with ciprofloxacin, gatifloxacin, levofloxacin, cefepime, ceftazidime and imipenem at clinically relevant concentrations." | ( Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli. Huynh, HK; Jones, RN; Sader, HS, 2003) | 1.5 |
| " Aztreonam at 4, 8 and 16 mg/L was combined with four other beta-lactam antimicrobials (cefepime, ceftazidime, meropenem and piperacillin/tazobactam or ampicillin/sulbactam), each tested at the recognized susceptible breakpoint concentration." | ( In vitro activity of beta-lactam antimicrobial agents in combination with aztreonam tested against metallo-beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter baumannii. Jones, RN; Rhomberg, PR; Sader, HS, 2005) | 1.47 |
| "25-8 μg/mL in combination with polyamines in all carbapenem-associated MDR-Ab." | ( Carbapenem-associated multidrug-resistant Acinetobacter baumannii are sensitised by aztreonam in combination with polyamines. Kwon, DH; Malone, L, 2013) | 0.61 |
| " This study evaluated in vitro antimicrobial synergy of ceftolozane/tazobactam in combination with aztreonam and fosfomycin against MDR PSA." | ( In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa. Cayô, R; Cuba, GT; Gales, AC; Kiffer, CRV; Nicolau, DP; Nodari, CS; Pignatari, ACC; Rocha-Santos, G; Streling, AP, 2020) | 1 |
| " The aim of this study was to evaluate the in vitro efficacy of aztreonam (ATM) in combination with CAZ/AVI, M/V, and I/R against 40 MDR, MBL-producing, and serine-β-lactamases co-producing Klebsiella pneumoniae using the Etest method." | ( Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae. Kasimati, A; Magkafouraki, E; Maraki, S; Mavromanolaki, VE; Moraitis, P; Scoulica, E; Stafylaki, D, 2021) | 1.08 |
| "The antimicrobial efficacy of meropenem (MEM), cefepime (FEP), and aztreonam (ATM), each in combination with NAC, were assessed in vitro and in vivo against Klebsiella pneumoniae and Escherichia coli." | ( Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection Asai, N; Hagihara, M; Kato, H; Koizumi, Y; Mikamo, H; Okade, H; Sakanashi, D; Sato, N; Shibata, Y; Suematsu, H; Sugano, T; Yamagishi, Y, 2021) | 1.11 |
| "To evaluate the in vitro activity of aztreonam in combination with novel β-lactamase inhibitors, namely avibactam, nacubactam, taniborbactam and zidebactam, against MDR MBL-producing Enterobacterales and Pseudomonas aeruginosa clinical isolates." | ( In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases. Le Terrier, C; Nordmann, P; Poirel, L, 2022) | 1.31 |
| " This study investigated the activity of aztreonam in combination with novel β-lactamase inhibitors (BLIs) against a national multi-centre study collection of strains co-producing MBLs and SBLs." | ( Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain. Alonso-Garcia, I; Álvarez-Fraga, L; Arca-Suárez, J; Beceiro, A; Bou, G; Cendón-Esteve, A; Guijarro-Sánchez, P; Lasarte-Monterrubio, C; Maceiras, R; Martínez-Guitián, M; Outeda, M; Peña-Escolano, A; Vázquez-Ucha, JC, 2023) | 1.56 |
| " The efficacy of CZA in combination with were determined by two methods: (i) Kirby-Bauer's double disk synergy test and; (ii) Determination of the minimum inhibitory concentration to CZA by E-test, in either Mueller-Hinton agar alone or, supplemented with ATM 4 mg/L." | ( In vitro effectiveness of ceftazidime-avibactam in combination with aztreonam on carbapenemase-producing Enterobacterales. Antonio, G; Federica, F; Inés, B; Leticia, C; Lucía, A; Pablo, Á; Rafael, V; Romina, PE; Verónica, S, 2023) | 1.15 |
The absolute bioavailability of aztreonam is very low (about 1%) after oral administration. It was shown that after intramuscular or intravenous administration there are not any considerable differences in theBioavailability of AZTreonam from BIOKTAM and of the drug from AZACTAM.
Aztreonam proved effective for severe urinary tract infections caused by members of the family Enterobacteriaceae in pediatric patients. The dosage should be adjusted in patients with renal failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients suspected of having high clearance rates, such as CF patients, should be monitored closely, with dosing regimens adjusted accordingly." | ( Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. Heijerman, HG; Mathôt, RA; Mouton, JW; van Rossem, RN; Vinks, AA, 2007) | 0.34 |
| " The superiority of aerosol dosing over systemic dosing was demonstrated in models of both acute and chronic lung infection." | ( Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Dudley, MN; Griffith, DC; Miller, CE; Nolan, TG; Sabet, M; Senekeo-Effenberger, K, 2009) | 0.35 |
| " maltophilia did not exhibit a gene dosage effect on beta-lactamase expression." | ( AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. Chung, TC; Hu, RM; Huang, YW; Lin, CW; Lin, YT; Yang, TC, 2010) | 0.36 |
| " aeruginosa, 2 was shown to have dose-dependent efficacy at 50 and 100 mg/kg q6h dosing in a mouse thigh infection model." | ( A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp. Bethel, CR; Bonomo, RA; Goldberg, JA; Hoyer, D; Hujer, AM; Hujer, KM; Jacobs, MR; Kreiswirth, BN; Kumar, V; Marshall, SH; Papp-Wallace, KM; Perez, F; Plummer, MS; Spencer, EJ; van den Akker, F; van Duin, D, 2021) | 0.62 |
| " The dose of 30 mg/kg and a dosage interval of 8 to 12 h could be recommended for the treatment of suitable bacterial infections in all premature infants." | ( Pharmacokinetics and renal tolerance of aztreonam in premature infants. Benoni, G; Cuzzolin, L; Fanos, V; Padovani, EM; Zambreri, D, 1991) | 0.55 |
| " Moreover, in 14 subjects affected by pulmonary interstitial diseases who underwent diagnostic broncho-alveolar lavage, we dosed AZT in lavage fluids about 1 hour after the injection of a 2 g dose (Group C: 8 cases) or a 4 g dose (Group D: 6 cases)." | ( Aztreonam activity in pneumology. Part 1: Clinical activity and pulmonary bioavailability of two different administration regimens. Bonucchi, ME; Calzati, A; Capelli, O; Covi, M; Gilioli, F; Lega, M; Rovatti, E; Velluti, G, 1991) | 1.72 |
| " The antibiotic was administered at a dosage of 1-2 g to adults, 50 mg/kg to children greater than 2 years old, and 30 mg/kg to infants three or four times daily." | ( Aztreonam in the treatment of gram-negative bacterial meningitis. Lentnek, AL; Williams, RR, ) | 1.57 |
| " This dosage is lower than usual." | ( Efficacy and safety of low-dose aztreonam in the treatment of moderate to severe infections due to gram-negative bacilli. Carbon, C; Clergeot, A; Rosset, MA; Steru, D, ) | 0.41 |
| " Excretion is largely dependent on renal mechanisms, so dosage can be adjusted in the presence of renal impairment." | ( Aztreonam activity, pharmacology, and clinical uses. Neu, HC, 1990) | 1.72 |
| " Intramuscular dosing results in peak serum levels in approximately one hour, while intravenous dosing results in peak levels within five minutes." | ( How and why aztreonam works. Rittenbury, MS, 1990) | 0.66 |
| " Serum levels of AZT examined were the highest at 30 minutes after dosage (the first sampling) and were 106." | ( [Pharmacokinetic and clinical evaluation of aztreonam in neonates and premature infants]. Kawamura, K; Nakamura, H; Seo, K; Sugita, M; Toyonaga, Y, 1990) | 0.54 |
| " The mean serum level at 6 hours after dosage was 13." | ( [Pharmacokinetic and clinical studies on aztreonam in neonates]. Nishimura, T; Tabuki, K, 1990) | 0.54 |
| " Average daily dosage of AZT 46." | ( [Pharmacokinetic and clinical evaluations of aztreonam monotherapy and aztreonam and ampicillin combination therapy in neonates and premature infants]. Aramaki, M; Kawakami, A; Koga, T; Motohiro, T; Oda, K; Sakata, Y; Shimada, Y; Tanaka, K; Tominaga, K; Tomita, S, 1990) | 0.54 |
| " Efficacy rate of AZT in the clinical application to 12 cases of perinatal infections via 2-4 g/day drip infusion (total dosage 8-24 g) was 91." | ( [Clinical studies on aztreonam in perinatal use]. Chimura, T; Funayama, T; Matsuo, M; Morisaki, N, 1990) | 0.6 |
| " administration of aztreonam (A) and cefuroxime (C), 10 adult CAPD patients (pts) with peritonitis were trained to start the following treatment procedure: a) sterile collection of dialysate effluent for cultures; b) 4 rapid in-and-out exchanges with antibiotic free dialysate; c) addition of 2 g C and 2 g A to a 2-L exchange for 6-h dwell time (the same dosage was repeated once a day in the overnight exchange); d) routine CAPD exchanges." | ( Effectiveness of single daily intraperitoneal administration of aztreonam and cefuroxime in the treatment of peritonitis in continuous ambulatory peritoneal dialysis (CAPD). Conte, G; Fuiano, G; Nani, E; Sepe, V; Viscione, M, 1989) | 0.84 |
| " nurse's monitoring specific drug therapy includes familiarity with a drug's action, with its performance in different clinical situations, with proper dosage and observations for adverse effects." | ( New drug therapies: esmolol HCL, aztreonam and ganciclovir. Pauley, SY, ) | 0.41 |
| "As part of a commitment to fully automate the manufacture of a lyophilized dosage form of Azactam (Aztreonam for Injection), an automated solution batching procedure was developed." | ( Aztreonam for injection (lyophilized): development of an automated solution batching process utilizing volumetric powder feeders. Augustine, R; Carleton, C; Haby, T; Kuspiel, E; Newman, R; Varia, S; Wadke, D; Weijer, K, ) | 1.79 |
| " An adequate standard dosage of aztreonam could be established as 3-4 g/day in compromised patients, and it should be combined with gram-positive coverage when used empirically." | ( A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients. Bosch-Perez, A; Rabinad, E, 1989) | 0.84 |
| " It has been established, for example, that with intramuscular or intravenous dosing (30 to 50 mg/kg in children and 1 to 2 g in adults), serum concentrations above the minimum inhibitory concentrations of most aerobic Gram-negative bacteria can be maintained for up to 8 hours." | ( Aztreonam: clinical pharmacology. Stutman, HR, 1989) | 1.72 |
| " In the treatment of children with urinary tract infection as well as other types of infections, aztreonam therapy in a dosage of 30 mg/kg given every 6 to 8 hours was associated with satisfactory clinical and microbiologic cure rates." | ( Clinical experience with aztreonam. Stutman, HR, 1989) | 0.8 |
| " Tolerance to the drug was good in both groups, and in no instance did side effects necessitate modification of the dosing regimen." | ( The clinical use of aztreonam. Car, V; Krznar, B; Schönwald, S; Schoss-Vidensek, Z, 1989) | 0.6 |
| " This dosage is lower than usual." | ( Efficacy and safety of low dose aztreonam in the treatment of moderate to severe gram-negative bacterial infections. Carbon, C; Clergeot, A; Rosset, MA; Steru, D, 1989) | 0.56 |
| " At the dosage used, aztreonam proved effective for severe urinary tract infections caused by members of the family Enterobacteriaceae in pediatric patients." | ( Aztreonam in the treatment of severe urinary tract infections in pediatric patients. Assael, BM; Boccazzi, A; Colombo, R; Crossignani, RM; Garlaschi, L; Rancilio, L; Rusconi, F, 1986) | 2.03 |
| "The minimum dosage of antibiotics which reduced mortality in rats intraperitoneally inoculated with an Escherichia coli isolate was determined." | ( In vivo significance of the inoculum effect of antibiotics on Escherichia coli. Castilla, C; Fernández-Roblas, R; Ponte, C; Santamaría, M; Soriano, F, 1988) | 0.27 |
| " Carumonam is well tolerated at both the dosage regimens; it is effective in the treatment of aerobic Gram-negative sepsis." | ( Clinical efficacy of carumonam. Blakemore, PH; Drabu, YJ; Mehtar, S, 1988) | 0.27 |
| " The dosage of aztreonam should be adjusted in patients with renal failure." | ( Aztreonam: the first monobactam. Neu, HC, 1988) | 2.07 |
| " Over a large dosage range plasma concentrations increase linearly with dose." | ( Clinical pharmacokinetics of aztreonam. Mattie, H, 1988) | 0.57 |
| " The pharmacokinetics of aztreonam after intravenous infusion or intramuscular dosing are presented as well as the dosage adjustments for hemodialysis and chronic ambulatory peritoneal dialysis (CAPD)." | ( Microbiology and pharmacology of aztreonam. Duma, RJ, 1988) | 0.86 |
| "The pharmacokinetics of carumonam after single and multiple intravenous administration of 1- and 2-g dosage regimens were studied in 12 young male volunteers." | ( Pharmacokinetics of carumonam after single and multiple 1- and 2-g dosage regimens. Bergeron, MG; Bérubé, D; LeBel, M; Panneton, AC; Vallée, F, 1988) | 0.27 |
| " Dosage reductions of these drugs may be appropriate in certain situations." | ( Therapeutic considerations in using combinations of newer beta-lactam antibiotics. Barriere, SL, 1986) | 0.27 |
| "7 hours, suggesting a dosing interval of 6-8 hours for severe or life-threatening infections and 8-12 hours for moderately severe infections and urinary tract infections." | ( Aztreonam. Bodey, GP; Childs, SJ, ) | 1.57 |
| "Aztreonam was given orally to eight healthy volunteers in two different dosage regimens." | ( Determination of aztreonam in faeces of human volunteers: a comparison of reversed-phase high pressure liquid chromatography and bioassay. Ehret, W; Probst, H; Ruckdeschel, G, 1987) | 2.06 |
| " Based on our results a dosage adjustment schedule for renal impairment is suggested." | ( Pharmacokinetics of aztreonam in infected patients. Mattie, H; Matze-van der Lans, A, 1986) | 0.59 |
| "1 micrograms/ml) 15 min after dosing and then declined with an apparent elimination half-life of 16." | ( Disposition of carumonam (AMA-1080/Ro 17-2301), a new N-sulfonated monocyclic beta-lactam, in rats and dogs. Mitani, M; Naeshiro, I; Tanayama, S; Torii, H; Yoshida, K, 1986) | 0.27 |
| " When these data are combined with in vitro susceptibility data for aztreonam against Pseudomonas aeruginosa isolated from the sputum of patients with cystic fibrosis, a dose of 200 mg aztreonam/kg/day divided six hourly would be predicted to maintain serum concentrations above the minimum inhibitory concentration (MIC) for these organisms for the majority of the dosing interval." | ( Single-dose pharmacokinetics of aztreonam in children with cystic fibrosis. Aronoff, SC; Blumer, JL; Friedhoff, LT; Myers, CM; Reed, MD; Stern, RC; Yamashita, TS, ) | 0.65 |
| " Renal insufficiency may significantly impair the elimination of aztreonam, thus requiring modification of the dosage regimen." | ( Review of the clinical pharmacology of the monobactam antibiotic aztreonam. Swabb, EA, 1985) | 0.74 |
| " Dosage of aztreonam was 2 to 8 g per day administered intravenously or intramuscularly for five to 52 days." | ( Aztreonam in the treatment of serious orthopedic infections. Beskin, J; Beville, R; Haddad, RJ; Holmes, B; Mogabgab, WJ; Pollock, B; Pribyl, C; Salzer, R, 1985) | 2.1 |
| " Dosage should be adjusted in patients with renal impairment." | ( Aztreonam, a new monobactam antimicrobial. Guay, DR; Koskoletos, C, ) | 1.57 |
| " The elimination of aztreonam may be significantly impaired by renal insufficiency; the dosage must be modified in patients with creatinine clearance rates of less than 30 ml/min." | ( Clinical pharmacology of aztreonam in healthy recipients and patients: a review. Swabb, EA, ) | 0.76 |
| " The dosage of aztreonam used most frequently was 1 g three times daily." | ( Overall clinical experience with aztreonam in the treatment of obstetric-gynecologic infections. Henry, SA, ) | 0.77 |
| " A single pharmacokinetic study was performed over one dosing interval after steady-state conditions were achieved." | ( Pharmacokinetics and extravascular penetration of aztreonam in patients with abdominal sepsis. Schentag, JJ; Simons, GW; Smith, IL; Swanson, DJ; Vigano, A; Wels, PB; Winslade, NE, ) | 0.38 |
| " Pharmacokinetic studies demonstrated that dosage adjustment of aztreonam in geriatric patients should be based on creatinine clearance." | ( Clinical experience with aztreonam in Germany and Austria. Gillissen, J; Stille, W, ) | 0.67 |
| " Serum concentration of AZT in 10 pediatric cases were measured by dosing 10, 20 and 40 mg/kg by one-shot intravenous injection to 3, 4 and 3 cases, respectively." | ( [Basic and clinical trials of aztreonam in the field of pediatrics]. Fujimoto, T; Kawakami, A; Koga, T; Motohiro, T; Nishiyama, T; Sakata, Y; Shimada, Y; Tanaka, K; Tominaga, K; Tomita, N, 1985) | 0.56 |
| " No functional or histopathologic evidence of ototoxicity was found in any neonatal rat dosed with aztreonam or saline." | ( Ototoxicity of subcutaneously administered aztreonam in neonatal rats. DePaoli, A; Keim, GR; Myhre, JL, 1985) | 0.75 |
| " After multiple dosing (1 g every 8 h), no significant accumulation of aztreonam was observed." | ( Pharmacokinetics of aztreonam in patients with gram-negative infections. Apicella, MA; Cafarell, RF; Janicke, DM; Jusko, WJ; Parker, SW, 1985) | 0.83 |
| " The dosage of aztreonam (1." | ( Safety of aztreonam and SQ 26,992 in elderly patients with renal insufficiency. Sattler, FR; Schramm, M; Swabb, EA, ) | 0.89 |
| " The levels of AZT into the feces by the multiple dosage were 0-840 micrograms/g." | ( [Fundamental and clinical studies of aztreonam in the field of pediatric]. Chikaoka, H; Kamigaki, M; Koido, R; Matsumoto, K; Nakada, Y; Nakazawa, S; Narita, A; Sato, H; Suzuki, H, 1985) | 0.54 |
| " AZT was administered to 4 patients with pyelonephritis and 10 patients with tonsillitis at a daily dosage of 40." | ( [Clinical evaluation of aztreonam in children]. Ito, S; Mikawa, H; Mochizuki, Y; Ohkubo, H; Yoshida, A, 1985) | 0.58 |
| " Susceptibility of the bacteria isolated from the 7 cases receiving consecutive dosage to AZT, cefmetazole (CMZ), latamoxef (LMOX), cefoperazone (CPZ) and ceftazidime (CAZ) as well as side effect and laboratory values were examined with the following results." | ( [Effect of aztreonam on bacterial flora in human feces]. Aramaki, M; Fujimoto, T; Kawakami, A; Koga, T; Motohiro, T; Nishiyama, T; Sakata, Y; Shimada, Y; Tanaka, K; Tomita, N, 1985) | 0.66 |
| " Therefore, there is no need to relate the timing of blood (and urine) sampling for creatinine assay to dosage of these antibiotics." | ( Lack of interference of five new beta-lactam antibiotics with serum creatinine determination. LeBel, M; Lewis, GP; Paone, RP, 1983) | 0.27 |
| " Aztreonam was bactericidal for growing bacilli in vitro and, when injected 1 and 5 hours after aerogenic exposure, provided greater than 80% protection after dosage at the level of 12." | ( Effect of aztreonam on the growth of Pasteurella multocida in the lung. Collins, FM, 1984) | 1.58 |
| " Azthreonam was given intramuscularly, as monotherapy, in a daily dosage of 2 g, in two divided doses, for 10 to 29 days (mean: 28 days)." | ( [Clinical evaluation of azthreonam in severe urinary tract infections]. Acar, JF; Guibert, J; Miegi, M, 1984) | 0.27 |
| " A dosage schedule of every 6 to 8 h in older children and every 8 to 12 h in neonates is suggested for multiple-dose clinical trials." | ( Single-dose pharmacokinetics of aztreonam in pediatric patients. Marks, MI; Stutman, HR; Swabb, EA, 1984) | 0.55 |
| " Although the handling of aztreonam differed in the three groups, the magnitude of the difference would warrant a change in aztreonam dosing only for the alcoholic cirrhosis group." | ( Effects of cirrhosis on kinetics of aztreonam. Bartley, EA; Devlin, RG; Hudes, E; MacLeod, CM; Payne, JA; Vernam, K, 1984) | 0.84 |
| "Eighteen patients with hematological malignancies received aztreonam in one of two dosing regimens, 1 or 2 g every 8 h for a total of 7 to 9 days." | ( Effect of aztreonam on throat and stool flora of cancer patients. Bodey, GP; Jones, PG; Rosenbaum, B; Swabb, EA, 1984) | 0.91 |
| " A nomogram was developed as a guide for adjustment of aztreonam dosage according to renal function." | ( Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction. Bolton, ND; Bolton, WK; Mihindu, JC; Scheld, WM; Spyker, DA; Swabb, EA, 1983) | 0.84 |
| " These changes suggest that the interval and magnitude of dosing should be adjusted, relative to the standard recommended dosages of each antibiotic, to maximize their efficacy." | ( Antibiotic pharmacokinetics following fluid resuscitation from traumatic shock. Boucher, BA; Croce, MA; Fabian, TC; McKindley, DS; Proctor, KG, 1995) | 0.29 |
| " Aztreonam was administered at a dosage of 2 g every 8 hours and gentamicin at 5 mg/kg for the first 24 hours and then adjusted by serum monitoring to a peak of 6 to 8 micrograms/mL and a trough of less than 2 micrograms/mL; all patients received 900 mg of clindamycin every 8 hours." | ( Superiority of aztreonam/clindamycin compared with gentamicin/clindamycin in patients with penetrating abdominal trauma. Boucher, BA; Charland, SL; Croce, MA; Fabian, TC; Hess, MM; Rodman, JH; Wilson, RS; Wilson, SE, 1994) | 1.55 |
| " Over a large dosage range, plasma concentrations increase dose proportionally." | ( Clinical pharmacokinetics of aztreonam. An update. Mattie, H, 1994) | 0.58 |
| " The control regimen was one of the following depending on the combination therapy that was designated standard at each of the three study institutions: amikacin, 5 mg/kg q8h, plus cefazolin, 1 gm q8h; amikacin, 500 mg every 12 hours plus mezlocillin, 4 gm q6h; or kinetically dosed tobramycin plus ticarcillin, 3 gm to 4 gm q4h." | ( Comparison of empiric aztreonam and aminoglycoside regimens in the treatment of serious gram-negative lower respiratory infections. Bjornson, HS; Hinthorn, DR; Liu, C; Ramirez-Ronda, C; Rivera-Vázquez, CR; Saavedra, S, ) | 0.45 |
| "To assess the pharmacokinetics of teicoplanin in combination with another antibiotic in Gram-positive infections in pediatric patients undergoing bone marrow transplantation and to determine the most appropriate dosage regimen for this type of patient." | ( Teicoplanin pharmacokinetics in pediatric patients. Dufort, G; Olivé, T; Ortega, JJ; Ventura, C, 1996) | 0.29 |
| " In Group A (n = 9) the dosage regimen consisted of 3 loading doses of 10 mg/kg at 12-h intervals, followed by a maintenance dosage of 10 mg/kg/day." | ( Teicoplanin pharmacokinetics in pediatric patients. Dufort, G; Olivé, T; Ortega, JJ; Ventura, C, 1996) | 0.29 |
| " All patients had received at least two aztreonam doses before the dosage interval being studied." | ( Pharmacokinetics of aztreonam in critically ill surgical patients. Asensio, J; Belzberg, H; Berne, TV; Cornwell, EE; Demetriades, D; Gill, MA; Kern, JW; Theodorou, D; Yu, W, 1997) | 0.89 |
| " Logarithmic-phase cultures were exposed to peak concentrations achieved in serum with 1- or 2-g intravenous doses, elimination pharmacokinetics were simulated, and viable bacterial counts were measured over three 8-h dosing intervals." | ( Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa. Lister, PD; Sanders, CC; Sanders, WE, 1998) | 0.72 |
| " In patients with normal renal function, the recommended dosing interval is every 8 hours." | ( Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Brewer, NS; Hellinger, WC, 1999) | 0.55 |
| " The three procedures are applied for the determination of aztreonam in pure and in pharmaceutical dosage forms applying the standard additions technique and the results obtained agreed well with those obtained by the official method." | ( Utilization of colorimetric and atomic absorption spectrometric determination of aztreonam through ion pair complex formation. Aly, HM; Amin, AS, 2000) | 0.78 |
| " Patients suspected of having high clearance rates, such as CF patients, should be monitored closely, with dosing regimens adjusted accordingly." | ( Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. Heijerman, HG; Mathôt, RA; Mouton, JW; van Rossem, RN; Vinks, AA, 2007) | 0.66 |
| "006) compared with placebo; no AZLI dose-response was observed." | ( Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Gibson, RL; McCoy, KS; Montgomery, AB; Oermann, CM; Quittner, AL; Retsch-Bogart, GZ, 2008) | 0.78 |
| " The superiority of aerosol dosing over systemic dosing was demonstrated in models of both acute and chronic lung infection." | ( Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Dudley, MN; Griffith, DC; Miller, CE; Nolan, TG; Sabet, M; Senekeo-Effenberger, K, 2009) | 0.35 |
| " Then, 65 patients underwent intramuscular test dosing with aztroenam, and none of them had a clinical reaction." | ( Tolerability of aztreonam in patients with cell-mediated allergy to β-lactams. Aruanno, A; Buonomo, A; Colagiovanni, A; De Pasquale, T; Lombardo, C; Nucera, E; Pascolini, L; Patriarca, G; Pecora, V; Rizzi, A; Sabato, V; Schiavino, D, 2011) | 0.72 |
| " The current dosing recommendations in the United States and Europe for aztreonam are lower than the literature supported dosing range of 200-300 mg/kg/day divided every 6 hr, maximum 8-12 g/day." | ( Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT, 2012) | 0.83 |
| " A humanized aztreonam dose of 2 g every 6 h (1-h infusion) was evaluated alone and in combination with avibactam at 375 or 600 mg every 6 h (1-h infusion), targeting the percentage of the dosing interval in which free-drug concentrations remained above the MIC (fT>MIC)." | ( Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers. Crandon, JL; Nicolau, DP, 2013) | 1.06 |
| "Six clinical Enterobacteriaceae isolates expressing MBLs and ESBLs were studied in an in vitro hollow-fibre infection model (HFIM) using various dosing regimens simulating human-like PK for aztreonam/avibactam." | ( Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. Bradford, PA; Eakin, AE; Harris, JJ; Kim, A; McLaughlin, RE; O'Donnell, JP; Patey, S; Singh, R; Tanudra, MA, 2015) | 0.82 |
| " Dose-response relationships between antibiotic exposure and extended-spectrum-beta-lactamase-producing or AmpC-producing isolates were not demonstrated." | ( Previous Antibiotic Exposure Increases Risk of Infection with Extended-Spectrum-β-Lactamase- and AmpC-Producing Escherichia coli and Klebsiella pneumoniae in Pediatric Patients. Adler, AL; Elward, A; Haaland, W; Kronman, MP; Miles-Jay, A; Newland, JG; Qin, X; Weissman, SJ; Zaoutis, T; Zerr, DM; Zhou, C, 2016) | 0.43 |
| " The aims of this study were to assess the impact of renal impairment on aztreonam exposure and to evaluate dosing regimens for patients with renal impairment." | ( Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis. Al-Huniti, N; Li, J; Xu, H; Zhou, D; Zhou, W, 2017) | 1.05 |
| " The probability of target attainment (PTA) was assessed using Monte Carlo simulations for 30-minute and 5-minute infusions of approved dosing regimens and alternative dosing schemes often used in clinical practice, including 500 mg every 6 hours and 1 g every 8 hours for meropenem, 1 g every 6 hours and 2 g every 8 hours for cefepime, and 2 g every 8 hours for aztreonam." | ( Effects of i.v. push administration on β-lactam pharmacodynamics. Burgner, K; Butterfield-Cowper, JM, 2017) | 0.62 |
| " pneumoniae ARLG-1002 (blaNDM-1, blaCTXM-15, blaDHA, blaSHV, blaTEM) were studied in the HFIM using simulated human dosing regimens of ceftazidime/avibactam and aztreonam." | ( Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. Boissonneault, KR; Bonomo, RA; Bulitta, JB; Chambers, HF; Eakin, AE; Fowler, VG; Holden, PN; Lodise, TP; O'Donnell, N; Smith, NM; Tao, X; Tsuji, BT; Zhou, J, 2020) | 0.97 |
| " In the prospective validation experiments, ceftazidime/avibactam with aztreonam dosed every 8 and 6 h, respectively (ceftazidime/avibactam 2/0." | ( Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. Boissonneault, KR; Bonomo, RA; Bulitta, JB; Chambers, HF; Eakin, AE; Fowler, VG; Holden, PN; Lodise, TP; O'Donnell, N; Smith, NM; Tao, X; Tsuji, BT; Zhou, J, 2020) | 1.01 |
| " This case illustrates the importance of TDM, and the logistical issues encountered with the use of alternative dosing strategies in pediatric patients with CF." | ( Optimization of Aztreonam in Combination With Ceftazidime/Avibactam in a Cystic Fibrosis Patient With Chronic Stenotrophomonas maltophilia Pneumonia Using Therapeutic Drug Monitoring: A Case Study. Cowart, MC; Ferguson, CL, 2021) | 0.97 |
| " Optimal dosing of aztreonam with avibactam is not well-defined in critically ill patients and contingent on ceftazidime/avibactam product labelling." | ( Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. Baldelli, S; Cattaneo, D; Di Paolo, A; Falcone, M; Galfo, V; Leonildi, A; Menichetti, F; Pai, MP; Tagliaferri, E; Tiseo, G, 2021) | 1.18 |
| "To identify a pragmatic dosing strategy for aztreonam with avibactam to maximize the probability of target attainment (PTA)." | ( Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. Baldelli, S; Cattaneo, D; Di Paolo, A; Falcone, M; Galfo, V; Leonildi, A; Menichetti, F; Pai, MP; Tagliaferri, E; Tiseo, G, 2021) | 1.12 |
| " Population pharmacokinetic (PK) analysis coupled with Monte Carlo simulations were used to create a dosing nomogram for aztreonam and ceftazidime/avibactam based on drug-specific pharmacodynamic (PD) targets." | ( Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. Baldelli, S; Cattaneo, D; Di Paolo, A; Falcone, M; Galfo, V; Leonildi, A; Menichetti, F; Pai, MP; Tagliaferri, E; Tiseo, G, 2021) | 1.06 |
| " However, in the light of dose-limiting hepatotoxicity of aztreonam, short half life of avibactam, significant protein binding of aztreonam, appropriate dosing and method of administration to optimize PK/PD and toxicodynamics for this combination is being debated." | ( Management of serious infections caused by metallo β-lactamases with or without OXA-48-like expressing Enterobacterales with aztreonam and ceftazidime/avibactam combination: Dosing strategy for better clinical outcome. Bakthavatchalam, YD; Manesh, A; Nagvekar, V; Nangia, V; Soman, R; Swaminathan, S; Veeraraghavan, B, 2021) | 1.07 |
| " For aztreonam/avibactam dosing regimens evaluated in clinical trials, fT>MPC values were >90% and >80%, whereas fTMSW measures were <10% and <20% in plasma and ELF, respectively." | ( Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases. Dong, D; Feng, K; Gong, H; Jia, N; Liu, Y; Lv, Z; Martins, FS; Sy, S; Sy, SKB; Yu, M; Zhang, J; Zhu, P; Zhu, S; Zhu, Y, 2021) | 2.58 |
| " A novel de-escalation approach to polymyxin B dosing was also explored, whereby a standard 0-h loading dose was followed by maintenance doses that were 50% of the typical clinical regimen." | ( Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity. Boissonneault, KR; Bulitta, JB; Bulman, ZP; Cha, R; Chen, L; Holden, PN; Kavaliauskas, P; Kreiswirth, BN; Lang, Y; Petraitiene, R; Petraitis, V; Smith, NM; Tao, X; Tsuji, BT; Walsh, TJ; Zhou, J, 2022) | 0.72 |
| " Various dosage regimens based on short infusion, PI or CI were simulated in virtual patients." | ( Defining standard and high dosages for β-lactam agents administered by intermittent, prolonged or continuous infusion: a PK/PD simulation study. Bru, JP; Canoui, E; Cattoir, V; Gauzit, R; Goutelle, S; Jullien, V; Lepeule, R; Lesprit, P; Lina, G; Schramm, F, 2023) | 0.91 |
| "Adequate PTAs were confirmed for most EUCAST short-infusion dosage regimens." | ( Defining standard and high dosages for β-lactam agents administered by intermittent, prolonged or continuous infusion: a PK/PD simulation study. Bru, JP; Canoui, E; Cattoir, V; Gauzit, R; Goutelle, S; Jullien, V; Lepeule, R; Lesprit, P; Lina, G; Schramm, F, 2023) | 0.91 |
| "These alternative standard and high dosage regimens are expected to provide antibiotic exposure compatible with new EUCAST definitions of susceptibility categories and associated MIC breakpoints." | ( Defining standard and high dosages for β-lactam agents administered by intermittent, prolonged or continuous infusion: a PK/PD simulation study. Bru, JP; Canoui, E; Cattoir, V; Gauzit, R; Goutelle, S; Jullien, V; Lepeule, R; Lesprit, P; Lina, G; Schramm, F, 2023) | 0.91 |
| Role | Description |
|---|---|
| EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor | An EC 2.4.1.* (hexosyltransferase) inhibitor that interferes with the action of peptidoglycan glycosyltransferase (EC 2.4.1.129). |
| antibacterial drug | A drug used to treat or prevent bacterial infections. |
| drug allergen | Any drug which causes the onset of an allergic reaction. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| monobactam | Monocyclic, bacterially produced or semisynthetic beta-lactam antibiotic. It lacks the double ring construction of the traditional beta-lactam antibiotics and can be easily synthesized. |
| beta-lactam antibiotic allergen | Any beta-lactam antibiotic which causes the onset of an allergic reaction. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 10.6822 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 7.0795 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 12.5893 | 0.6561 | 9.4520 | 25.1189 | AID927 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 0.0003 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 0.0452 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 12.5893 | 1.5849 | 13.0043 | 25.1189 | AID927 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 0.0040 | 1.0000 | 10.4756 | 28.1838 | AID901 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 14.2999 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
| Ataxin-2 | Homo sapiens (human) | Potency | 14.2999 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Beta-lactamase | Citrobacter freundii | Ki | 2.0000 | 0.0600 | 0.6000 | 2.0000 | AID405083 |
| Beta-lactamase | Escherichia coli | IC50 (µMol) | 0.0320 | 0.0260 | 0.0290 | 0.0320 | AID394491 |
| Beta-lactamase | Acinetobacter baumannii | Ki | 0.0070 | 0.0070 | 0.2023 | 0.5000 | AID567279 |
| Beta-lactamase | Acinetobacter baumannii | Ki | 3.0000 | 0.5000 | 2.0000 | 3.0000 | AID567280 |
| Penicillin-binding protein 1A | Pseudomonas aeruginosa PAO1 | IC50 (µMol) | 3.3400 | 3.3400 | 3.3400 | 3.3400 | AID1139451 |
| Efflux transporter | Salmonella enterica subsp. enterica serovar Newport | IC50 (µMol) | 0.0060 | 0.0040 | 0.0050 | 0.0060 | AID545146 |
| Beta-lactamase | Klebsiella pneumoniae | IC50 (µMol) | 0.0060 | 0.0040 | 0.0050 | 0.0060 | AID545147 |
| AmpC | Escherichia coli | IC50 (µMol) | 0.0600 | 0.0600 | 0.2800 | 0.5000 | AID518501 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Beta-lactamase | Citrobacter gillenii | Km | 938.0000 | 10.0000 | 10.0000 | 10.0000 | AID285442 |
| Beta-lactamase | Burkholderia cenocepacia | Km | 2,500.0000 | 10.0000 | 10.0000 | 10.0000 | AID541022 |
| Beta-lactamase | Klebsiella pneumoniae | Km | 10.0000 | 3.2000 | 5.8250 | 10.0000 | AID562754 |
| Beta-lactamase | Pseudomonas aeruginosa | Km | 0.3600 | 0.3000 | 2.0063 | 8.0000 | AID495661 |
| Beta-lactamase | Aeromonas allosaccharophila | Km | 40.0000 | 1.5000 | 6.3000 | 10.0000 | AID584846 |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | Km | 938.0000 | 10.0000 | 10.0000 | 10.0000 | AID285442 |
| Beta-lactamase | Acinetobacter pittii | Km | 6.0100 | 0.0200 | 2.1814 | 6.7300 | AID555223 |
| Beta-lactamase | Acinetobacter pittii | Km | 3.8500 | 0.1800 | 1.3683 | 3.8500 | AID555225 |
| Beta-lactamase | Acinetobacter pittii | Km | 4.5400 | 0.1300 | 1.5250 | 4.5400 | AID555227 |
| Beta-lactamase | Salmonella enterica subsp. enterica serovar Westhampton | Km | 14.0000 | 10.0000 | 10.0000 | 10.0000 | AID556340 |
| Beta-lactamase | Klebsiella pneumoniae | Km | 5.0000 | 5.0000 | 7.1667 | 10.0000 | AID519982 |
| Beta-lactamase | Pseudomonas luteola | Km | 40.0000 | 7.0000 | 7.5000 | 8.0000 | AID495635 |
| BlaVIM-1 | Escherichia coli | Km | 1,000.0000 | 1.5000 | 1.5000 | 1.5000 | AID495914 |
| Carbapenem-hydrolyzing beta-lactamase KPC | Klebsiella pneumoniae | Km | 310.0000 | 1.6000 | 3.8000 | 6.0000 | AID374025 |
| Beta-lactamase class B VIM-2 | Pseudomonas aeruginosa | Km | 1,000.0000 | 2.0000 | 6.6500 | 9.4000 | AID531315 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1476615 | Antibacterial activity against Salmonella typhimurium ATCC 13311 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID530347 | Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID524392 | Antibacterial activity against Escherichia coli NKE1369 harboring deletion mutation in acrB, acrD, mdtABC protein and plasmid expressing nlpE gene | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID529497 | Antimicrobial activity against Escherichia coli T-625 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID517981 | Antimicrobial activity against Providencia rettgeri J96 harboring beta-lactamase IMP-1 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID372610 | Antibacterial activity against Escherichia coli DH5alpha producing beta-lactamase TEM-1 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID558324 | Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P835 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID532406 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B1 isolate SS-09X-45 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID555556 | Antimicrobial activity against Pseudomonas aeruginosa isolate 22843 expressing VIM-2 beta lactamase gene by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID573212 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB C25T mutant gene selected at 1 ug/ml of azithromycin after 2 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID373761 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii ab1265 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID323690 | Antibacterial activity against TEM92 ESBL-producing Acinetobacter baumannii by CLSI method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase. |
| AID649187 | Antibacterial activity against Enterobacter aerogenes after 16 to 20 hrs by broth microdilution method | 2012 | Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2 | Potent inhibitors of LpxC for the treatment of Gram-negative infections. |
| AID250266 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH19; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID544492 | Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-2 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID656347 | Antimicrobial activity against Serratia marcescens | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID523488 | Antimicrobial activity against Pseudomonas aeruginosa R70 Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID585176 | Activity of Beta-lactamase GES-7 K104, G170 mutant | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID541016 | Antimicrobial activity against Escherichia coli TOP10 harboring beta-lactamase PenB1 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID560489 | Antibacterial activity against 5 x 10'5 CFU/ml CMY-2 producing Escherichia coli MC4100 harboring plasmid AC-cmy2 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase. |
| AID279186 | Activity of Enterobacter cloacae S3 isolate beta lactamase LAP1 expressed in Escherichia coli DH10B | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1. |
| AID394696 | Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing OXA2 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID558050 | Antimicrobial activity against blaKPC-positive Klebsiella oxytoca S13 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID1373289 | Antimicrobial activity against Escherichia coli expressing beta-lactamase NMC-A by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID520797 | Antimicrobial activity against CTX-M-59 producing Klebsiella pneumoniae with PFGE pulsotype E by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID564228 | Activity of Escherichia coli TOP10 beta-lactamase OXA-143 | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. |
| AID532027 | Antimicrobial activity against Kluyvera georgiana 14751 expressing beta-lactamase CTX-M-78 obtained from bloodstream of patient by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Novel chromosome-encoded CTX-M-78 beta-lactamase from a Kluyvera georgiana clinical isolate as a putative origin of CTX-M-25 subgroup. |
| AID561441 | Antibacterial activity against Escherichia coli 1285 harboring beta-lactamase CMY-33 gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. |
| AID523512 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1240 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID585186 | Ratio of Kcat to Km for Beta-lactamase GES-13 K104, N170 mutant | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID532407 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-20 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID576265 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 19039 harboring porin OmpK36V mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID422495 | Antimicrobial activity against Escherichia coli BL21 (DE3) harboring pAT514 by E-test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID555193 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox deltaampDh3::lox deltanagZ::Gm after 18 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID497691 | Antimicrobial activity against colistin-resistant Klebsiella pneumoniae isolated from bacteremia patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea. |
| AID498302 | Antibacterial activity against Pseudomonas aeruginosa PA1054 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID554407 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2716 expressing inactivated mexB gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID323037 | Antimicrobial activity against extended-spectrum-beta-lactamase producing Escherichia coli isolates | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. |
| AID372617 | Activity of Escherichia coli CF0042 beta-lactamase TEM-35 by microacidimetric method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID285442 | Activity of Citrobacter gillenii CIP 106783 Beta-lactamase GIL1 expressed in Escherichia coli DH10B | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii. |
| AID519628 | Antimicrobial activity against beta-lactamase OXA-63 producing Brachyspira pilosicoli isolate BM4442 isolated from feces of patient with diarrhea by disc diffusion method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442. |
| AID394687 | Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing AmpC, MexXY-OprM pump by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID340729 | Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-14 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. |
| AID524244 | Antimicrobial activity against Escherichia coli DH5alpha | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID558337 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1650 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID369640 | Antibacterial activity against Acinetobacter baumannii A clone expressing carbapenemase-encoding blaOXA-40 gene by Etest method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital. |
| AID520975 | Antibacterial activity against Pseudomonas aeruginosa 2404 plasmid by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID534287 | Antimicrobial activity against ampN deficient Stenotrophomonas maltophilia KJ harboring ampG with xylE-Gmomega cassette insertion by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID511669 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD3 harboring oprD spontaneous mutant and deficient in dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID285595 | Antimicrobial activity against Pseudomonas aeruginosa 1B9 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID534283 | Antimicrobial activity against Stenotrophomonas maltophilia KJ by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID524259 | Ratio of Kcat to Km in Escherichia coli beta-lactamase SHV-84 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID368713 | Total body clearance in human cystic fibrosis patient at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID428271 | Antimicrobial activity against Klebsiella sp. assessed as resistant isolates by CLSI breakpoint assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID534286 | Antimicrobial activity against Stenotrophomonas maltophilia KJG harboring ampG with xylE-Gmomega cassette insertion by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID544584 | Antimicrobial activity against Escherichia coli ATCC 25922 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID523511 | Antimicrobial activity against Pseudomonas aeruginosa isolate 13167 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID585184 | Ratio of Kcat to Km for Beta-lactamase GES-5 E104, S170 mutant | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID518187 | Antimicrobial activity against Acinetobacter baumannii HPA 4737 harboring beta-lactamase OXA-26 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID561628 | Antimicrobial activity against ampD1-deficient Stenotrophomonas maltophilia KJ by twofold serial agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID565528 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-07 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID565533 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-02 harboring T residue at 105 position in PDC- 1 and polymorphic OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID518491 | Ratio of Kcat to Km for Escherichia coli Penicillin-binding protein 1A | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID522359 | Antibacterial activity against tatC deficient Pseudomonas aeruginosa TNP080 transformant harboring pTatPlcMexA carrying entire tatC gene and the chimeric mexA gene | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Tat pathway-mediated translocation of the sec pathway substrate protein MexA, an inner membrane component of the MexAB-OprM xenobiotic extrusion pump in Pseudomonas aeruginosa. |
| AID529664 | Ratio of Kcat to Km for Pseudomonas aeruginosa 166301 beta-lactamase VIM-16 relative to cephaloridine | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID498107 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID517983 | Antimicrobial activity against Enterobacter cloacae 908R harboring beta-lactamase AmpC by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID560060 | Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID374366 | Antimicrobial activity against Escherichia coli DH5alpha by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France. |
| AID761209 | Antibacterial activity against Escherichia coli expressing ESBL by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID530325 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID576274 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18260 by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID374363 | Activity of Aeromonas caviae A324R metallo-beta-lactamase IMP-19 expressed in Escherichia coli DH5alpha by computerized microacidimetric method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France. |
| AID573529 | Antibacterial activity against Acinetobacter baumannii isolate AbN450 harboring IblaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID529659 | Activity of Pseudomonas aeruginosa COL-1 beta-lactamase VIM-2 | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID555557 | Antimicrobial activity against Pseudomonas aeruginosa isolate 27135 expressing VIM-2 beta lactamase gene by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID555648 | Ratio of MIC for ampDh2 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG to MIC for ampDh2 gene-deficient Pseudomonas aeruginosa PAO1 in absence of nagZ inhibitor EtBuPUG | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID572140 | Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 37 expressing ampC, ompA, adeB, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID519983 | Activity of Klebsiella pneumoniae Beta-Lactamase SHV-1 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae. |
| AID511687 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PA01 deficient in dacB gene by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID587732 | Activity of Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-1 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States. |
| AID1395489 | Antibacterial activity against extended-spectrum beta-lactamase harboring Escherichia coli 13-1 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria. |
| AID522012 | Antimicrobial activity against Escherichia coli isolate J53 harboring pE containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID531777 | Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4663 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID531969 | Antibacterial activity against Klebsiella pneumoniae blood isolate A28008 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. |
| AID1373292 | Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-4 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID567272 | Ratio of Kcat to Ki for Acinetobacter baumannii ADC-11 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID532912 | Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID529480 | Antimicrobial activity against Enterobacter cloacae isolate 1 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID576262 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17829 harboring pSHA2-encoded porin OmpK36 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID533000 | Antibacterial activity against IMP-18 producing Pseudomonas aeruginosa isolate P85 exhibiting PFGE K pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID555645 | Antimicrobial activity against ampDh2 gene-deficient Pseudomonas aeruginosa PAO1 using 30 ug/disk by agar diffusion method in presence of 0.5 mM nagZ inhibitor EtBuPUG | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID571920 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 24 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID530326 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pUCP carrying VIM-1 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID529579 | Ratio of Kcat to Km for Legionella gormanii ATCC 33297T beta-Lactamase FEZ-1 | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID1373308 | Antimicrobial activity against Escherichia coli expressing beta-lactamase SPM-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID587978 | Antibacterial activity against Escherichia coli AS226 carrying pBSDN104A mutant after 18 hrs by broth microdilution method | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID520801 | Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype I by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID585195 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-2 E104, N170 mutant by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID428269 | Antimicrobial activity against Klebsiella sp. by CLSI broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID761213 | Antibacterial activity against Pseudomonas aeruginosa expressing metallo-beta-lactamase by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID573508 | Antibacterial activity against Klebsiella oxytoca isolate Ko1156 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID587730 | Activity of Pseudomonas aeruginosa strain PS 297 metallo-beta-lactamase IMP-18 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis using 100 uM nitrocefin | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States. |
| AID532391 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A1 isolate FG-17X-14 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID571910 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 19 expressing ampC, ompA, adeB, adeM, aacC2 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID583186 | Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 0.5 mM NagZ inhibitor PUGNAc | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID495798 | Ratio of Kcat to Km of Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B using nitrocefin hydrolysis | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France. |
| AID567091 | Drug absorption in human assessed as human intestinal absorption rate | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1 | Prediction of drug intestinal absorption by new linear and non-linear QSPR. |
| AID511581 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD and dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID548951 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 after18 to 20 hrs by broth dilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antimicrobial evaluation of some fused heterocyclic [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives. |
| AID368714 | Total body clearance in healthy human at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID1373295 | Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID340730 | Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase TEM-ES by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. |
| AID678714 | Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID517952 | Antimicrobial activity against Enterobacter cloacae by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID495914 | Hydrolytic activity of beta-lactamase VIM-1 expressed in Escherichia coli TOP10 by spectrophotometry | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID285579 | Antimicrobial activity against Pseudomonas aeruginosa IA5 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID396027 | Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID558318 | Antibacterial activity against Campylobacter jejuni by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID518522 | Antimicrobial activity against Capnocytophaga sputigena CIP 104301T after 2 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena. |
| AID532403 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone E isolate VA-06X-29 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID529492 | Antimicrobial activity against Enterobacter cloacae isolate 658 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID1733056 | Antibacterial activity against Enterobacter cloacae 700323 assessed as reduction in bacterial growth by CLSI based broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 39 | Synthesis and antibacterial evaluation of new monobactams. |
| AID497944 | Antibacterial activity against Burkholderia cepacia clinical isolates by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID519006 | Antimicrobial activity against Escherichia coli HB101 harboring empty vector pBK-SK by broth macrodilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID52923 | In vitro antibacterial activity against J-82-24 strain of Citrobacter diversus | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID394493 | Antimicrobial activity against Escherichia coli MC4100 harboring pA-acc1 plasmid by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID587729 | Antimicrobial activity against Escherichia coli DH5alpha carrying empty pBC-SK after 18 hrs by microdilution broth method | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States. |
| AID564017 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID584835 | Antimicrobial activity against Aeromonas allosaccharophila AL-1 expressing beta-lactamase PER6 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila. |
| AID525548 | Antimicrobial activity against ampicillin resistant nontypeable Haemophilus influenzae isolate BB1051 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination. |
| AID565514 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-21 harboring A residue at 105 position in PDC- 4 and polymorphic OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID520876 | Antibacterial activity against Achromobacter xylosoxidans CIP69598 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID534531 | Antimicrobial activity against Escherichia coli KCTC 1039 after 18 hrs by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases. |
| AID1278332 | Antibacterial activity against beta-lactamase producing Morganella morganii 25830 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID374025 | Activity of Klebsiella pneumoniae KPC-1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase. |
| AID562740 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBC-CTX-M-15 plasmid by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID585185 | Ratio of Kcat to Km for Beta-lactamase GES-6 K104, S170 mutant | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID519815 | Inhibition of Bocillin FL binding to PBP4 in Pseudomonas aeruginosa 27853 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID573494 | Antibacterial activity against Enterobacter cloacae isolate El3518 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID511577 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID534303 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA483 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID1476623 | Antibacterial activity against clinical isolates of Acinetobacter baumannii ARC 5079 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID565201 | Antimicrobial activity against Klebsiella pneumoniae isolate T-1504 expressing VIM-1 and KPC-2 genes by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. |
| AID511287 | Antibacterial activity against Pseudomonas aeruginosa NL68 expressing GES-13 beta lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. |
| AID573330 | Antibacterial activity against Klebsiella pneumoniae isolate Kp1239 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1373300 | Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-16 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID495915 | Ratio of Kcat to Km for beta-lactamase VIM-1 expressed in Escherichia coli TOP10 by spectrophotometry | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID588210 | Human drug-induced liver injury (DILI) modelling dataset from Ekins et al | 2010 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12 | A predictive ligand-based Bayesian model for human drug-induced liver injury. |
| AID517984 | Antimicrobial activity against Escherichia coli Libyien harboring beta-lactamase CMY-2 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID285582 | Antimicrobial activity against Pseudomonas aeruginosa 65.33-1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID285270 | Activity of Escherichia coli BL21(DE3) beta-lactamase TEM36 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID556341 | Ratio of Kcat/Km for Salmonella enterica serotype Westhampton beta-lactamase CTX-M-53 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID583187 | Antimicrobial activity against dacB::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 0.5 mM NagZ inhibitor PUGNAc | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID524246 | Antimicrobial activity against Escherichia coli DH5alpha expressing SHV-84 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID523516 | Antimicrobial activity against Pseudomonas aeruginosa isolate 13120 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID521842 | Antibacterial activity against Escherichia coli J53 by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID532418 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C3 isolate PG-12X-03 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID523515 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1253 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID524387 | Antibacterial activity against Escherichia coli NKE1365 harboring deletion mutation in acrB and mdtABC protein | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID565723 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-28 harboring A residue at 105 position in PDC- 7 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID559583 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID520880 | Antibacterial activity against Achromobacter xylosoxidans TB1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID565282 | Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A3 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID520877 | Antibacterial activity against Achromobacter xylosoxidans MER by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID520387 | Ratio of Kcat to Km for Pseudomonas aeruginosa M5109 metallo-beta-lactamase VIM-11 | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain. |
| AID1139454 | Displacement of fluorescent Bocillin FL from Pseudomonas aeruginosa PBP3 | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Siderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteria. |
| AID582764 | Antimicrobial activity against eaeA negative verocytotoxin-producing non-O157 Escherichia coli isolates obtained from human assessed as percentage of resistant isolates | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26. |
| AID340735 | Antimicrobial activity against Escherichia coli HB101 harboring pBC-IND-5 plasmid containing metallo-beta-lactamase IND5 assessed as drug level at which microbial resistance was observed by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes. |
| AID531337 | Antibacterial activity against MeXAB-OprM deficient Pseudomonas aeruginosa TNP077 selected after 1.0 ug/ml of azithromycin by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID532404 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone F isolate RM-11X-09 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID1443407 | Antibacterial activity against extended spectrum beta-lactamase KPC-2 producing multidrug resistant Klebsiella pneumoniae clinical isolates after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections. |
| AID588218 | FDA HLAED, lactate dehydrogenase (LDH) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1476614 | Antibacterial activity against Proteus mirabilis X235 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID587961 | Activity of Escherichia coli wild type beta-lactamase Toho-1 assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID533756 | Antibacterial activity against SHV-2a producing Pseudomonas aeruginosa isolate P102 exhibiting PFGE H pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID1476612 | Antibacterial activity against clinical isolates of Pseudomonas aeruginosa ISR-14-004 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID656444 | Antimicrobial activity against Escherichia coli clinical isolate | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID554389 | Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY F1018L mutant by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID564016 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring Pseudomonas aeruginosa plasmid DNA isolated from wound infection of patient by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID534300 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA459 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID587960 | Activity of Escherichia coli beta-lactamase Toho-1 A237A mutant assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID525545 | Antimicrobial activity against Haemophilus influenzae Rd KW20 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination. |
| AID571933 | Antimicrobial activity against Escherichia coli MC4100 harboring strong promoter in beta-lactamase GES-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter. |
| AID588216 | FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID521838 | Antibacterial activity against Klebsiella pneumoniae isolate VA375 with blaKPC-3, qnrA1, blaTEM-1, blaSHV-11 genes by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID559896 | Antimicrobial activity against Klebsiella oxytoca KO279 harboring beta-lactamase OXY-1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | First detection of plasmid-encoded blaOXY beta-lactamase. |
| AID522002 | Antimicrobial activity against Escherichia coli isolate J53 harboring p6A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID495834 | Antimicrobial activity against Escherichia coli DH5alpha harbouring plasmid BK-VIM-19 expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID1733054 | Antibacterial activity against Klebsiella pneumoniae 700603 assessed as reduction in bacterial growth by CLSI based broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 39 | Synthesis and antibacterial evaluation of new monobactams. |
| AID322314 | Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID554393 | Antimicrobial activity against Pseudomonas aeruginosa isolate 3020R obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID322320 | Antibacterial activity against Escherichia coli INSRA5776 isolates expressing CTX-M-14 and TEM-1B enzymes by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID544489 | Antibacterial activity against Enterobacter cancerogenus E624 harboring beta-lactamase KPC-4 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID1476630 | Antibacterial activity against clinical isolates of Pseudomonas aeruginosa ISR-14-004 after 18 hrs in presence of tazobactam by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID498106 | Antibacterial activity against Pseudomonas aeruginosa PA5020 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID428272 | Antimicrobial activity against carbapenemase producing Enterobacter sp. by CLSI broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID565532 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-03 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID544488 | Antibacterial activity against Pseudomonas aeruginosa PR100 harboring beta-lactamase KPC-2 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1373288 | Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-8 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID529463 | Antimicrobial activity against Klebsiella pneumoniae isolate 21 expressing beta-lactamase Oxa-48, TEM-1 and Oxa-9 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID250262 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH06; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID565716 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-21 harboring A residue at 105 position in PDC- 4 and polymorphic OprD gene by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID1476607 | Antibacterial activity against Pseudomonas aeruginosa 01 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID374365 | Antimicrobial activity against Escherichia coli DH5alpha expressing pIP19 containing Aeromonas caviae A324R metallo-beta-lactamase blaIMP-19 gene by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France. |
| AID1198152 | Half life in Wistar Han rat at 1 mg/kg, iv infusion | 2015 | Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5 | Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model. |
| AID372603 | Antibacterial activity against Escherichia coli BER1 producing beta-lactamase TEM-158 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID522005 | Antimicrobial activity against Klebsiella pneumoniae isolate KpI-1 expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID341106 | Antibacterial activity against metallo-beta-lactamase VIM12 expressing Escherichia coli 28 isolate from decubitus ulcer infection patient by Etest | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12. |
| AID542584 | Antimicrobial activity against Acinetobacter radioresistens 251-39C expressing beta-lactamase OXA-133 by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program. |
| AID285258 | Antimicrobial activity against recombinant Escherichia coli DH5-alpha CL1179 isolate expressing pBK-TEM-152 and CMT by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID531972 | Antibacterial activity against Klebsiella pneumoniae blood isolate A28006 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. |
| AID529485 | Antimicrobial activity against Enterobacter cloacae isolate 293 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID588215 | FDA HLAED, alkaline phosphatase increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID495807 | Antimicrobial activity against Escherichia coli C600 2878 transconjugate expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID1373323 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-181 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID563976 | Activity of Klebsiella pneumoniae 05-560 beta-lactamase VIM2 by spectrophotometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID285365 | Susceptibility of qnr positive Enterobacter cloacae producing IMP8 and/or SHV2 assessed as percentage nonsusceptible isolates | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Prevalence of plasmid-mediated quinolone resistance determinants QnrA, QnrB, and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital. |
| AID588213 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID498091 | Antibacterial activity against Pseudomonas aeruginosa PA5026 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID518217 | Antimicrobial activity against Escherichia coli W3110 assessed as appearance of spheroplast at 64 ug/mL after 3 hrs by phase-contrast microscopy | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID405082 | Antimicrobial activity against Escherichia coli 33587-TC9 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Biochemical characterization of PER-2 and genetic environment of blaPER-2. |
| AID529482 | Antimicrobial activity against Enterobacter cloacae isolate 140 containing PFGE genetic clone A expressing beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID1357447 | Antibacterial activity against KPC-2 producing Klebsiella pneumoniae isolate 209735 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria. |
| AID567313 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2204 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID573205 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 4 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID529647 | Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-15 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID541013 | Antimicrobial activity against Burkholderia cenocepacia 5007902 expressing beta-lactamase PenB4 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID368699 | Drug level in human cystic fibrosis patient serum at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID573511 | Antibacterial activity against Morganella morganii isolate Mm1614 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1443408 | Antibacterial activity against extended spectrum beta-lactamase OXA-23 producing multidrug resistant Acinetobacter baumannii clinical isolates after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections. |
| AID519004 | Antimicrobial activity against Serratia marcescens isolate CT-118 by broth macrodilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID372615 | Activity of Escherichia coli DH5alpha beta-lactamase TEM-12 by microacidimetric method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID520795 | Antimicrobial activity against CTX-M-59 producing Klebsiella pneumoniae with PFGE pulsotype C by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID532908 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID531679 | Antimicrobial activity against Acinetobacter baumannii Ab290 by broth dilution test | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii. |
| AID529496 | Antimicrobial activity against Escherichia coli T-622 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID573198 | Antimicrobial activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMAA biofilm harboring nfxB C25T mutant gene selected at 1 ug/ml of azithromycin after 2 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID522026 | Antimicrobial activity against Escherichia coli isolate J53 harboring pEcA containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID285611 | Antimicrobial activity against Pseudomonas aeruginosa 65.68-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID523508 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1726 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID531754 | Antibacterial activity against Pseudomonas aeruginosa 2439 harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID531333 | Antibacterial activity against Pseudomonas aeruginosa PAO4290 selected after 1.0 ug/ml of azithromycin by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID1373314 | Antimicrobial activity against Escherichia coli expressing beta-lactamase P99 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID571698 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 6 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID532894 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID573200 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB C116T mutant gene selected at 1 ug/ml of azithromycin after 1 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID394684 | Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID560706 | Inhibition of Escherichia coli MC4100 Beta-Lactamase CMY-2 using cephalothin as reporter substrate | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase. |
| AID322319 | Antibacterial activity against Escherichia coli DH5 alpha isolates by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID562756 | Ratio of Kcat to Km for Klebsiella pneumoniae AH24-270 CTX-M-71 beta-lactamase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID585175 | Activity of Beta-lactamase GES-1 E104, G170 mutant | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID521283 | Antimicrobial activity against CTX-M-59 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype G by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID495655 | Antimicrobial activity against Pseudomonas aeruginosa 51170 expressing beta-lactamase BEL-1 by solid agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID565519 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-16 harboring A residue at 105 position in PDC- 3 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID285573 | Antimicrobial activity against Pseudomonas aeruginosa P21.21 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID520974 | Antibacterial activity against Escherichia coli harboring pBC2303 expressing blaKPC gene plasmid by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID531746 | Antibacterial activity against Pseudomonas aeruginosa FE60 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID574429 | Antimicrobial activity against Escherichia coli isolate 386 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from wound of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID574431 | Antimicrobial activity against Escherichia coli isolate 540 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from synovial fluid of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID405635 | Antibacterial activity against Escherichia coli MC4100 by CLSI method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. |
| AID1373325 | Chemical stability in pH 7.4 potassium phosphate buffer assessed as half life for compound hydrolysis at 37 degC by UPLC and mass spectrometry | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID573518 | Antibacterial activity against Klebsiella pneumoniae isolate Kp211 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID495661 | Activity at Pseudomonas aeruginosa 531 beta-lactamase BEL-2 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID524393 | Antibacterial activity against Escherichia coli NKE1359 harboring deletion mutation in acrB protein and plasmid expressing BADnlpE gene in presence of increasing concentration of arabinose | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID497948 | Antibacterial activity against methicillin-sensitive Staphylococcus aureus by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1357456 | Antibacterial activity against IMP-4 producing Pseudomonas aeruginosa isolate 212886 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria. |
| AID519809 | Inhibition of Bocillin FL binding to PBP5/6 in Pseudomonas aeruginosa PAO1 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID587972 | Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 D240S mutant assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID498105 | Antibacterial activity against Pseudomonas aeruginosa PA861 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID519981 | Ratio of Kcat to Km for Klebsiella pneumoniae Beta-Lactamase SHV-1 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae. |
| AID573510 | Antibacterial activity against Citrobacter freundii isolate Cf1614 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID405084 | Activity of Citrobacter freundii PER2 beta lactamase | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Biochemical characterization of PER-2 and genetic environment of blaPER-2. |
| AID518730 | Antimicrobial activity against Pseudomonas stutzeri clinical isolate expressing beta-lactamase DIM-1 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands. |
| AID425864 | Antimicrobial activity against Carnobacterium divergens CIP101029 at 3 McFarland inoculum size by E-test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID509865 | Antibacterial activity against Acinetobacter baumannii ATCC 17978 isolated from human CSF | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID522357 | Antibacterial activity against tatC deficient Pseudomonas aeruginosa TNP080 transformant harboring pMEXA1 carrying wild type mexA gene | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Tat pathway-mediated translocation of the sec pathway substrate protein MexA, an inner membrane component of the MexAB-OprM xenobiotic extrusion pump in Pseudomonas aeruginosa. |
| AID521438 | Ratio of induction of xylE gene expression in Stenotrophomonas maltophilia isolate KJ deficient in L1 beta lactamase gene to induction of xylE gene expression in Stenotrophomonas maltophilia isolate KJ deficient in L2 beta lactamase gene assessed as catec | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID522388 | Activity of Aeromonas enteropelogenes Beta-lactamase TRU1 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes. |
| AID498117 | Antibacterial activity against Pseudomonas aeruginosa PA876 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID544533 | Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8130 expressing bla SHV-1 gene by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID511578 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID555638 | Antimicrobial activity against ampDDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID555681 | Antimicrobial activity against Escherichia coli DH10B by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID70776 | In vitro antibacterial activity against MOR-84-20 strain of Escherichia coli | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID531313 | Activity of Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. |
| AID678722 | Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID368702 | Distribution half life in healthy human at 2000 mg after 20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID495840 | Hydrolytic activity of beta-lactamase VIM-1 in Escherichia coli DH5alpha expressing pBCLL/39H by microacidimetric method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID521435 | Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L2 beta lactamase gene at 8 ug/ml | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID203311 | In vitro antibacterial activity against CMC-83-74 strain of Serratia marcescens | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID559589 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutT::Gm mutant gene assessed as doubling time | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID1229259 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method | 2015 | ACS medicinal chemistry letters, May-14, Volume: 6, Issue:5 | SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3. |
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID1278326 | Antibacterial activity against beta-lactamase producing Salmonella typhi H901 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID285691 | Antimicrobial susceptibility of Citrobacter freundii CF6010 isolate expressing carbapenemase KPC2 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. |
| AID533765 | Antibacterial activity against OXA-19 producing Pseudomonas aeruginosa isolate P9 exhibiting PFGE A pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID522006 | Antimicrobial activity against Klebsiella pneumoniae isolate KpI-2 expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID532413 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C1 isolate AV-13X-28 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID560080 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1037 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID279941 | Antibiotic susceptibility by resistance against non-MDR Pseudomonas aeruginosa from samples collected from patients | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. |
| AID560263 | Antimicrobial activity against Pseudomonas aeruginosa isolate NH57388A by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. |
| AID565719 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-24 harboring A residue at 105 position in PDC- 5 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID396029 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate in presence of 20 ug/ml efflux pump inhibitor Phe-Arg-beta-naphthylamide by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID394697 | Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing AmpC, MexAB-OprM pump, MexXY-OprM pump by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID322313 | Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID761215 | Antibacterial activity against Klebsiella pneumoniae 1487-07 by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID285260 | Antimicrobial activity against recombinant Escherichia coli DH5-alpha isolate expressing pBK-TEM-28 and ESBL by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID396033 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pBGS18 plasmid by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID573197 | Antimicrobial activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMAB biofilm harboring nfxB G125T mutant gene selected at 0.5 ug/ml of azithromycin after 1 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID498086 | Antibacterial activity against Pseudomonas aeruginosa PA899 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID529578 | Ratio of Kcat to Km for Chryseobacterium meningosepticum beta-Lactamase GOB-1 | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID511582 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD1 harboring oprD spontaneous mutant selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID523487 | Antimicrobial activity against Pseudomonas aeruginosa M1251 by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1373313 | Antimicrobial activity against Escherichia coli expressing beta-lactamase MIR-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID554406 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2715 expressing inactivated mexB gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID558319 | Antibacterial activity against Campylobacter coli by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID560069 | Antimicrobial activity against Klebsiella pneumoniae isolate 5427 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID372611 | Antibacterial activity against Escherichia coli DH5alpha by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID587959 | Activity of Escherichia coli beta-lactamase Toho-1 N104D mutant assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID556340 | Activity of Salmonella enterica serotype Westhampton beta-lactamase CTX-M-53 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID1198146 | Clearance in Wistar Han rat at 1 mg/kg, iv infusion | 2015 | Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5 | Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model. |
| AID285598 | Antimicrobial activity against Pseudomonas aeruginosa 2C1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID394713 | Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing AmpC by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID521998 | Antimicrobial activity against Klebsiella pneumoniae isolate Kp5A expressing beta-lactamase OXA-48 and SHV-5 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID1373282 | Antimicrobial activity against Escherichia coli expressing beta-lactamase CTXM-15 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID1373297 | Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-7 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID656358 | Antimicrobial activity against extended spectrum beta-lactamase-producing Escherichia coli | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID285574 | Antimicrobial activity against Pseudomonas aeruginosa 65.18-1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID125422 | In vitro antibacterial activity against VGH-84-12 strain of Morganella morganii | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID562328 | Antimicrobial activity against Chryseobacterium indologenes 597 expressing metallo-beta-lactamase IND-6 after 18 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. |
| AID94361 | In vitro antibacterial activity against IO-83-5 strain of Klebsiella pneumoniae | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID659490 | Antimicrobial activity against Enterobacter aerogenes after 16 to 20 hrs by 2-fold microbroth dilution method | 2012 | Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4 | Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. |
| AID571912 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 20 expressing ampC, ompA, adeB, adeM, aacC2 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID529580 | Ratio of Kcat to Km for Caulobacter crescentus beta-Lactamase CAU-1 | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID533758 | Antibacterial activity against PER-1 producing Pseudomonas aeruginosa isolate P170 exhibiting PFGE G pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID588217 | FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID520985 | Antibacterial activity against Klebsiella pneumoniae 633 by Etest method in presence of beta-lactamase inhibitor clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID405642 | Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 1a | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. |
| AID565198 | Antimicrobial activity against Klebsiella pneumoniae isolate A-1797 expressing VIM-1 and KPC-2 genes by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. |
| AID1278335 | Antibacterial activity against beta-lactamase producing Enterobacter cloacae 45301 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID573401 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB T77C mutant gene selected at 4 ug/ml of azithromycin after 3 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID532910 | Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID571890 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 9 expressing ampC, ompA, adeB, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID572132 | Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 33 expressing ampC, ompA, adeB, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1373350 | Drug excretion in mouse assessed as unchanged parent drug level at 2.5 mg/kg, iv | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID585177 | Activity of Beta-lactamase GES-2 E104, N170 mutant | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID560057 | Antimicrobial activity against ESBL-producing Escherichia coli by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID564535 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid carrying entire blaAmpC gene with alanine residue insertion at 215 position and R210P substitution by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID518185 | Antimicrobial activity against Serratia marcescens 1T9 harboring beta-lactamase Class C by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID541007 | Antimicrobial activity against Burkholderia cenocepacia 09-54 expressing beta-lactamase PenB2 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID523510 | Antimicrobial activity against Pseudomonas aeruginosa isolate 16008 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID528603 | Antimicrobial activity against Escherichia coli J53 harboring blaKPC-2 and blaTEM-1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID495819 | Antimicrobial activity against Klebsiella pneumoniae 2878 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID518823 | Antibacterial activity against Pulsotype C Acinetobacter genomosp. 3 isolate 1 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID1198148 | Antimicrobial activity against Escherichia coli by broth microdilution method | 2015 | Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5 | Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model. |
| AID533760 | Antibacterial activity against OXA-30, PSE-1, VIM-2 and PER-1 producing Pseudomonas aeruginosa isolate P19 exhibiting PFGE F pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID519797 | Inhibition of Bocillin FL binding to PBP1B in Escherichia coli MC4100 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID519814 | Inhibition of Bocillin FL binding to PBP3 in Pseudomonas aeruginosa 27853 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID250263 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH07; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID497943 | Antibacterial activity against Pseudomonas aeruginosa by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID394695 | Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing AmpC, MexXY-OprM pump, TEM-2 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID573524 | Antibacterial activity against Escherichia coli isolate Ec221 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID573509 | Antibacterial activity against Citrobacter amalonaticus isolate Ca1614 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID279187 | Ratio of kcat to Km of Enterobacter cloacae S3 isolate beta lactamase LAP1 expressed in Escherichia coli DH10B | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1. |
| AID530817 | Antibacterial activity against Escherichia coli J53 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. |
| AID285255 | Antimicrobial activity against Escherichia coli DH5-alpha CF1179 isolate expressing CMT and TEM1 by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID405083 | Inhibition of Citrobacter freundii PER2 beta lactamase | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Biochemical characterization of PER-2 and genetic environment of blaPER-2. |
| AID323039 | Antimicrobial activity against extended-spectrum-beta-lactamase producing Klebsiella pneumoniae isolates | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. |
| AID559686 | Antibacterial activity against Escherichia coli Top10 | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. |
| AID1373333 | Stability assessed as assessed as Escherichia coli beta-lactamase KPC-2-mediated compound hydrolysis by measuring molar enthalpy of hydrolysis at 1 mM by isothermal titration calorimetry | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID444054 | Oral bioavailability in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID495654 | Antimicrobial activity against Pseudomonas aeruginosa 531 expressing beta-lactamase BEL-2 by solid agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID405643 | Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 2 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. |
| AID374024 | Ratio of Kcat to Km for Enterobacter cloacae IMI1 beta lactamase Escherichia coli DH5alpha by SDS-PAGE | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase. |
| AID1476616 | Antibacterial activity against Enterobacter aerogenes X816 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID555643 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by using 30 ug/disk by agar diffusion method in presence of 0.5 mM nagZ inhibitor EtBuPUG | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID565516 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-19 harboring A residue at 105 position in PDC- 3 wild-type OprD porin gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID573517 | Antibacterial activity against Serratia marcescens isolate Sm203 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID555646 | Antimicrobial activity against ampDDh2 and ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs using 30 ug/ml by agar diffusion method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID543419 | Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime. |
| AID565283 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring plasmid pA1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID532893 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 475 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1278333 | Antibacterial activity against beta-lactamase producing Serratia marcescens 41002 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID546619 | Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-18 by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID534395 | Activity of Beta-lactamase KHM-1 in Escherichia coli JM109 harboring recombinant pKHM-1 assessed as compound hydrolysis at >1 mM by UV-visible spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate. |
| AID285262 | Antimicrobial activity against recombinant Escherichia coli DH5-alpha isolate expressing pBK-TEM-1 and TEM1 by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID495911 | Antimicrobial activity in Escherichia coli J53 strain | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID518728 | Activity of Pseudomonas stutzeri beta-lactamase DIM-1 by UV-spectrophotometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands. |
| AID565520 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-15 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID573496 | Antibacterial activity against Enterobacter cloacae isolate El1573 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID531605 | Activity of Escherichia coli beta-lactamase SHV-11 | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID524245 | Antimicrobial activity against Escherichia coli DH5alpha expressing SHV-1 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID1139451 | Displacement of fluorescent Bocillin FL from N-terminal His tagged Pseudomonas aeruginosa PAO1 PBP1a (residues 36 to 822) expressed in Escherichia coli BL21 (Gold cells) | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Siderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteria. |
| AID563972 | Activity of Klebsiella pneumoniae 05-560 beta-lactamase NDM-1 by spectrophotometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID285269 | Activity of Escherichia coli BL21(DE3) beta-lactamase TEM28 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID649185 | Antibacterial activity against Klebsiella pneumoniae after 16 to 20 hrs by broth microdilution method | 2012 | Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2 | Potent inhibitors of LpxC for the treatment of Gram-negative infections. |
| AID495903 | Antimicrobial activity in Escherichia coli DIH-1 expressing beta-lactamase VIM-19 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID522000 | Antimicrobial activity against Escherichia coli isolate J53 harboring p4A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID498114 | Antibacterial activity against Pseudomonas aeruginosa PA881 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID533569 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA475 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID518729 | Ratio of Kcat to Km for Pseudomonas stutzeri beta-lactamase DIM-1by UV-spectrophotometry | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands. |
| AID544493 | Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-4 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID342018 | Antibacterial activity against Klebsiella pneumoniae NK29 by Etest | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae. |
| AID518498 | Inhibition of beta-lactamase KPC-2 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID521284 | Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype H by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID467613 | Volume of distribution at steady state in human | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data. |
| AID425863 | Antimicrobial activity against Carnobacterium divergens CIP101029 at 0.5 McFarland inoculum size by E-test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID1373344 | Half life in dog at 10 mg/kg, iv | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID532394 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-32 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID532895 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 ST 277 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID573497 | Antibacterial activity against Serratia marcescens isolate Sm2723 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID587980 | Antibacterial activity against Escherichia coli AS226 carrying pBSDS237A mutant after 18 hrs by broth microdilution method | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID523506 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1712c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID560707 | Inhibition of Escherichia coli DH5alpha beta-lactamase CMY-2 assessed as aztreonam hydrolysis | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase. |
| AID523500 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1681c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID761223 | Inhibition of PBP2 in Pseudomonas aeruginosa ATCC 27853 after 20 mins by fluorescence assay | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID372614 | Ratio of Kcat to Km for Escherichia coli DH5alpha beta-lactamase TEM-158 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID531752 | Antibacterial activity against Pseudomonas aeruginosa 3308 harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID576267 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18918 harboring porin OmpK36V mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID583184 | Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID517963 | Antimicrobial activity against Pseudomonas aeruginosa by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID533764 | Antibacterial activity against OXA-19 producing Pseudomonas aeruginosa isolate P11 exhibiting PFGE A pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID532393 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-26 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID394492 | Antimicrobial activity against Escherichia coli MC4100 harboring pA-acc4 plasmid by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID530346 | Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID373753 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab4 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID542585 | Antimicrobial activity against plasmid encoded beta-lactamase OXA-58 deficient Acinetobacter radioresistens by CLSI method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program. |
| AID518480 | Binding affinity to Escherichia coli Penicillin-binding protein 2 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID517947 | Antimicrobial activity against Enterobacter aerogenes by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID531676 | Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid containing OXA-58-3 by broth dilution test | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii. |
| AID1198145 | Half life in PBS buffer in pH 7.4 by UPLC analysis | 2015 | Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5 | Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model. |
| AID1592958 | Antibacterial activity against multi-drug resistant Escherichia coli NMI 3898/15 assessed as reduction in microbial growth incubated for 20 hrs | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae. |
| AID394690 | Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing AmpC, PSE-1, MexXY-OprM pump by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID532417 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-12 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID522380 | Antimicrobial activity against blaKPC-possessing Klebsiella pneumoniae isolates in presence of 4 ug/ml by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniae isolates. |
| AID341594 | Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 469 transformants producing KPC2, OXA4 and CTX-M-10 carbapenemases | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. |
| AID529489 | Antimicrobial activity against Enterobacter cloacae isolate 656 containing PFGE genetic clone A expressing beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID554392 | Antimicrobial activity against Pseudomonas aeruginosa isolate 3020S obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID372606 | Antibacterial activity against rifampin-resistant Escherichia coli C600 transconjugant producing beta-lactamase of pI 5.2 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID520971 | Antibacterial activity against Klebsiella pneumoniae 633 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID573331 | Antibacterial activity against Klebsiella pneumoniae isolate Kp1945 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 and dfrA12-orfF-aadA2 arrays by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID521488 | Antibacterial activity against Pseudomonas aeruginosa KG2505 harboring pCOL plasmid by Etest method in presence of beta-lactamase inhibitor clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID511667 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD1 harboring oprD spontaneous mutant and deficient in dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID524266 | Antibacterial activity against Escherichia coli NKE128 harboring deletion mutation in acrB and tolC protein | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID373755 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab12 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID556342 | Activity of Beta-lactamase CTX-M-15 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID66225 | In vitro antibacterial activity against K-84-10 strain of Enterobacter cloacae | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID567316 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2207 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID373764 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh11 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID517965 | Antimicrobial activity against Escherichia coli K802N harboring beta-lactamase TEM-3 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID1476613 | Antibacterial activity against Escherichia coli DC0 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID564022 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring cloned pUCPOXA-161 by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID587962 | Activity of Escherichia coli beta-lactamase Toho-1 N104A mutant assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID573203 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 3 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID565727 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-32 harboring A residue at 105 position in PDC- 10 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID394693 | Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing MexAB-OprM pump by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID525037 | Activity of Enterobacter cloacae P99 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Updated functional classification of beta-lactamases. |
| AID761206 | Antibacterial activity against Acinetobacter spp. by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID1357453 | Antibacterial activity against KPC-2 producing Klebsiella pneumoniae isolate 212229 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria. |
| AID495791 | Antimicrobial activity against Pseudomonas fluorescens isolate PF-1 expressing beta-lactamase BIC-1 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France. |
| AID1373332 | Stability assessed as assessed as Escherichia coli beta-lactamase CTX-M-15-mediated compound hydrolysis by measuring molar enthalpy of hydrolysis at 1 mM by isothermal titration calorimetry | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID520808 | Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype B by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID540210 | Clearance in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID534533 | Antimicrobial activity against Citrobacter freundii KCTC 2359 after 18 hrs by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases. |
| AID250292 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH17; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID518484 | Ratio of Kcat to Km for beta-lactamase KPC-2 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID520982 | Antibacterial activity against Escherichia coli harboring pRYC plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID558322 | Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni NCTC 11168 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID285609 | Antimicrobial activity against Pseudomonas aeruginosa 65.68-1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID340727 | Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-2 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. |
| AID369641 | Antibacterial activity against Acinetobacter baumannii B clone by Etest method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital. |
| AID529576 | Ratio of Kcat to Km for Erwinia carotovora subsp. atroseptica DSM 30184 beta-Lactamase CAR-1 | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID1373343 | Half life in rat at 10 mg/kg, iv | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID518471 | Binding affinity to beta-lactamase KPC-2 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID373774 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh39 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID519803 | Antimicrobial activity against Escherichia coli MC4100 by CLSI protocol based broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID565726 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-31 harboring A residue at 105 position in PDC- 9 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID558336 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1618 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID560066 | Antimicrobial activity against Escherichia coli isolate 5411 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID519012 | Activity of Beta-lactamase TEM-10 | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID567286 | Antimicrobial activity against Acinetobacter baumannii expressing ESAC beta-lactamase by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID498872 | Antimicrobial activity against Acinetobacter baumannii B9 containing carbapenemase blaOXA-23 gene assessed as growth inhibition by Etest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate. |
| AID1373351 | Drug excretion in rat assessed as unchanged parent drug level at 10 mg/kg, iv | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID498304 | Antibacterial activity against Pseudomonas aeruginosa PA5063 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1373303 | Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-121 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID341597 | Antibacterial activity against sEscherichia coli GeneHogs harboring blaKPC-encoding plasmids | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. |
| AID531773 | Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4688 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID428270 | Antimicrobial activity against Klebsiella sp. assessed as susceptible isolates by CLSI breakpoint assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID1278322 | Antibacterial activity against ESBL positive Escherichia coli 09-1 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID372613 | Activity of Escherichia coli DH5alpha beta-lactamase TEM-158 by microacidimetric method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID548947 | Antimicrobial activity against Escherichia coli ATCC 25922 after18 to 20 hrs by broth dilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antimicrobial evaluation of some fused heterocyclic [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives. |
| AID565548 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-12 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID560090 | Bactericidal activity against Enterobacter cloacae isolate 5420 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID1733053 | Antibacterial activity against Klebsiella pneumoniae clinical isolate assessed as reduction in bacterial growth by CLSI based broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 39 | Synthesis and antibacterial evaluation of new monobactams. |
| AID1278307 | Antibacterial activity against ESBL negative Klebsiella pneumoniae 7 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID497947 | Antibacterial activity against methicillin-resistant Staphylococcus aureus by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID250257 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH01; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID573506 | Antibacterial activity against Klebsiella pneumoniae isolate Kp3799 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID573495 | Antibacterial activity against Citrobacter amalonaticus isolate Ca3927 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID584317 | Antimicrobial activity against azide-resistant Escherichia coli J53 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss. |
| AID564018 | Antibacterial activity against Pseudomonas aeruginosa isolated from wound infection of patient by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID285576 | Antimicrobial activity against Pseudomonas aeruginosa 65.18-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID519744 | Antibacterial activity against Klebsiella pneumoniae INSRA1229 harboring SHV-72 Ile8Phe, Ala146Val, and Lys234Arg mutations by agar dilution method in presence of 2 ug/ml clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID1373320 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-51 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID656448 | Antibacterial activity against Pseudomonas aeruginosa clinical isolate | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID519010 | Activity of Beta-lactamase TEM-149 T182M mutant expressed in Escherichia coli HB101 | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID516140 | Antibacterial activity against Pulsotype M Acinetobacter genomosp. 3 isolate 5 containing IMP-1, OXA-58, ADC-43, ISAba2, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID560590 | Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ798 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID1209736 | Inhibition of human OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4 | Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics. |
| AID529649 | Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-16 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID564532 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid with entire blaAmpC gene with alanine residue deletion at 215 position by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID574426 | Antimicrobial activity against Escherichia coli isolate 339T expressing beta-lactamase KPC2 and PFGE cluster 5 isolated from peritoneal fluid of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID534382 | Antibacterial activity against Escherichia coli K-12 W1895 transconjugant harboring pCF243 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate. |
| AID521991 | Antimicrobial activity against Klebsiella pneumoniae isolate Kp11978 expressing beta-lactamase OXA-48, SHV-2a and TEM-1 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID368718 | Unbound fraction in healthy human urine at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID369576 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii 06-74 isolate by CLSI microdilution test | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. |
| AID373206 | Antimicrobial activity against Bacillus clausii OC by agar-dilution technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID534391 | Antibacterial activity against Escherichia coli JM109 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate. |
| AID659488 | Antimicrobial activity against Klebsiella pneumoniae after 16 to 20 hrs by 2-fold microbroth dilution method | 2012 | Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4 | Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. |
| AID368722 | Volume of distribution in central compartment in healthy human by NPAG | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID532031 | Antimicrobial activity against Escherichia coli TOP10F' by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Novel chromosome-encoded CTX-M-78 beta-lactamase from a Kluyvera georgiana clinical isolate as a putative origin of CTX-M-25 subgroup. |
| AID518499 | Inhibition of Beta-lactamase IMP1 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID656446 | Antimicrobial activity against Klebsiella pneumoniae clinical isolate | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID250267 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH20; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID524258 | Activity at Escherichia coli beta-lactamase SHV-84 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID656356 | Antimicrobial activity against Citrobacter freundii | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID531756 | Antibacterial activity against Pseudomonas aeruginosa 2126 harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID495825 | Antimicrobial activity against Providencia stuartii 6858 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID571932 | Antimicrobial activity against Escherichia coli MC4100 harboring a weak promoter in beta-lactamase GES-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter. |
| AID573192 | Antimicrobial activity against mexD::lox-deficient Pseudomonas aeruginosa PAOMxD biofilm by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID495904 | Antimicrobial activity in Klebsiella pneumoniae DIH-2 clinical isolate expressing beta-lactamase VIM-19 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID497945 | Antibacterial activity against Stenotrophomonas maltophilia by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID560078 | Antimicrobial activity against Pseudomonas aeruginosa isolate 956 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID523504 | Antimicrobial activity against Pseudomonas aeruginosa isolate 15110c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID573202 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring deletion od C534 in nfxB mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID495804 | Antimicrobial activity against Klebsiella pneumoniae 2878 strain expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID565521 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-14 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID524264 | Antibacterial activity against Escherichia coli NKE158 harboring deletion mutation in acrB protein and vector expressing cpxAR gene | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID585198 | Antimicrobial activity against Escherichia coli DH5[alpha] by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID563974 | Activity of Klebsiella pneumoniae 05-560 beta-lactamase IMP1 by spectrophotometry | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID522011 | Antimicrobial activity against Klebsiella pneumoniae isolate KpE expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID560070 | Antimicrobial activity against Klebsiella pneumoniae isolate 5436 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID394691 | Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing PSE-1 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID373756 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab20 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID571936 | Antimicrobial activity against Escherichia coli MC4100 harboring weak promoter and active promoter P2 in beta-lactamase GES-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter. |
| AID518478 | Binding affinity to Escherichia coli Penicillin-binding protein 1A | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID522353 | Antibacterial activity against Pseudomonas aeruginosa PAO4290 harboring leu-10 argF10 aph-9004 FP(-) | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Tat pathway-mediated translocation of the sec pathway substrate protein MexA, an inner membrane component of the MexAB-OprM xenobiotic extrusion pump in Pseudomonas aeruginosa. |
| AID531334 | Antibacterial activity against Pseudomonas aeruginosa TNP030 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID565338 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-23 harboring A residue at 105 position in PDC- 5 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID498126 | Antibacterial activity against Pseudomonas aeruginosa PA880 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID585179 | Activity of Beta-lactamase GES-6 K104, S170 mutant | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID560058 | Antimicrobial activity against ESBL-producing Klebsiella pneumoniae by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID125420 | In vitro antibacterial activity against CMC-84-38 strain of Morganella morganii | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID562741 | Antimicrobial activity against Escherichia coli DH5[alpha] by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID429079 | Antibacterial activity against Klebsiella pneumoniae Greece producing KPC-2 beta-lactamase by E test method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece. |
| AID554405 | Antimicrobial activity against Pseudomonas aeruginosa isolate 3020R expressing inactivated mexB gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID535697 | Antimicrobial activity against Azide-resistant Escherichia coli J53 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. |
| AID530348 | Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID588209 | Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset | 2010 | Chemical research in toxicology, Jul-19, Volume: 23, Issue:7 | Developing structure-activity relationships for the prediction of hepatotoxicity. |
| AID495837 | Antimicrobial activity against Escherichia coli harbouring plasmidBK-CMV expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID531767 | Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4682-1 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID573505 | Antibacterial activity against Enterobacter cloacae isolate El3799 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1357429 | Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli isolate 208687 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria. |
| AID529658 | Ratio of Kcat to Km for Pseudomonas aeruginosa 166301 beta-lactamase VIM-16 | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID544495 | Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-2 to MIC for Escherichia coli TOP10 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID517948 | Antimicrobial activity against Citrobacter freundii by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID567306 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2204 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID656360 | Antimicrobial activity against Stenotrophomonas maltophilia | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID558326 | Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1962 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID565513 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-22 harboring A residue at 105 position in PDC- 4 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID425652 | Total body clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Physicochemical determinants of human renal clearance. |
| AID1373286 | Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-3 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID562809 | Antimicrobial activity against Escherichia coli J53 | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID556343 | Activity of Escherichia coli beta-lactamase CTX-M-16 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID523514 | Antimicrobial activity against Pseudomonas aeruginosa isolate 12102 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID524256 | Activity at Escherichia coli beta-lactamase SHV-1 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID428266 | Antimicrobial activity against carbapenemase producing Enterobacteriaceae by CLSI broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID541022 | Activity at Burkholderia cenocepacia 07-34 beta-lactamase PenB1 expressed in Escherichia coli Top10 by UV-spectrophotometry | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID534526 | Antimicrobial activity against Bacillus subtilis KCTC 2213 after 18 hrs by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases. |
| AID517971 | Antimicrobial activity against Pseudomonas aeruginosa 1973E harboring beta-lactamase PSE-1 and class C enzymes by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID565526 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-09 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID495635 | Activity of Pseudomonas luteola LAM Beta-lactamase LUT-1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. |
| AID522385 | Antimicrobial activity against Aeromonas enteropelogenes M1 hyperproducing beta-lactamase AmpC | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes. |
| AID1373361 | Protein binding in rat plasma | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID518519 | Antimicrobial activity against Capnocytophaga sputigena isolate NOR after 2 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena. |
| AID525550 | Antimicrobial activity against ampicillin resistant serotype-e Haemophilus influenzae isolate BB1053 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination. |
| AID571898 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 13 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID564015 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring Pseudomonas aeruginosa plasmid DNA lung biopsy specimen of patient by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID560073 | Antimicrobial activity against Enterobacter cloacae isolate 4073 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID562331 | Antimicrobial activity against Escherichia coli DH5alpha harboring metallo-beta-lactamase IND-6 after 18 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. |
| AID405633 | Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 1b | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. |
| AID1373362 | Protein binding in dog plasma | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID554398 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2804 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID533567 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA465 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID428273 | Antimicrobial activity against carbapenemase producing Enterobacter sp. assessed as susceptible isolates by CLSI breakpoint assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID563971 | Antibacterial activity against Escherichia coli NF-NDM-1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID341108 | Antibacterial activity against Escherichia coli 26R793 by Etest | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12. |
| AID573332 | Antibacterial activity against Klebsiella pneumoniae isolate Kp2730 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 and dfrA12-orfF-aadA2 arrays by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID573207 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB G461A mutant gene selected at 4 ug/ml of azithromycin after 5 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID656361 | Antimicrobial activity against Acinetobacter sp. | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID1395495 | Antibacterial activity against carbapenem-resistant Acinetobacter calcoaceticus 12-6 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria. |
| AID495912 | Hydrolytic activity of beta-lactamase VIM-19 expressed in Escherichia coli TOP10 by spectrophotometry | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID522358 | Antibacterial activity against tatC deficient Pseudomonas aeruginosa TNP080 transformant harboring pPlcMexA carrying chimeric mexA gene with plcH signal sequence | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Tat pathway-mediated translocation of the sec pathway substrate protein MexA, an inner membrane component of the MexAB-OprM xenobiotic extrusion pump in Pseudomonas aeruginosa. |
| AID555191 | Ratio of MIC for Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox deltaampDh3::lox deltanagZ::Gm to MIC for nagZ gene-deficient Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID498092 | Antibacterial activity against Pseudomonas aeruginosa PA876 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID517978 | Antimicrobial activity against Pseudomonas aeruginosa HPA101-1477 harboring beta-lactamase IMP-1 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID517953 | Antimicrobial activity against Escherichia coli by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID563975 | Ratio of Kcat to Km for Klebsiella pneumoniae 05-560 beta-lactamase IMP1 | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID517954 | Antimicrobial activity against Klebsiella oxytoca by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID1649584 | Antimicrobial activity against Escherichia coli clinical isolates by standard broth microdilution method | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11 | A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli. |
| AID509869 | Antibacterial activity against Acinetobacter baumannii isolate 4860 isolated from human urine | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID588211 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID1139446 | Antibacterial activity against Escherichia coli EC-28 by CLSI broth microdilution method | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Siderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteria. |
| AID373205 | Antimicrobial activity against Bacillus clausii T by agar-dilution technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID564531 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid with entire blaAmpC gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID374022 | Activity of Serratia fonticola UTAD54 SFC1 beta lactamase expressed in Escherichia coli BL21(DE3) by SDS-PAGE | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase. |
| AID497950 | Antibacterial activity against Pseudomonas aeruginosa PA1042 assessed as inhibition of biofilm formation by microtiter plate reader assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID573514 | Antibacterial activity against Klebsiella pneumoniae isolate Kp149 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID498088 | Antibacterial activity against Pseudomonas aeruginosa PA880 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID518481 | Binding affinity to Escherichia coli Penicillin-binding protein 3 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID659487 | Antimicrobial activity against Escherichia coli after 16 to 20 hrs by 2-fold microbroth dilution method | 2012 | Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4 | Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. |
| AID324310 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa isolate | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. |
| AID523499 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1247c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID534528 | Antimicrobial activity against vancomycin-resistant Enterococcus faecium CCARM 5028 after 18 hrs by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases. |
| AID522379 | Antimicrobial activity against blaKPC-possessing Klebsiella pneumoniae isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniae isolates. |
| AID495910 | Antimicrobial activity in Escherichia coli TOP10 strain | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID529488 | Antimicrobial activity against Enterobacter cloacae isolate 625 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID572142 | Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 38 expressing ampC, ompA, adeB, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID322316 | Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID567312 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2203 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID519629 | Antimicrobial activity against Escherichia coli JM83 without producing beta-lactamase OXA-63 after 3 days by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442. |
| AID540217 | Volume of distribution at steady state in dog after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID554391 | Antimicrobial activity against Pseudomonas aeruginosa isolate 615R obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID444057 | Fraction escaping hepatic elimination in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID498125 | Antibacterial activity against Pseudomonas aeruginosa PA5043 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID571886 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 7 expressing ampC, ompA, adeB, adeM, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID498121 | Antibacterial activity against Pseudomonas aeruginosa PA1054 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID554408 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2721 expressing inactivated mexB gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID533759 | Antibacterial activity against OXA-10, PSE-1, VIM-2 and PER-1 producing Pseudomonas aeruginosa isolate P22 exhibiting PFGE F pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID1733051 | Antibacterial activity against Escherichia coli clinical isolate assessed as reduction in bacterial growth by CLSI based broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 39 | Synthesis and antibacterial evaluation of new monobactams. |
| AID1373316 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-18 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID587965 | Activity of Escherichia coli beta-lactamase Toho-1 C69A mutant assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID576071 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 50748 harboring porin OmpK36 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID567287 | Antimicrobial activity against Acinetobacter baumannii beta-lactamase by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID559903 | Antimicrobial activity against Escherichia coli TF-KO281 harboring beta-lactamase OXY-1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | First detection of plasmid-encoded blaOXY beta-lactamase. |
| AID565546 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-10 harboring A residue at 105 position in PDC- 2 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID573187 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMS biofilm by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID520881 | Antibacterial activity against Escherichia coli TOP10 harboring recombinant p6S3 expressing beta lactamase OXA-114a by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID531683 | Antimicrobial activity against Acinetobacter baumannii ATCC 15151T by broth dilution test | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii. |
| AID584316 | Antimicrobial activity against beta-lactamase AmpC producing meropenem-resistant Serratia marcescens by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss. |
| AID585196 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-6 K104, S170 mutant by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID394689 | Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing PSE-1, MexXY-OprM pump by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID529490 | Antimicrobial activity against Enterobacter cloacae isolate 354 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID1733057 | Antibacterial activity against Acinetobacter baumannii clinical isolate assessed as reduction in bacterial growth by CLSI based broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 39 | Synthesis and antibacterial evaluation of new monobactams. |
| AID518472 | Binding affinity to Beta-lactamase IMP1 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID285443 | Ratio of kcat to Km of Citrobacter gillenii CIP 106783 Beta-lactamase GIL1 expressed in Escherichia coli DH10B relative to benzyl-penicillin | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii. |
| AID508741 | Antibacterial activity against Pseudomonas aeruginosa assessed as percent nonsusceptible isolates by broth microdilution assay | 2010 | Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2 | Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. |
| AID584839 | Antimicrobial activity against Escherichia coli DH10B by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila. |
| AID573515 | Antibacterial activity against Serratia marcescens isolate Sm220 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID529494 | Antimicrobial activity against Enterobacter cloacae isolate 837 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID560079 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1019 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID340728 | Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-9 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. |
| AID564527 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID368700 | Drug level in healthy human serum at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID323041 | Antimicrobial activity against extended-spectrum-beta-lactamase producing Proteus mirabilis isolates | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. |
| AID532405 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone G isolate NA-14X-13 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID573194 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 A biofilm harboring duplication mutation at nucleotide 333 in nfxB gene selected at 0.5 ug/ml of azithromycin by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID250265 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH18; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID565538 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-02 harboring T residue at 105 position in PDC- 1, and polymorphic OprD gene by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID573520 | Antibacterial activity against Klebsiella pneumoniae isolate Kp266 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID518520 | Antimicrobial activity against Escherichia coli TOP10(pNOR-1) expressing CSP-1 gene after 2 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena. |
| AID555671 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring recombinant plasmid carrying CTX-M-53 gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID583651 | Antibacterial activity against Escherichia coli isolate 271 | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. |
| AID565527 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-08 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID518523 | Antimicrobial activity against Escherichia coli TOP10 after 2 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena. |
| AID531776 | Antimicrobial activity against Pseudomonas aeruginosa catheter isolate 4680 containing PFGE clone A2 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID1782792 | Antibacterial activity against 98 member subset of carbapenem resistant Acinetobacter baumannii assessed as assessed as inhibition of bacterial growth by microdilution method | 2021 | European journal of medicinal chemistry, Aug-05, Volume: 220 | A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp. |
| AID285265 | Antimicrobial activity against Escherichia coli DH5-alpha isolate expressing pBK-CMV by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID534302 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA479 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID571914 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 21 expressing ampC, ompA, adeB, adeM, aacC2, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID571916 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 22 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1373338 | Volume of distribution in mouse at 2.5 mg/kg, iv | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID405089 | Antibacterial activity against blaVIM2-harboring integrons containing Pseudomonas aeruginosa 42 isolate from ventilator-associated pneumonia patient | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | blaVIM-2-harboring integrons isolated in India, Russia, and the United States arise from an ancestral class 1 integron predating the formation of the 3' conserved sequence. |
| AID405818 | Antimicrobial activity against Acinetobacter sp. 5248 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID531748 | Antibacterial activity against Pseudomonas aeruginosa EryR harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID529456 | Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone A expressing beta-lactamase Oxa-48, TEM-1, SHV-12 and Oxa-9 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID495517 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4675 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID372608 | Antibacterial activity against Escherichia coli DH5alpha producing beta-lactamase TEM-12 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID1373285 | Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-2 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID340726 | Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-15 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. |
| AID571938 | Antimicrobial activity against Escherichia coli MC4100 harboring promoter hybrid 1 and active promoter P2 in beta-lactamase GES-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter. |
| AID525546 | Antimicrobial activity against Haemophilus influenzae Rd KW20 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination. |
| AID285266 | Activity of Escherichia coli BL21(DE3) beta-lactamase TEM151 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID322325 | Antibacterial activity against Escherichia coli DH5 alpha-URA5924 isolates expressing CTX-M-32 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID1373315 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-10 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID532402 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D4 isolate VA-06X-47 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID394683 | Antibacterial activity against Pseudomonas aeruginosa clinical isolate by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID520388 | Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 metallo-beta lactamase VIM-2 | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain. |
| AID572136 | Antimicrobial activity against Acinetobacter baumannii eta clonal group isolate 35 expressing ampC, ompA, adeB, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID285590 | Antimicrobial activity against Pseudomonas aeruginosa 65.38-1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID543415 | Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 transconjugant by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime. |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID565717 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-22 harboring A residue at 105 position in PDC- 4 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID582977 | Antimicrobial activity against ampD::lox, ampDh2::lox and ampDh3::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID572144 | Antimicrobial activity against Acinetobacter baumannii unique clonal group isolate 39 expressing ampC, ompA, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID324361 | Activity of Acinetobacter johnsonii SCO1 | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina. |
| AID532396 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A3 isolate FG-17X-08 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID1357459 | Antibacterial activity against IMP-4 producing Pseudomonas aeruginosa isolate 209471 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria. |
| AID573189 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1278319 | Antibacterial activity against ESBL positive Klebsiella pneumoniae 09-25 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID405090 | Antimicrobial activity against integron carrying Enterobacteriaceae assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome. |
| AID520969 | Antibacterial activity against Klebsiella pneumoniae GR by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID532903 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 ST 376 expressing beta-lactamase SHV-1 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID529653 | Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID498093 | Antibacterial activity against Pseudomonas aeruginosa PA861 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1373317 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-23 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID524385 | Antibacterial activity against Escherichia coli NKE156 harboring deletion mutation in acrB protein and vector expressing acrD gene | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID1592959 | Antibacterial activity against multi-drug resistant Klebsiella pneumoniae NMI 2697/14 assessed as reduction in microbial growth incubated for 20 hrs | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae. |
| AID517964 | Antimicrobial activity against Escherichia coli HB101 harboring beta-lactamase TEM-5 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID517968 | Antimicrobial activity against Escherichia coli A harboring beta-lactamase CTX-M 15 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID523492 | Antimicrobial activity against Pseudomonas aeruginosa 2779-con by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID555225 | Activity of Acinetobacter genomosp. 3 isolate 103 ADC-16 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID405080 | Antimicrobial activity against Citrobacter freundii 33587 isolate by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Biochemical characterization of PER-2 and genetic environment of blaPER-2. |
| AID571918 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 23 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, aphA6 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID565539 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-03 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID520976 | Antibacterial activity against Pseudomonas aeruginosa KG2505 harboring pCOL plasmid by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID588212 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID424858 | Antimicrobial activity against Pseudomonas aeruginosa GY3 producing blaVIM-2 by E-test | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID394491 | Inhibition of Escherichia coli beta-lactamase ACC4 | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID583097 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 A64W mutant beta-lactamase by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding. |
| AID163896 | In vitro antibacterial activity against CMC-83-3 strain of Providencia stuartii | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID1373346 | AUC in mouse at 2.5 mg/kg, iv | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID495822 | Antimicrobial activity against Klebsiella pneumoniae 6828 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID532029 | Antimicrobial activity against Escherichia coli TOP10F' transformant harboring beta-lactamase CTX-M-78 by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Novel chromosome-encoded CTX-M-78 beta-lactamase from a Kluyvera georgiana clinical isolate as a putative origin of CTX-M-25 subgroup. |
| AID584848 | Ratio of Kcat to Km for Aeromonas allosaccharophila AL-1 beta-lactamase PER2 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila. |
| AID519811 | Inhibition of Bocillin FL binding to PBP1A in Pseudomonas aeruginosa 27853 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID540216 | Clearance in dog after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID285600 | Antimicrobial activity against Pseudomonas aeruginosa 2C2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID495509 | Antibacterial activity against Acinetobacter baumannii BM4587 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID555686 | Antimicrobial activity against Escherichia coli ATCC 25922 by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID495797 | Activity at Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B carrying pSau1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France. |
| AID523507 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1495c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID518521 | Antimicrobial activity against Capnocytophaga sputigena CRBIP 17.39 after 2 days by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Characterization of CSP-1, a novel extended-spectrum beta-lactamase produced by a clinical isolate of Capnocytophaga sputigena. |
| AID1373326 | Antimicrobial activity against ESBL, KPC and MBL producing Enterobacteriaceae by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID373767 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh17 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID495792 | Antimicrobial activity against Escherichia coli DH10B harbouring recombinant plasmid pSau1 expressing beta-lactamase BIC-1 from Pseudomonas fluorescens PF-1 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France. |
| AID498099 | Antibacterial activity against Pseudomonas aeruginosa PA5043 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID761210 | Antibacterial activity against Klebsiella pneumoniae expressing KPC by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID1733055 | Antibacterial activity against Enterobacter cloacae clinical isolate assessed as reduction in bacterial growth by CLSI based broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 39 | Synthesis and antibacterial evaluation of new monobactams. |
| AID531974 | Antibacterial activity against Escherichia coli DH10B by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. |
| AID565711 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-16 harboring A residue at 105 position in PDC- 3 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID530813 | Antibacterial activity against Escherichia coli J53 harboring plasmid pA-1carrying beta-lactamase OXA-48 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. |
| AID498133 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID519799 | Inhibition of Bocillin FL binding to PBP3 in Escherichia coli MC4100 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID1373298 | Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID558538 | Antibacterial activity against bla-positive and beta-lactamase-weakly positive Campylobacter coli isolate P1627 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID543427 | Antimicrobial activity against Escherichia coli XL-1 Blue harboring plasmid CL1920 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime. |
| AID517985 | Antimicrobial activity against Pseudomonas aeruginosa BA harboring beta-lactamase Class C by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID565511 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-29 harboring A residue at 105 position in PDC- 8 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1278324 | Antibacterial activity against ESBL negative Escherichia coli 25922 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID394698 | Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, TEM-2 by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID495511 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4665 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID529481 | Antimicrobial activity against Enterobacter cloacae isolate 18 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID369643 | Antibacterial activity against Acinetobacter haemolyticus expressing carbapenemase-encoding blaOXA-40 gene by Etest method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital. |
| AID70796 | In vitro antibacterial activity against VGH-84-19 strain of Escherichia coli | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID524593 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolate Kpn-DK2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea. |
| AID1443410 | Antibacterial activity against extended spectrum beta-lactamases producing Escherichia coli clinical isolates after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections. |
| AID511289 | Antibacterial activity against Escherichia coli DH5alpha pB-ges-1 | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. |
| AID1373340 | Volume of distribution in dog at 10 mg/kg, iv | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID1198142 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 ARC545 by broth microdilution method | 2015 | Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5 | Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model. |
| AID405819 | Antimicrobial activity against Acinetobacter sp. 5227 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID1209734 | Inhibition of mouse OAT1 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4 | Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics. |
| AID660262 | Ratio of MIC for wild type Escherichia coli TG1 to MIC for acrB-deficient Escherichia coli KAM3 by two-fold serial dilution method | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics. |
| AID498306 | Antibacterial activity against Pseudomonas aeruginosa PA5043 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID586085 | Antimicrobial activity against verocytotoxin-producing Escherichia coli isolate O157 obtained from human assessed as percentage of resistant isolates by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26. |
| AID564524 | Antimicrobial activity against Acinetobacter baumannii KI by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID531314 | Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. |
| AID1373307 | Antimicrobial activity against Escherichia coli expressing beta-lactamase NDM-5 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID522356 | Antibacterial activity against tatC deficient Pseudomonas aeruginosa TNP080 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Tat pathway-mediated translocation of the sec pathway substrate protein MexA, an inner membrane component of the MexAB-OprM xenobiotic extrusion pump in Pseudomonas aeruginosa. |
| AID573208 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB C116T mutant gene selected at 4 ug/ml of azithromycin after 5 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID656443 | Antimicrobial activity against CTX-M-positive extended spectrum beta-lactamase-producing Escherichia coli | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID518724 | Antimicrobial activity against Escherichia coli TOP10 harboring beta-lactamase DIM-1 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands. |
| AID535727 | Antibacterial activity against Klebsiella pneumoniae urine isolate A28011 PFGE pattern A expressing KPC-2 CTX-M-2 beta-lactamase by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. |
| AID530321 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SD2 harboring blaVIM-1 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID285605 | Antimicrobial activity against Pseudomonas aeruginosa 2F6 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1541985 | Oral bioavailability in human at 500 mg administered as solution measured 16 hrs post dosing | 2020 | ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2 | Toward Orally Absorbed Prodrugs of the Antibiotic Aztreonam. Design of Novel Prodrugs of Sulfate Containing Drugs. Part 2. |
| AID1476620 | Antibacterial activity against Acinetobacter baumannii ATCC BAA 1797 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID559900 | Antimicrobial activity against Klebsiella pneumoniae 278 harboring beta-lactamase OXY-1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | First detection of plasmid-encoded blaOXY beta-lactamase. |
| AID534527 | Antimicrobial activity against Micrococcus luteus KCTC 9341 after 18 hrs by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases. |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID279812 | Antimicrobial activity against carbapenem-resistant Klebsiella pneumoniae ZR01 from patient sputum by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. |
| AID534291 | Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring pRK-G plasmid and ampN with xylE-Gmomega cassette insertion by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID573191 | Antimicrobial activity against mutS::lox,nfxB gene-deficient Pseudomonas aeruginosa PAOMSNB biofilm by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID588214 | FDA HLAED, liver enzyme composite activity | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID532416 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-11 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID1649583 | Antimicrobial activity against Klebsiella pneumoniae clinical isolates by standard broth microdilution method | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11 | A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli. |
| AID678716 | Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID546621 | Antimicrobial activity against Escherichia coli harboring plasmid pPCRScript by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID341107 | Antibacterial activity against Escherichia coli transconjugant carrying pEC28 isolate eby Etest | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | First occurrence of an Escherichia coli clinical isolate producing the VIM-1/VIM-2 hybrid metallo-beta-lactamase VIM-12. |
| AID554400 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2933 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID560131 | Activity of recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID405085 | Ratio of Kcat to Km of Citrobacter freundii PER2 beta lactamase | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Biochemical characterization of PER-2 and genetic environment of blaPER-2. |
| AID498130 | Antibacterial activity against Pseudomonas aeruginosa PA876 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID529498 | Antimicrobial activity against Escherichia coli T-781 harboring expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID560592 | Antimicrobial activity against multidrug resistant Pseudomonas aeruginosa isolate IMCJ2S1 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID1198151 | Plasma protein binding in Wistar Han rat as percentage unbound | 2015 | Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5 | Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model. |
| AID520878 | Antibacterial activity against Achromobacter xylosoxidans LOL by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID520777 | Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K10 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID373759 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1316 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID576311 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 29830 harboring porin OmpK36V mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID517970 | Antimicrobial activity against Klebsiella oxytoca 1028E harboring beta-lactamase K1 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID467611 | Dissociation constant, pKa of the compound | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data. |
| AID524261 | Antibacterial activity against Escherichia coli NKE154 harboring vector expressing acrB deletion mutant | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID531769 | Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4698 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID560088 | Bactericidal activity against Pseudomonas aeruginosa isolate 1037 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID529573 | Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid pLBII carrying beta-lactamase CAR-1 gene after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID373762 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii ab1266 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID531604 | Activity of Escherichia coli Inhibitor-resistant beta-lactamase SHV-56 | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID564534 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid carrying entire blaAmpC gene with alanine residue deletion at 215 position and R210P substitution by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID555555 | Antimicrobial activity against Pseudomonas aeruginosa isolate 26285 expressing IMP-13 beta lactamase gene by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID560074 | Antimicrobial activity against Enterobacter cloacae isolate 5420 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID476929 | Human intestinal absorption in po dosed human | 2010 | European journal of medicinal chemistry, Mar, Volume: 45, Issue:3 | Neural computational prediction of oral drug absorption based on CODES 2D descriptors. |
| AID405790 | Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. |
| AID517959 | Antimicrobial activity against Acinetobacter sp. by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID495664 | Ratio of Kcat to Km for Pseudomonas aeruginosa 51170 beta-lactamase BEL-1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID322315 | Antibacterial activity against CTX-M group 1 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID529461 | Antimicrobial activity against Escherichia coli J53 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID560274 | Toxicity in Pseudomonas aeruginosa ATCC 27853 infected Swiss mouse | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. |
| AID555206 | Antimicrobial activity against ampD gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID1278500 | Antibacterial activity against Proteus sp. at 30 ug/ml by disc diffusion method | 2016 | Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5 | Metal-based biologically active azoles and β-lactams derived from sulfa drugs. |
| AID1891023 | Antibacterial activity against Escherichia coli 308 producing SHV-5 assessed as inhibition of bacterial growth by CLSI based broth microdilution method | 2022 | Bioorganic & medicinal chemistry, 05-15, Volume: 62 | Broad-spectrum cyclic boronate β-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability. |
| AID285268 | Activity of Escherichia coli BL21(DE3) beta-lactamase TEM152 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID565715 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-20 harboring A residue at 105 position in PDC- 4 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID554427 | Ratio of MIC for mexB deficient Pseudomonas aeruginosa FB1 mutant to Pseudomonas aeruginosa PAO1 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID565710 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-15 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID1395494 | Antibacterial activity against new delhi metallo-beta-lactamase-1 harboring Acinetobacter calcoaceticus 13-1 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria. |
| AID283218 | Antimicrobial susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patient assessed as percent susceptible isolates | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. |
| AID498131 | Antibacterial activity against Pseudomonas aeruginosa PA861 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID583095 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 W87A mutant beta-lactamase by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding. |
| AID498094 | Antibacterial activity against Pseudomonas aeruginosa PA5020 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1278316 | Antibacterial activity against BL positive Pseudomonas aeruginosa 09-14 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID582975 | Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID522019 | Antimicrobial activity against Enterobacter cloacae isolate 1 expressing beta-lactamase OXA-48 and SHV-5 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID534301 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA460 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID761247 | Antibacterial activity against Pseudomonas aeruginosa from cystic fibrosis patients by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID560705 | Inhibition of Escherichia coli MC4100 Beta-Lactamase CMY-30 using cephalothin as reporter substrate | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase. |
| AID587973 | Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 D240A mutant assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID582973 | Antimicrobial activity against dacB::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID540215 | Volume of distribution at steady state in rat after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID521285 | Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype I by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID519734 | Antibacterial activity against Escherichia coli DH5alpha with deltaampC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID561447 | Antibacterial activity against Escherichia coli DH10B harboring plasmid BCSK by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. |
| AID1373328 | Antimicrobial activity against Pseudomonas aeruginosa expressing delta-mexB/delta-mexXY/delta-mexCD and delta-ampC mutant by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID587968 | Ratio of Kcat to Km for Escherichia coli wild type beta-lactamase Toho-1 assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID541010 | Antimicrobial activity against Burkholderia cenocepacia 212 expressing beta-lactamase PenB3 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID571904 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 16 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID582970 | Antimicrobial activity against nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID519802 | Inhibition of Bocillin FL binding to PBP6 in Escherichia coli MC4100 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID587977 | Antibacterial activity against Escherichia coli AS226 carrying pBSD-H2 after 18 hrs by broth microdilution method | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID444053 | Renal clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID498119 | Antibacterial activity against Pseudomonas aeruginosa PA5020 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID467612 | Fraction unbound in human plasma | 2009 | European journal of medicinal chemistry, Nov, Volume: 44, Issue:11 | Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data. |
| AID519805 | Inhibition of Bocillin FL binding to PBP1B in Pseudomonas aeruginosa PAO1 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID556344 | Activity of Escherichia coli beta-lactamase CTX-M-27 | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID567309 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2207 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID372619 | Activity of Escherichia coli DH5alpha beta-lactamase TEM-1 by microacidimetric method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID576290 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 6267 harboring porin OmpK36V mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID518188 | Antimicrobial activity against Acinetobacter baumannii HPA I-16 harboring beta-lactamase OXA-27 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID587963 | Activity of Escherichia coli beta-lactamase Toho-1 D240S mutant assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID522013 | Antimicrobial activity against Klebsiella pneumoniae isolate KpBEL expressing beta-lactamase OXA-48 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID520966 | Antibacterial activity against Klebsiella pneumoniae YC by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID761207 | Antibacterial activity against Escherichia coli expressing defined beta-lactamase by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID522008 | Antimicrobial activity against Escherichia coli isolate J53 harboring pI-2 containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID660265 | Antimicrobial activity against wild type Escherichia coli expressing AcrAB-TolC efflux pump | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics. |
| AID1373281 | Antimicrobial activity against Escherichia coli expressing beta-lactamase CTXM-3 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID285263 | Antimicrobial activity against Escherichia coli DH5-alpha TC1295 isolate expressing TEM-1 by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID544497 | Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-5 to MIC for Escherichia coli TOP10 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID374361 | Antimicrobial activity against Escherichia coli DH5alpha expressing pJDB2 containing Aeromonas caviae A324R metallo-beta-lactamase gene by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France. |
| AID524382 | Antibacterial activity against Escherichia coli NKE160 harboring deletion mutation in acrB protein and vector expressing tolC gene | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID656357 | Antimicrobial activity against Enterobacter aerogenes | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID250270 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH23; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID368706 | Volume of distribution of central compartment in healthy human at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID519007 | Antimicrobial activity against Escherichia coli HB101 expressing plasmid encoded TEM-149 T182M mutant by broth macrodilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID534534 | Antimicrobial activity against Salmonella enterica KCTC 2930 after 18 hrs by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases. |
| AID565549 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-13 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID531976 | Antibacterial activity against Escherichia coli DH10B expressing KPC-2 CTX-M-2 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. |
| AID1357421 | Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli isolate 212648 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria. |
| AID583093 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pBC-SK plasmid by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding. |
| AID396030 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP2 plasmid containing Enterobacter cloacae acrA gene by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID1373304 | Antimicrobial activity against Escherichia coli expressing beta-lactamase GIM-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID531766 | Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4677 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID1373306 | Antimicrobial activity against Escherichia coli expressing beta-lactamase NDM-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID529495 | Antimicrobial activity against Enterobacter cloacae isolate 4469 containing PFGE genetic clone C expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID509866 | Antibacterial activity against Acinetobacter baumannii isolate 510 isolated from human sputum | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID66236 | In vitro antibacterial activity against VGH-84-39 strain of Enterobacter cloacae | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID531316 | Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. |
| AID531772 | Antimicrobial activity against Pseudomonas aeruginosa pleural fluid isolate 4679 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID532411 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate PV-05X-02 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID523489 | Antimicrobial activity against Pseudomonas aeruginosa R20 Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID585178 | Activity of Beta-lactamase GES-5 E104, S170 mutant | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID511583 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD2 harboring oprD spontaneous mutant selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID544491 | Antibacterial activity against Escherichia coli TOP10 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID368719 | Protein binding in human cystic fibrosis patient serum at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID529462 | Antimicrobial activity against Klebsiella pneumoniae isolate 11 expressing beta-lactamase Oxa-48, TEM-1 and Oxa-1 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID373752 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab3 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID373751 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ATCC 19606 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID1373309 | Antimicrobial activity against Escherichia coli expressing beta-lactamase VIM-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID285580 | Antimicrobial activity against Pseudomonas aeruginosa IC7 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID520805 | Antimicrobial activity against Escherichia coli str. K-12 substr. DH10B harboring plasmid CTX-M-59 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID573190 | Antimicrobial activity against nfxB gene-deficient Pseudomonas aeruginosa PAONB biofilm by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1373356 | Clearance in dog at 10 mg/kg, iv | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID520707 | Antibacterial activity against Acinetobacter baumannii phenotype 2 by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97. |
| AID571038 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA24 obtained from patient with cystic fibrosis by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID541019 | Antimicrobial activity against Escherichia coli TOP10 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID560092 | Bactericidal activity against Klebsiella pneumoniae isolate 5436 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID285366 | Susceptibility of metallo beta lactamase and extended spectrum beta lactamase deficient qnr positive Enterobacter cloacae assessed as percentage nonsusceptible isolates | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Prevalence of plasmid-mediated quinolone resistance determinants QnrA, QnrB, and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital. |
| AID544490 | Antibacterial activity against Pseudomonas aeruginosa PR280 harboring beta-lactamase KPC-5 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID498090 | Antibacterial activity against Pseudomonas aeruginosa PA1036 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID529663 | Activity of Pseudomonas aeruginosa 166301 beta-lactamase VIM-16 relative to cephaloridine | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID324358 | Antibacterial activity against Escherichia coli DH10B expressing SCO1 by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina. |
| AID1733058 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 assessed as reduction in bacterial growth by CLSI based broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 39 | Synthesis and antibacterial evaluation of new monobactams. |
| AID523517 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1665 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID582763 | Antimicrobial activity against eaeA positive verocytotoxin-producing non-O157 Escherichia coli isolates obtained from human assessed as percentage of resistant isolates | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26. |
| AID405791 | Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 4 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. |
| AID534299 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA510 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID546428 | Activity at Pseudomonas aeruginosa PDC-3 by spectrophotometer | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. |
| AID571032 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID373766 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh14 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID495634 | Antimicrobial activity against Escherichia coli DH10B by Etest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. |
| AID497951 | Antibacterial activity against Pseudomonas aeruginosa PA5063 assessed as inhibition of biofilm formation by microtiter plate reader assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1278334 | Antibacterial activity against beta-lactamase producing Enterobacter aerogenes 45102 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID341593 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 469 isolate producing KPC2, OXA4 and CTX-M-10 carbapenemases | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. |
| AID521486 | Antibacterial activity against Escherichia coli harboring pBC2303 expressing blaKPC gene plasmid by Etest method in presence of beta-lactamase inhibitor clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID533001 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa isolate P67 exhibiting PFGE J pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID1198153 | Volume of distribution at steady state in Wistar Han rat at 1 mg/kg, iv infusion | 2015 | Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5 | Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model. |
| AID559685 | Antibacterial activity against Acinetobacter baumannii BM4652 harboring plasmid IP847 | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. |
| AID567303 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2201 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID573209 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB G539A mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID761212 | Antibacterial activity against Klebsiella pneumoniae expressing defined beta-lactamase by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID577650 | Antimicrobial activity against Escherichia coli isolate 329T expressing beta-lactamase KPC2 and PFGE cluster 2 isolated from blood of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID405640 | Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 2 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. |
| AID573522 | Antibacterial activity against Citrobacter koseri isolate Ck211 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID546620 | Antimicrobial activity against Escherichia coli harboring beta-lactamase VIM-2 by Etest | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID1139448 | Antibacterial activity against Pseudomonas aeruginosa 1091-05 by CLSI broth microdilution method | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Siderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteria. |
| AID521426 | Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L1 beta lactamase gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID524386 | Antibacterial activity against Escherichia coli NKE157 harboring deletion mutation in acrB, acrD protein and plasmid expressing nlpE gene | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID368708 | Volume of distribution at steady state in healthy human at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID517966 | Antimicrobial activity against Escherichia coli CF102 harboring beta-lactamase TEM-3 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID405825 | Antimicrobial activity against Acinetobacter baumannii 694 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID531606 | Ratio of Kcat to Km for Escherichia coli Inhibitor-resistant beta-lactamase SHV-56 | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID520794 | Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype B by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID585197 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-13 K104, N170 mutant by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID530350 | Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID531335 | Antibacterial activity against Pseudomonas aeruginosa TNP030 selected after 1.0 ug/ml of azithromycin by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID498305 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID516141 | Antibacterial activity against Pulsotype K Acinetobacter genomosp. 3 isolate 6 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID555666 | Antimicrobial activity against Escherichia coli DH10B harboring natural plasmid pWES-1 carrying CTX-M-53 gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID1649582 | Antimicrobial activity against Pseudomonas aeruginosa clinical isolates by standard broth microdilution method | 2020 | Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11 | A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli. |
| AID531750 | Antibacterial activity against Pseudomonas aeruginosa FK06 harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID1476618 | Antibacterial activity against Acinetobacter baumannii ATCC 17961 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID558533 | Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1698 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID531775 | Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4659 containing PFGE clone A2 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID567315 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2206 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID560262 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. |
| AID372612 | Antibacterial activity against rifampin-resistant Escherichia coli C600 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID534388 | Antibacterial activity against Escherichia coli JM109 harboring recombinant pKHM-1 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate. |
| AID567314 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2205 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID587985 | Antibacterial activity against Escherichia coli AS226 carrying pBSD6 mutant after 18 hrs by broth microdilution method | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID498095 | Antibacterial activity against Pseudomonas aeruginosa PA1054 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID532401 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D3 isolate VA-06X-65 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID498118 | Antibacterial activity against Pseudomonas aeruginosa PA861 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID587966 | Activity of Escherichia coli beta-lactamase Toho-1 F160T mutant assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID495810 | Antimicrobial activity against Escherichia coli harbouring plasmid BK-CMV expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID495913 | Ratio of Kcat to Km for beta-lactamase VIM-19 expressed in Escherichia coli TOP10 by spectrophotometry | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID555205 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID573206 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T562C mutant gene selected at 4 ug/ml of azithromycin after 4 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID585180 | Activity of Beta-lactamase GES-13 K104, N170 mutant | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID1373310 | Antimicrobial activity against Escherichia coli expressing beta-lactamase AmpC by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID535702 | Antibacterial activity against Escherichia coli TOP10 expressing AmpC-A by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. |
| AID554443 | Antimicrobial activity against mexXY operon inactivated Pseudomonas aeruginosa PAO1 by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1782791 | Antibacterial activity against panel of 198 clinical isolates Acinetobacter baumannii assessed as inhibition of bacterial growth by microdilution method | 2021 | European journal of medicinal chemistry, Aug-05, Volume: 220 | A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp. |
| AID558048 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S11 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID1476609 | Antibacterial activity against Pseudomonas aeruginosa ARC 3502 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID497946 | Antibacterial activity against Alcaligenes xylosoxidans by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID520977 | Antibacterial activity against Escherichia coli DH10B expressing blaKPC gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID285689 | Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4012 isolate expressing carbapenemase KPC2 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. |
| AID424862 | Antimicrobial activity against carbapenem-susceptible Pseudomonas aeruginosa clinical isolate assessed as resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID425653 | Renal clearance in human | 2009 | Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15 | Physicochemical determinants of human renal clearance. |
| AID518485 | Ratio of Kcat to Km for Beta-lactamase IMP1 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID521282 | Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype F by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID250261 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH05; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID511291 | Activity of Pseudomonas aeruginosa GES-13 beta lactamase assessed as hydrolysis by spectrometry | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. |
| AID546429 | Activity at Pseudomonas aeruginosa PDC-5 by spectrophotometer | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. |
| AID587983 | Antibacterial activity against Escherichia coli AS226 carrying pBSDC69A mutant after 18 hrs by broth microdilution method | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID558046 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S9 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID584318 | Antimicrobial activity against Serratia marcescens ATCC 8100 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss. |
| AID519013 | Ratio of Kcat to Km for Beta-lactamase TEM-10 | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID558330 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P316 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID587976 | Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 G232A mutant assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID495905 | Antimicrobial activity in Escherichia coli TOP10 hourbouring recombinant plasmid VIM-19 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID534532 | Antimicrobial activity against Klebsiella oxytoca KCTC 1686 after 18 hrs by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases. |
| AID561627 | Antimicrobial activity against Stenotrophomonas maltophilia KJ by twofold serial agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID422493 | Antimicrobial activity against Carnobacterium divergens BM4490 expressing beta-lactamase CAD1 at 3 McFarland inoculum size by E-test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID250260 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH04; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID573528 | Antibacterial activity against Acinetobacter isolate A74510 harboring blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID519816 | Inhibition of Bocillin FL binding to PBP5/6 in Pseudomonas aeruginosa 27853 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID528599 | Antimicrobial activity against blaKPC-2 and blaTEM-1 producing Escherichia coli 2138 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID1373301 | Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-24 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID279182 | Antibacterial activity against Enterobacter cloacae S3 isolate by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1. |
| AID520967 | Antibacterial activity against Escherichia coli harboring pNYC plasmid expressing blaKPC gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID518824 | Antibacterial activity against Pulsotype L Acinetobacter genomosp. 3 isolate 2 containing IMP-8, OXA-58, ADC-43, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID531757 | Antibacterial activity against Pseudomonas aeruginosa 1956 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID565279 | Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A1 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID558040 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S3 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID529484 | Antimicrobial activity against Enterobacter cloacae isolate 185 containing PFGE genetic clone A expressing qnrB2 aac(6')-Ib-cr and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID495805 | Antimicrobial activity against Klebsiella pneumoniae 6828 strain expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID529662 | Ratio of Kcat to Km for Pseudomonas aeruginosa 9551 beta-lactamase VIM-15 relative to cephaloridine | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID1209735 | Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4 | Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics. |
| AID584838 | Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER2 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila. |
| AID571688 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 1 expressing ampC, ompA, adeB, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID546431 | Ratio of Kcat to Km for Pseudomonas aeruginosa PDC-2 by spectrophotometer | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. |
| AID555647 | Antimicrobial activity against ampDDh2 and ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs using 30 ug/ml by agar diffusion method in presence of 0.5 mM nagZ inhibitor EtBuPUG | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID534296 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA477 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID520802 | Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype J by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID561443 | Antibacterial activity against Escherichia coli 34943 harboring beta-lactamase CMY-44 gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. |
| AID372616 | Ratio of Kcat to Km for Escherichia coli DH5alpha beta-lactamase TEM-12 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID532906 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID374360 | Antimicrobial activity against Aeromonas caviae A324R by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France. |
| AID518505 | Inhibition of Escherichia coli Penicillin-binding protein 1A | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID562812 | Antimicrobial activity against Escherichia coli DH5[alpha] | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID678449 | Antibacterial activity against beta-lactam- and quinolone-resistant Pseudomonas aeruginosa 1042-06 | 2012 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18 | Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections. |
| AID576280 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17830 harboring porin OmpK36V mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID523509 | Antimicrobial activity against Pseudomonas aeruginosa isolate 15107 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID495793 | Antimicrobial activity against Escherichia coli DH10B by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID394685 | Antibacterial activity against wild type Pseudomonas aeruginosa isolate by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID444056 | Fraction escaping gut-wall elimination in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID523502 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1333c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID555207 | Antimicrobial activity against ampD gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID285604 | Antimicrobial activity against Pseudomonas aeruginosa 2A6 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID543423 | Antimicrobial activity against Escherichia coli XL-1 Blue transconjugant harboring beta-lactamase CTX-M-64 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime. |
| AID761217 | Antibacterial activity against Pseudomonas aeruginosa 1091-05 by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID528606 | Activity of Escherichia coli 2138 beta-lactamase KPC-2 by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID396028 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID509868 | Antibacterial activity against Acinetobacter baumannii isolate 2898 isolated from human ankle | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID576289 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 16855 harboring porin OmpK36 and OmpK35 genes by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID560093 | Bactericidal activity against Escherichia coli isolate 5401 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID425865 | Antimicrobial activity against Carnobacterium divergens BM4489 expressing beta-lactamase CAD1 at 0.5 McFarland inoculum size by E-test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID656353 | Antibacterial activity against imipenem-sensitive Pseudomonas aeruginosa isolate 1091-05 infected in sc dosed neutropenic-C3H/HeN mouse assessed as mouse survival administered 4 hrs post infection followed by BID dosing for two days measured on day 10 | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID522382 | Antimicrobial activity against blaKPC-possessing Klebsiella pneumoniae isolates assessed as susceptible isolates in presence of 4 ug/ml by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniae isolates. |
| AID541004 | Antimicrobial activity against Burkholderia cenocepacia 07-34 expressing beta-lactamase PenB1 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID524390 | Antibacterial activity against Escherichia coli NKE1316 harboring deletion mutation in acrB, acrD and mdtABC protein | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID394682 | Antibacterial activity against Pseudomonas aeruginosa clinical isolates assessed as resistant rate by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID531749 | Antibacterial activity against Pseudomonas aeruginosa FK06 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID678712 | Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID285439 | Antimicrobial activity against Citrobacter gillenii CIP 106783 after 18 hrs by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii. |
| AID571937 | Antimicrobial activity against Escherichia coli MC4100 harboring strong promoter and active promoter P2 in beta-lactamase GES-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter. |
| AID519743 | Antibacterial activity against Klebsiella pneumoniae INSRA1229 harboring SHV-72 Ile8Phe, Ala146Val, and Lys234Arg mutations by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID405820 | Antimicrobial activity against Acinetobacter baumannii 501 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID368912 | Clearance in healthy human by NPAG | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID522016 | Antimicrobial activity against Escherichia coli isolate J53 harboring pL containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID567308 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2206 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID761211 | Antibacterial activity against Klebsiella pneumoniae expressing ESBL by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID583192 | Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by broth microdilution method in presence of 5 mM NagZ inhibitor PUGNAc | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID1395490 | Antibacterial activity against extended-spectrum beta-lactamase harboring Escherichia coli CDC1001728 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria. |
| AID285267 | Activity of Escherichia coli BL21(DE3) beta-lactamase TEM29 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID546430 | Ratio of Kcat to Km for Pseudomonas aeruginosa PDC-1 by spectrophotometer | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. |
| AID533566 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA462 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID572138 | Antimicrobial activity against Acinetobacter baumannii eta clonal group isolate 36 expressing ampC, ompA, adeB, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID521489 | Antibacterial activity against Escherichia coli DH10B expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID1229258 | Unbound fraction in human plasma after 16 hrs by LC-MS/MS analysis | 2015 | ACS medicinal chemistry letters, May-14, Volume: 6, Issue:5 | SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3. |
| AID656359 | Antimicrobial activity against carbapenemase-producing Klebsiella pneumoniae | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID576317 | Antimicrobial activity against ESBL-negative Klebsiella pneumoniae 30018 harboring porin OmpK35 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID573504 | Antibacterial activity against Morganella morganii isolate Mm1229 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID560059 | Antimicrobial activity against AmpC-depressed Enterobacter cloacae by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID368911 | Volume of distribution in central compartment in human cystic fibrosis patient by NPAG | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID396032 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pAP3 plasmid containing Enterobacter aerogenes acrR gene by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID558327 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P285 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID565506 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-24 harboring A residue at 105 position in PDC- 5 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID519813 | Inhibition of Bocillin FL binding to PBP2 in Pseudomonas aeruginosa 27853 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID659489 | Antimicrobial activity against Acinetobacter sp. after 16 to 20 hrs by 2-fold microbroth dilution method | 2012 | Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4 | Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. |
| AID524262 | Antibacterial activity against Escherichia coli NKE155 harboring deletion mutation in acrB protein and plasmid expressing nlpE gene | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID554395 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2716 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID584846 | Activity at Aeromonas allosaccharophila AL-1 beta-lactamase PER6 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila. |
| AID588219 | FDA HLAED, gamma-glutamyl transferase (GGT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID341595 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. |
| AID585183 | Ratio of Kcat to Km for Beta-lactamase GES-2 E104, N170 mutant | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID285608 | Antimicrobial activity against Pseudomonas aeruginosa 3B1 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID529666 | Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 beta-lactamase VIM-2 relative to cephaloridine | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID571042 | Antimicrobial activity against Pseudomonas aeruginosa isolate GB57 obtained from patient with non-cystic fibrosis by Etest | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID517976 | Antimicrobial activity against Klebsiella pneumoniae YC harboring beta-lactamase KPC-2,TEM-1and SHV-2 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID560077 | Antimicrobial activity against Pseudomonas aeruginosa isolate 796 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID529655 | Activity of Pseudomonas aeruginosa 9551 beta-lactamase VIM-15 | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID520972 | Antibacterial activity against Escherichia coli harboring pBC633 plasmid expressing blaKPC gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID498127 | Antibacterial activity against Pseudomonas aeruginosa PA881 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID531774 | Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4703 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID519800 | Inhibition of Bocillin FL binding to PBP4 in Escherichia coli MC4100 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID564530 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-33 plasmid with entire blaAmpC gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID523503 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1248c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID576065 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 69928 harboring porin OmpK36V mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID571939 | Antimicrobial activity against Escherichia coli MC4100 expressing promoterless beta-lactamase GES-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter. |
| AID495662 | Ratio of Kcat to Km for Pseudomonas aeruginosa 531 beta-lactamase BEL-2 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID573500 | Antibacterial activity against Klebsiella pneumoniae isolate Kp38009 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID422499 | Activity of Carnobacterium divergens BM4489 penicillinase Cad-1 at 1 uM enzyme concentration assessed as initial rate of hydrolysis by spectrophotometer | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID562754 | Activity of Klebsiella pneumoniae AH24-270 CTX-M-71 beta-lactamase | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID532400 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D2 isolate VA-06X-17 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID656445 | Antimicrobial activity against extended spectrum beta-lactamase-producing Klebsiella pneumoniae | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID573512 | Antibacterial activity against Klebsiella pneumoniae isolate Kp4614 | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID678717 | Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID372604 | Antibacterial activity against Escherichia coli BER1 producing TEM-158 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID572128 | Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 31 expressing ampC, ompA, adeB, adeM, aadB, aadA2 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID583191 | Antimicrobial activity against dacB::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 5 mM NagZ inhibitor PUGNAc | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID531770 | Antimicrobial activity against Pseudomonas aeruginosa urine isolate 4706 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID573188 | Antimicrobial activity against mucA::lox-deficient Pseudomonas aeruginosa PAOMA biofilm by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID574428 | Antimicrobial activity against Escherichia coli isolate 360T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from urine of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID368715 | Renal clearance in human cystic fibrosis patient at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID565541 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-05 harboring A residue at 105 position in PDC- 2 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID516142 | Antibacterial activity against Pulsotype L Acinetobacter genomosp. 3 isolate 7 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID518479 | Binding affinity to Escherichia coli Penicillin-binding protein 1B | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID558038 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S1 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID656364 | Ratio of drug uptake in lung to plasma of cynomolgus monkey at 20 mg/kg, im | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID518726 | Antimicrobial activity against Escherichia coli TOP10 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands. |
| AID555637 | Antimicrobial activity against ampDDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID523494 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1530c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID565534 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-01 harboring T residue at 105 position in PDC- 1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID562810 | Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID574437 | Antimicrobial activity against Escherichia coli isolate 1679 expressing beta-lactamase KPC2, SHV-12, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID554385 | Antimicrobial activity against Pseudomonas aeruginosa mutGR1 overexpressing mexXY mutant by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1891025 | Antibacterial activity against Klebsiella pneumoniae 1004 producing KPC assessed as inhibition of bacterial growth by CLSI based broth microdilution method | 2022 | Bioorganic & medicinal chemistry, 05-15, Volume: 62 | Broad-spectrum cyclic boronate β-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability. |
| AID555632 | Antimicrobial activity against ampDh2 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID555649 | Ratio of MIC for ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method presence of 0.5 mM nagZ inhibitor EtBuPUG to MIC for ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 in absence of nagZ inhibitor EtBuPUG | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID373204 | Antimicrobial activity against Bacillus clausii SIN by agar-dilution technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID761208 | Antibacterial activity against Escherichia coli expressing CTX-M by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID1373305 | Antimicrobial activity against Escherichia coli expressing beta-lactamase IMP-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID565724 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-29 harboring A residue at 105 position in PDC- 8 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID1373319 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-48 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID495842 | Hydrolytic activity of Escherichia coli DH10B beta-lactamase VIM-2 by microacidimetric method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID372609 | Antibacterial activity against Escherichia coli DH5alpha producing beta-lactamase TEM-35 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID521995 | Antimicrobial activity against Klebsiella pneumoniae isolate Kp3A expressing beta-lactamase OXA-48 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID429077 | Antibacterial activity against Escherichia coli J53 by E test method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece. |
| AID555223 | Activity of Acinetobacter genomosp. 3 isolate 65 ADC-14 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID518219 | Antimicrobial activity against Escherichia coli W3110 assessed as appearance of long filaments at 64 ug/mL after 3 hrs by phase-contrast microscopy | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID374023 | Activity of Enterobacter cloacae IMI1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase. |
| AID573403 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB C89T mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID521836 | Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA367 containing blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, aac(6')-1b genes by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID558039 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S2 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID522001 | Antimicrobial activity against Escherichia coli isolate J53 harboring p5A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID573498 | Antibacterial activity against Klebsiella pneumoniae isolate Kp7564 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID511668 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD2 harboring oprD spontaneous mutant and deficient in dacB gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID555634 | Antimicrobial activity against ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID678713 | Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID561444 | Antibacterial activity against Escherichia coli DH10B harboring plasmid BCSK carrying beta-lactamase CMY-33 gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. |
| AID558042 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S5 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID520984 | Antibacterial activity against Escherichia coli harboring pNGR plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID285364 | Susceptibility of qnr positive Enterobacter cloacae assessed as percentage nonsusceptible isolates | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Prevalence of plasmid-mediated quinolone resistance determinants QnrA, QnrB, and QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital. |
| AID498128 | Antibacterial activity against Pseudomonas aeruginosa PA1036 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID559905 | Antimicrobial activity against Escherichia coli DH5alpha by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | First detection of plasmid-encoded blaOXY beta-lactamase. |
| AID573523 | Antibacterial activity against Enterobacter cloacae isolate El216 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1278327 | Antibacterial activity against beta-lactamase producing Proteus mirabilis 09-1 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID1891027 | Antibacterial activity against Escherichia coli 1010 producing CMY-6 assessed as inhibition of bacterial growth by CLSI based broth microdilution method | 2022 | Bioorganic & medicinal chemistry, 05-15, Volume: 62 | Broad-spectrum cyclic boronate β-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability. |
| AID522027 | Antimicrobial activity against Escherichia coli isolate J53 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID279816 | Antimicrobial activity against Escherichia coli DH5alpha by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. |
| AID559899 | Antimicrobial activity against Klebsiella pneumoniae 101A harboring beta-lactamase CMY-2 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | First detection of plasmid-encoded blaOXY beta-lactamase. |
| AID564021 | Antibacterial activity against Pseudomonas aeruginosa PAO1 harboring cloned pUCPOXA-2 by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID534292 | Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring pRK-NG plasmid and ampN with xylE-Gmomega cassette insertion by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID532399 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D2 isolate VA-06X-16 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID587728 | Antimicrobial activity against Escherichia coli DH5alpha carrying Pseudomonas aeruginosa strain PS 297 IMP-1-pLBII after 18 hrs by microdilution broth method | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States. |
| AID428274 | Antimicrobial activity against carbapenemase producing Enterobacter sp. assessed as resistant isolates by CLSI breakpoint assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID528600 | Antimicrobial activity against Escherichia coli TOP10 harboring blaKPC-2 and blaTEM-1 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID368705 | Volume of distribution of central compartment in human cystic fibrosis patient at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID518816 | Antibacterial activity against Acinetobacter genomosp. 3 isolates by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID544586 | Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8128 expressing bla SHV-105 gene by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID285601 | Antimicrobial activity against Pseudomonas aeruginosa 2A3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID565537 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-01 harboring T residue at 105 position in PDC- 1 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID279184 | Antibacterial activity against Escherichia coli DH10B | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1. |
| AID558537 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter coli isolate P321 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID532900 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID340733 | Antimicrobial activity against Chryseobacterium indologenes NF16 isolate assessed as drug level at which microbial resistance was observed by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes. |
| AID524394 | Antibacterial activity against Escherichia coli NKE1355 harboring deletion mutation in acrB protein and plasmid expressing BAD gene in presence of increasing concentration of arabinose | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID576302 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 26077 harboring porin OmpK36V mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID561442 | Antibacterial activity against Escherichia coli YD006 harboring beta-lactamase CMY-33 gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. |
| AID524247 | Antimicrobial activity against Escherichia coli INSRA4590 expressing SHV-84 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID1373358 | Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase NDM-1 infected in neutropenic mouse thigh infection model assessed as compound dose causing 1 log10 CFU reduction in bacterial load dosed subcutaneously every 4 hrs | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID565545 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-09 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID1198141 | Antimicrobial activity against MexABCDXY-deficient Pseudomonas aeruginosa PAO1 ARC546 by broth microdilution method | 2015 | Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5 | Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model. |
| AID522004 | Antimicrobial activity against Escherichia coli isolate J53 harboring p7A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID565522 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-13 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID523505 | Antimicrobial activity against Pseudomonas aeruginosa isolate 12142c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID571894 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 11 expressing ompA, adeB, adeM, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID584836 | Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER6 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila. |
| AID373207 | Antimicrobial activity against Bacillus clausii ATCC 21536 by agar-dilution technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID573402 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB C89T mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID322318 | Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent nonsusceptible isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID373770 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh26 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID678715 | Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID1476611 | Antibacterial activity against clinical isolates of Pseudomonas aeruginosa ISR-14-003 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID285594 | Antimicrobial activity against Pseudomonas aeruginosa 1A9 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID573513 | Antibacterial activity against Escherichia coli isolate Ec158 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID520327 | Antimicrobial activity against Acinetobacter baumannii isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Outbreak of Acinetobacter baumannii with chromosomally encoded VIM-1 undetectable by imipenem-EDTA synergy tests. |
| AID530323 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pUCP carrying VIM-1 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID511579 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD and ampDh3 gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID529572 | Antimicrobial activity against Erwinia carotovora subsp. atroseptica DSM 30184 after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID546426 | Activity at Pseudomonas aeruginosa PDC-1 by spectrophotometer | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. |
| AID522003 | Antimicrobial activity against Klebsiella pneumoniae isolate Kp7A expressing beta-lactamase OXA-48 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID535713 | Antibacterial activity against Escherichia coli TOP10 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. |
| AID372620 | Ratio of Kcat to Km for Escherichia coli DH5alpha beta-lactamase TEM-1 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID495809 | Antimicrobial activity against Escherichia coli DH5alpha harbouring plasmid BK-VIM-19 expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID518492 | Ratio of Kcat to Km for Escherichia coli Penicillin-binding protein 1B | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID405792 | Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 5/6 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID520382 | Antimicrobial activity Escherichia coli DH5alpha harboring bacteriophage T4 plasmid alpha omega by agar macrodilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain. |
| AID574430 | Antimicrobial activity against Escherichia coli isolate 386T expressing beta-lactamase KPC2, OXA-9 and PFGE cluster 1 isolated from wound of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID529657 | Activity of Pseudomonas aeruginosa 166301 beta-lactamase VIM-16 | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID573186 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 biofilm by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID520779 | Antibacterial activity against Escherichia coli EC600 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID405081 | Antimicrobial activity against Escherichia coli CAG12177 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Biochemical characterization of PER-2 and genetic environment of blaPER-2. |
| AID522024 | Antimicrobial activity against Escherichia coli isolate J53 harboring pCF containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID374021 | Ratio of Kcat to Km for Serratia fonticola UTAD54 SFC1 beta lactamase expressed in Escherichia coli BL21(DE3) by SDS-PAGE | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase. |
| AID562341 | Ratio of Kcat to Km for Chryseobacterium meningosepticum CCUG 4310 beta-lactamase BlaB1 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. |
| AID559588 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutY::Gm mutant gene assessed as doubling time | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID554386 | Antimicrobial activity against mexXY deficient ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID587967 | Activity of Escherichia coli beta-lactamase Toho-1 G232A mutant assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID1229261 | Half life of the compound at pH 7.4 at 37 degC | 2015 | ACS medicinal chemistry letters, May-14, Volume: 6, Issue:5 | SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3. |
| AID532913 | Antimicrobial activity against Escherichia coli Genehogs by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID495828 | Antimicrobial activity against Escherichia coli C600 2878 transconjugate expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID533757 | Antibacterial activity against SHV-2a producing Pseudomonas aeruginosa isolate P60 exhibiting PFGE H pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID369642 | Antibacterial activity against Acinetobacter baumannii C clone by Etest method | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital. |
| AID540214 | Clearance in rat after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID1476606 | Antibacterial activity against Staphylococcus aureus SG 511 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID565524 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-11 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID656351 | Antibacterial activity against Pseudomonas aeruginosa | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID1395496 | Antibacterial activity against carbapenem-resistant Enterobacter aerogenes 11-4 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria. |
| AID585199 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-5 E104, S170 mutant by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID561630 | Antimicrobial activity against ampD1-, ampD2-deficient Stenotrophomonas maltophilia KJ by twofold serial agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID495663 | Activity at Pseudomonas aeruginosa 51170 beta-lactamase BEL-1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID523497 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1529c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1476622 | Antibacterial activity against clinical isolates of Acinetobacter baumannii ISR14-005 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID517969 | Antimicrobial activity against Klebsiella pneumoniae 26768WU harboring beta-lactamase SHV-5 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID529499 | Antimicrobial activity against Escherichia coli GeneHogs by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID565722 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-27 harboring A residue at 105 position in PDC- 7 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID519741 | Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-72 by agar dilution method in presence of 2 ug/ml clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID1357462 | Antibacterial activity against IMP-4 producing Pseudomonas aeruginosa isolate 208247 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria. |
| AID529651 | Antimicrobial activity against Escherichia coli DH5alpha harboring beta-lactamase VIM-2 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID534385 | Antibacterial activity against Escherichia coli K-12 W1895 by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate. |
| AID323038 | Antimicrobial activity against extended-spectrum-beta-lactamase producing Escherichia coli assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. |
| AID535707 | Antibacterial activity against Escherichia coli TOP10 expressing AmpC-B2 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. |
| AID574434 | Antimicrobial activity against Escherichia coli isolate 544 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from abscess of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID532390 | Antibacterial activity against VIM-1 producing Pseudomonas putida isolate RM-11X-11 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID520778 | Antibacterial activity against beta-lactamase KPC-2 producing Escherichia coli isolate E1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID373771 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh29 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID555554 | Antimicrobial activity against Pseudomonas aeruginosa isolate M136074 expressing IMP-22 beta lactamase gene by Etest | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. |
| AID250271 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH24; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID548948 | Antimicrobial activity against Enterobacter cloacae ATCC 49141 after18 to 20 hrs by broth dilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antimicrobial evaluation of some fused heterocyclic [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives. |
| AID565515 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-20 harboring A residue at 105 position in PDC- 4 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID521427 | Antibacterial activity against Stenotrophomonas maltophilia isolate KJ deficient in L2 beta lactamase gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID495516 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii AYE by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID516143 | Antibacterial activity against Pulsotype B Acinetobacter genomosp. 3 isolate 8 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID495813 | Antimicrobial activity against Escherichia coli 138 expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID585194 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-7 K104, G170 mutant by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID1476625 | Antibacterial activity against cephalosporinase producing Acinetobacter baumannii ATCC 17978-PNT-320 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID519812 | Inhibition of Bocillin FL binding to PBP1B in Pseudomonas aeruginosa 27853 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID567310 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2201 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID567279 | Activity of Acinetobacter baumannii ADC-33 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID368717 | Unbound fraction in human cystic fibrosis patient urine at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID520882 | Antibacterial activity against Escherichia coli TOP10 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID373758 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1254 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID573519 | Antibacterial activity against Escherichia coli isolate Ec211 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID511288 | Antibacterial activity against Escherichia coli DH5alpha pB-ges-13 plasmid | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. |
| AID529577 | Ratio of Kcat to Km for Pseudomonas maltophilia ULA-511 beta-Lactamase L-1 | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID521484 | Antibacterial activity against Escherichia coli harboring pBC633 plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID555661 | Antimicrobial activity against Salmonella enterica serotype Westhampton isolate 04CEB8273SAL expressing CTX-M-53 gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID498123 | Antibacterial activity against Pseudomonas aeruginosa PA1022 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID528608 | Ratio of Kcat to Km for Escherichia coli 2138 beta-lactamase KPC-2 by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID1476624 | Antibacterial activity against carbapenemase producing Acinetobacter baumannii ATCC 17978-PNT-165 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID573516 | Antibacterial activity against Serratia marcescens isolate Sm201 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID405427 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| AID519740 | Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-72 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID279939 | Antibiotic susceptibility by resistance against Pseudomonas aeruginosa from samples collected from patients | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. |
| AID529483 | Antimicrobial activity against Enterobacter cloacae isolate 151 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID533568 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA469 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID532397 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D isolate VA-06X-69 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID517972 | Antimicrobial activity against Pseudomonas aeruginosa 1937E harboring beta-lactamase PSE-4 and class C enzymes by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID1541989 | Oral bioavailability in human at 500 mg administered twice as 250 mg tablet formulation measured 16 hrs post dose | 2020 | ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2 | Toward Orally Absorbed Prodrugs of the Antibiotic Aztreonam. Design of Novel Prodrugs of Sulfate Containing Drugs. Part 2. |
| AID498116 | Antibacterial activity against Pseudomonas aeruginosa PA5026 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID495518 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4676 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID522018 | Antimicrobial activity against Escherichia coli isolate TOP10 harboring pPR containing beta-lactamase and TEM-101 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID554412 | Antimicrobial activity against Pseudomonas aeruginosa isolate 3066 expressing inactivated mexB gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID516146 | Antibacterial activity against Pulsotype J Acinetobacter genomosp. 3 isolate 15 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID528492 | Antimicrobial activity against Pseudomonas aeruginosa clinical isolates assessed as resistant isolates by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID560085 | Bactericidal activity against Pseudomonas aeruginosa isolate 796 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID519005 | Antimicrobial activity against Escherichia coli HB101 expressing recombinant plasmid encoded TEM-149 by broth macrodilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID554404 | Antimicrobial activity against Pseudomonas aeruginosa isolate 3020S expressing inactivated mexB gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID368712 | AUC in healthy human at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID498129 | Antibacterial activity against Pseudomonas aeruginosa PA5026 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID587981 | Antibacterial activity against Escherichia coli AS226 carrying pBSDD240S mutant after 18 hrs by broth microdilution method | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID1891026 | Antibacterial activity against Enterobacter cloacae 1002 producing AmpC assessed as inhibition of bacterial growth by CLSI based broth microdilution method | 2022 | Bioorganic & medicinal chemistry, 05-15, Volume: 62 | Broad-spectrum cyclic boronate β-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability. |
| AID518506 | Inhibition of Escherichia coli Penicillin-binding protein 1B | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID373768 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh18 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID554399 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2858 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID522017 | Antimicrobial activity against Providencia rettgeri isolate expressing beta-lactamase OXA-48 and TEM-101 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID523496 | Antimicrobial activity against Pseudomonas aeruginosa isolate 17145c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID565281 | Antibacterial activity against mexB and mexY expressing Pseudomonas aeruginosa PA-A2 harboring GyrA T83I, ParC S87L and IS1001 insertion at position 629 in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID285592 | Antimicrobial activity against Pseudomonas aeruginosa 65.38-3 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID529487 | Antimicrobial activity against Enterobacter cloacae isolate 622 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID1278317 | Antibacterial activity against BL positive Pseudomonas aeruginosa PAO1 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID509870 | Antibacterial activity against Acinetobacter baumannii isolate 5191 isolated from human urine | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID1733060 | Antibacterial activity against Pseudomonas aeruginosa 9027 assessed as reduction in bacterial growth by CLSI based broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 39 | Synthesis and antibacterial evaluation of new monobactams. |
| AID322322 | Antibacterial activity against Escherichia coli INSRA5905 isolates expressing CTX-M-15 and TEM-1B enzymes by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID520717 | Antibacterial activity against Acinetobacter baumannii CIP7010 harboring pOXA-97 by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97. |
| AID558329 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P305 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID326268 | Antibacterial activity against Escherichia coli DH5-alpha by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli. |
| AID659491 | Antimicrobial activity against Citrobacter freundii after 16 to 20 hrs by 2-fold microbroth dilution method | 2012 | Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4 | Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. |
| AID524257 | Ratio of Kcat to Km in Escherichia coli beta-lactamase SHV-1 | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Biochemical study of a new inhibitor-resistant beta-lactamase, SHV-84, produced by a clinical Escherichia coli strain. |
| AID524391 | Antibacterial activity against Escherichia coli NKE1368 harboring deletion mutation in acrB, acrD and vector expressing mdtABC gene | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID573507 | Antibacterial activity against Klebsiella oxytoca isolate Ko0426 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID573526 | Antibacterial activity against Klebsiella pneumoniae isolate Kp204 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1395498 | Antibacterial activity against new delhi metallo-beta-lactamase-1 harboring Enterobacter cloacae 13-1 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria. |
| AID520799 | Antimicrobial activity against CTX-M-59 producing Klebsiella pneumoniae with PFGE pulsotype G by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID1373352 | Drug excretion in dog assessed as unchanged parent drug level at 10 mg/kg, iv | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID518817 | Antibacterial activity against Acinetobacter genomosp. 3 isolates assessed as percent of resistance isolates by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID559683 | Antibacterial activity against Acinetobacter baumannii BM4674 isolated from the tibia fracture of a patient by Etest method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. |
| AID577647 | Antimicrobial activity against Escherichia coli isolate 157 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 3 isolated from urine of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID326265 | Antibacterial activity against Escherichia coli 3521r carrying pR352 encoding SCO1 by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli. |
| AID531332 | Antibacterial activity against Pseudomonas aeruginosa PAO4290 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID521992 | Antimicrobial activity against Escherichia coli isolate J53 harboring pA-1 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID565197 | Antimicrobial activity against Klebsiella pneumoniae isolate H-1406 expressing VIM-1 and KPC-2 genes by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. |
| AID519630 | Antimicrobial activity against Escherichia coli JM83 harboring beta-lactamase OXA-63 after 3 days by Etest | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442. |
| AID544494 | Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase KPC-5 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID559688 | Antibacterial activity against ESBL-positive and OmpF and OmpC porin-deficient Escherichia coli HB4 | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. |
| AID285585 | Antimicrobial activity against Pseudomonas aeruginosa 65.33-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID558539 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter coli isolate P1826 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID573193 | Antimicrobial activity against mutS::lox,mexD::lox-deficient Pseudomonas aeruginosa PAOMSMxD biofilm by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID571693 | Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 2 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID373209 | Activity of Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3) | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID567311 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2202 isolated from burn patient by broth microdilution method in presence of beta-lactamase inhibitor clavulanic acid | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID1373283 | Antimicrobial activity against Escherichia coli expressing beta-lactamase GES-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID565512 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-30 harboring A residue at 105 position in PDC- 8 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID519008 | Activity of Beta-lactamase TEM-149 expressed in Escherichia coli HB101 | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID761216 | Antibacterial activity against Klebsiella pneumoniae 1000-02 by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID1198143 | Inhibition of Pseudomonas aeruginosa PBP3 acylation activity by BOCILLIN FL-based assay | 2015 | Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5 | Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model. |
| AID532904 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 531 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID565529 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-06 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID405793 | Antibacterial activity against Pseudomonas aeruginosa PAO1 after 1.5 hrs by CLSI method | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. |
| AID559586 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutM::Gm mutant gene by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID574427 | Antimicrobial activity against Escherichia coli isolate 360 expressing beta-lactamase KPC2, CTX-M-15, OXA-9, TEM and PFGE cluster 1 isolated from urine of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID405453 | Antibacterial activity against Pseudomonas aeruginosa PAOdeltamutS by Etest | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. |
| AID511666 | Antimicrobial activity against beta-lactam resistant beta-lactam resistant Pseudomonas aeruginosa PAOD3 harboring oprD spontaneous mutant and deficient in ampD gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID373769 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh20 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID374026 | Ratio of Kcat to Km for Klebsiella pneumoniae KPC-1 beta lactamase expressed in Escherichia coli DH5alpha by SDS-PAGE | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase. |
| AID577649 | Antimicrobial activity against Escherichia coli isolate 329 expressing beta-lactamase KPC2, CTX-M-2, TEM and PFGE cluster 2 isolated from blood of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID322317 | Antibacterial activity against CTX-M group 9 enzyme producing Escherichia coli isolates assessed as percent resistant isolates by broth microdilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID558051 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S14 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID498102 | Antibacterial activity against Pseudomonas aeruginosa PA1036 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID587979 | Antibacterial activity against Escherichia coli AS226 carrying pBSDN104D mutant after 18 hrs by broth microdilution method | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID497949 | Antibacterial activity against Pseudomonas aeruginosa PA1054 assessed as inhibition of biofilm formation by microtiter plate reader assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID531675 | Antimicrobial activity against Escherichia coli DH5alpha by broth dilution test | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii. |
| AID540212 | Mean residence time in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID1373357 | Antimicrobial activity against Klebsiella pneumoniae expressing beta-lactamase NDM-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID1373331 | Stability assessed as assessed as Escherichia coli beta-lactamase SHV-12-mediated compound hydrolysis by measuring molar enthalpy of hydrolysis at 1 mM by isothermal titration calorimetry | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID576277 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17834 harboring porin OmpK36V mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID564529 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID520978 | Antibacterial activity against Escherichia coli harboring pCOL plasmid expressing blaKPC gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID1373354 | Clearance in mouse at 2.5 mg/kg, iv | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID534284 | Antimicrobial activity against Stenotrophomonas maltophilia KJN1 harboring ampN with xylE-Gmomega cassette insertion by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID394494 | Antimicrobial activity against Escherichia coli MC4100 harboring pACYC184 plasmid by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID529574 | Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid BC-SK after 24 hrs by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID571696 | Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 5 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID25254 | Pseudo-first-order Rate constant for hydrolysis at pH 10 | 1988 | Journal of medicinal chemistry, Jun, Volume: 31, Issue:6 | The acylating potential of gamma-lactam antibacterials: base hydrolysis of bicyclic pyrazolidinones. |
| AID565725 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-30 harboring A residue at 105 position in PDC- 8 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID1373342 | Half life in mouse at 2.5 mg/kg, iv | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID521425 | Antibacterial activity against Stenotrophomonas maltophilia isolate KJ by Etest | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID678718 | Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID1474166 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID1278329 | Antibacterial activity against Providencia rettgeri 31052 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID555650 | Ratio of MIC for ampD gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method presence of 0.5 mM nagZ inhibitor EtBuPUG to MIC for ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 in absence of nagZ inhibitor EtBuPUG | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID368913 | Clearance in human cystic fibrosis patient by NPAG | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID565525 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-10 harboring A residue at 105 position in PDC- 2 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID523493 | Antimicrobial activity against Pseudomonas aeruginosa 1405-con D2 by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID576299 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 25008 by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID531684 | Antimicrobial activity against Acinetobacter baumannii ATCC 15151T containing plasmid harboring OXA-58-3 by broth dilution test | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii. |
| AID559897 | Antimicrobial activity against Klebsiella oxytoca KO280 harboring beta-lactamase OXY-1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | First detection of plasmid-encoded blaOXY beta-lactamase. |
| AID511584 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD3 harboring oprD spontaneous mutant selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID394497 | Antimicrobial activity against Escherichia coli MC4100 harboring pBCSK plasmid by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID583185 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 0.5 mM NagZ inhibitor PUGNAc | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID94229 | In vitro antibacterial activity against CMC-84-31 strain of Klebsiella pneumoniae | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID285603 | Antimicrobial activity against Pseudomonas aeruginosa 2B5 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID1198144 | Percentage unbound in human plasma at 10 uM after 16 hrs by LC-MS/MS analysis | 2015 | Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5 | Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model. |
| AID532395 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A3 isolate NA-14X-34 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID531745 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID563969 | Antibacterial activity against Escherichia coli J53 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID535694 | Antimicrobial activity against Azide-resistant Escherichia coli J53 transconjugant harboring Escherichia coli DH5alpha-5825 qnrB2 gene by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. |
| AID1476631 | Antibacterial activity against clinical isolates of Acinetobacter baumannii ISR14-005 after 18 hrs in presence of tazobactam by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID571922 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 25 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID555203 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID517967 | Antimicrobial activity against Klebsiella pneumoniae 1357E harboring beta-lactamase TEM-10 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID285259 | Antimicrobial activity against recombinant Escherichia coli DH5-alpha isolate expressing pBK-TEM-29 and ESBL by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID565518 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-17 harboring A residue at 105 position in PDC- 3 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID1373284 | Antimicrobial activity against Escherichia coli expressing beta-lactamase IMI-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID368701 | Distribution half life in human cystic fibrosis patient serum at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID405637 | Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 5 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. |
| AID558045 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S8 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID535704 | Antibacterial activity against Escherichia coli TOP10 expressing AmpC-A S287N mutant protein by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. |
| AID559901 | Antimicrobial activity against Klebsiella pneumoniae 278sp by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | First detection of plasmid-encoded blaOXY beta-lactamase. |
| AID520798 | Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype F by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID559591 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutL mutant gene complemented with wild type DNA oxidative repair system mutY gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID540218 | Clearance in monkey after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID560065 | Antimicrobial activity against Escherichia coli isolate 5401 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID543411 | Antimicrobial activity against Shigella sonnei UIH-1 expressing beta-lactamase CTX-M-64 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime. |
| AID532896 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 469 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID524383 | Antibacterial activity against Escherichia coli NKE161 harboring deletion mutation in acrB protein, vector expressing tolC gene and plasmid expressing nlpE gene | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID560132 | Activity of recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay relative to benzylpenicillin | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. |
| AID587971 | Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 A237A mutant assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID561446 | Antibacterial activity against Escherichia coli DH10B harboring plasmid BCSK carrying beta-lactamase CMY-2 gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. |
| AID1139447 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by CLSI broth microdilution method | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Siderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteria. |
| AID519798 | Inhibition of Bocillin FL binding to PBP2 in Escherichia coli MC4100 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID511586 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD2 harboring oprD spontaneous mutant and deficient in ampD gene by selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution metho | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID518474 | Binding affinity to Escherichia coli ATCC 25922 AmpC | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID498089 | Antibacterial activity against Pseudomonas aeruginosa PA881 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID340734 | Antimicrobial activity against Escherichia coli HB101 harboring pBC-SK plasmid assessed as drug level at which microbial resistance was observed by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes. |
| AID285602 | Antimicrobial activity against Pseudomonas aeruginosa 2A5 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID517979 | Antimicrobial activity against Pseudomonas aeruginosa HPA10586 harboring beta-lactamase VIM-1 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID520721 | Antibacterial activity against Escherichia coli DH10B harboring pOXA-97 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97. |
| AID532392 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone A2 isolate NA-14X-21 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID540209 | Volume of distribution at steady state in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID498104 | Antibacterial activity against Pseudomonas aeruginosa PA876 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID586086 | Antimicrobial activity against verocytotoxin-producing Escherichia coli isolate O157 obtained from animals and food assessed as percentage of resistant isolates by disk diffusion method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Antimicrobial resistance testing of verocytotoxin-producing Escherichia coli and first description of TEM-52 extended-spectrum β-lactamase in serogroup O26. |
| AID1476626 | Antibacterial activity against Burkholderia dolosa AU0018 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID368914 | Antimicrobial activity against Pseudomonas aeruginosa isolated from cystic fibrosis patient sputum culture | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID555636 | Antimicrobial activity against ampDDh2 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID522014 | Antimicrobial activity against Escherichia coli isolate J53 harboring pBEL containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID1373294 | Antimicrobial activity against Escherichia coli expressing beta-lactamase SME-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID520709 | Antibacterial activity against Acinetobacter baumannii MAD by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97. |
| AID498087 | Antibacterial activity against Pseudomonas aeruginosa PA1022 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID558043 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S6 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID573201 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSA biofilm harboring nfxB T533C mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID283320 | Antimicrobial activity against Klebsiella pneumoniae KPN15-NL | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands. |
| AID555184 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox delta ampDh3::lox and plasmid pUCP27 after 18 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID531315 | Activity of Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. |
| AID520719 | Antibacterial activity against Escherichia coli DH10B | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97. |
| AID531317 | Activity of Escherichia coli beta-lactamase VIM-1 by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. |
| AID558041 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S4 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID323042 | Antimicrobial activity against extended-spectrum-beta-lactamase producing Proteus mirabilis assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID520980 | Antibacterial activity against Klebsiella pneumoniae YC by Etest method in presence of beta-lactamase inhibitor clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID541023 | Ratio of Kcat to Km for Burkholderia cenocepacia 07-34 beta-lactamase PenB1 expressed in Escherichia coli Top10 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex. |
| AID571896 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 12 expressing ompA, adeB, adeM, aacA4, aacC2, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID656352 | Antibacterial activity against imipenem-sensitive Pseudomonas aeruginosa isolate 1091-05 infected in ip dosed SF-1 mouse assessed as survival of animal administered 0.5 and 4 hrs post infected measured on day 4 | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID529486 | Antimicrobial activity against Enterobacter cloacae isolate 533 containing PFGE genetic clone A expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID373208 | Antimicrobial activity against Bacillus clausii DSM 8716 by agar-dilution technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID531771 | Antimicrobial activity against Pseudomonas aeruginosa secretion isolate 4658 containing PFGE clone A1 expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID530815 | Antibacterial activity against human urinary Klebsiella pneumoniae UCL-1 harboring plasmid-encoded beta-lactamase OXA-48 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. |
| AID519737 | Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-1 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID585182 | Ratio of Kcat to Km for Beta-lactamase GES-7 K104, G170 mutant | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID530324 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pUCP carrying VIM-13 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID534285 | Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring ampN with xylE-Gmomega cassette insertion by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID587986 | Antibacterial activity against Escherichia coli AS226 after 18 hrs by broth microdilution method | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID567304 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2202 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID517975 | Antimicrobial activity against Klebsiella pneumoniae CRE harboring beta-lactamase KPC-2 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID521999 | Antimicrobial activity against Klebsiella pneumoniae isolate Kp6A expressing beta-lactamase OXA-48 and TEM-150 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID326266 | Antibacterial activity against Escherichia coli K12 carrying pR3521 encoding SCO1 by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli. |
| AID66226 | In vitro antibacterial activity against MOR-84-30 strain of Enterobacter cloacae | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID1395497 | Antibacterial activity against new delhi metallo-beta-lactamase-1 harboring Enterobacter cloacae CDC1000654 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria. |
| AID285256 | Antimicrobial activity against Escherichia coli DH5-alpha CF1295 isolate expressing CMT and TEM1 by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID373210 | Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3) | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID520809 | Antimicrobial activity against CTX-M-59 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype C by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID428268 | Antimicrobial activity against carbapenemase producing Enterobacteriaceae assessed as resistant isolates by CLSI breakpoint assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID534297 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA481 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID582978 | Antimicrobial activity against ampD::lox, ampDh2::lox,ampDh3::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID576296 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 16830 harboring porin OmpK36 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID546427 | Activity at Pseudomonas aeruginosa PDC-2 by spectrophotometer | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. |
| AID521997 | Antimicrobial activity against Klebsiella pneumoniae isolate Kp4A expressing beta-lactamase OXA-48 and CTX-M-15 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID558049 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S12 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID555633 | Antimicrobial activity against ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID571924 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii zeta clonal group isolate 26 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID405091 | Antimicrobial activity against non-integron carrying Enterobacteriaceae assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome. |
| AID1476629 | Antibacterial activity against clinical isolates of Pseudomonas aeruginosa ISR-14-003 after 18 hrs in presence of tazobactam by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID563977 | Ratio of Kcat to Km for Klebsiella pneumoniae 05-560 beta-lactamase VIM2 | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID405824 | Antimicrobial activity against Acinetobacter baumannii 696 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID572124 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 29 expressing ampC, ompA, adeM, aadB, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID545148 | Inhibition of CMY-2 by UV spectrophotometer in presence of 100 uM of cephalothin | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID573527 | Antibacterial activity against Serratia marcescens isolate Sm265 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID394495 | Antimicrobial activity against Escherichia coli MC4100 harboring pB-acc4 plasmid by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID574438 | Antimicrobial activity against Escherichia coli isolate 1679T expressing beta-lactamase KPC2, TEM and PFGE cluster 6 isolated from peritoneal fluid of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID565424 | Antimicrobial activity against beta-lactamase-producing Pseudomonas aeruginosa clinical isolate assessed as susceptible isolates by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil. |
| AID555635 | Antimicrobial activity against ampDDh2 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID559684 | Antibacterial activity against Acinetobacter baumannii BM4652 | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. |
| AID495831 | Antimicrobial activity against Escherichia coli DH5alpha 2878 transformant expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID1373290 | Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-1 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID522028 | Antimicrobial activity against Escherichia coli isolate TOP10 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID555639 | Antimicrobial activity against ampDh2 and ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID495510 | Antibacterial activity against Acinetobacter baumannii BM4454 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID571216 | Antimicrobial activity against Pseudomonas aeruginosa isolate TX291 obtained from patient with non-cystic fibrosis by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID554396 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2721 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1139450 | Antibacterial activity against Acinetobacter baumannii AB-3167 by CLSI broth microdilution method | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Siderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteria. |
| AID1373360 | Protein binding in mouse plasma | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID531768 | Antimicrobial activity against Pseudomonas aeruginosa catheter isolate 4696 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID532415 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-10 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID562739 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pBC-CTX-M-71 plasmid by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID656447 | Antibacterial activity against metallo-beta-lactamase producing Pseudomonas aeruginosa | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID372607 | Antibacterial activity against Escherichia coli DH5alpha producing beta-lactamase TEM-158 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID446143 | Inhibition of protein synthesis in Pseudomonas aeruginosa ATCC 27853 assessed as decrease in incorporation of L-[4,5-3H]leucine at 10 times MIC by liquid scintillation counter relative to control | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID656442 | Antibacterial activity against Pseudomonas aeruginosa cystic fibrosis isolate | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID555641 | Antimicrobial activity against ampDDh2 and ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID495632 | Antimicrobial activity against Pseudomonas luteola expressing blaLUT-2 to blaLUT-6 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. |
| AID544583 | Antimicrobial activity against Escherichia coli DH5[alpha] by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID521487 | Antibacterial activity against Pseudomonas aeruginosa 2404 plasmid by Etest method in presence of beta-lactamase inhibitor clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID368716 | Renal clearance in healthy human at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID495656 | Antimicrobial activity against Escherichia coli TOP10 expressing recombinant beta-lactamase BEL-2 by solid agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID573499 | Antibacterial activity against Citrobacter amalonaticus isolate Ca38009 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID516144 | Antibacterial activity against Pulsotype I Acinetobacter genomosp. 3 isolate 10 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID573525 | Antibacterial activity against Klebsiella oxytoca isolate Ko238 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID279813 | Antimicrobial activity against Escherichia coli DH5-alpha pYW1 transformants expressing KPC2 gene by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. |
| AID529493 | Antimicrobial activity against Enterobacter cloacae isolate 781 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID1706293 | Drug excretion in human urine assessed as inactive metabolite | 2020 | European journal of medicinal chemistry, Dec-15, Volume: 208 | β-lactam antibiotics: An overview from a medicinal chemistry perspective. |
| AID522354 | Antibacterial activity against mexA deficient Pseudomonas aeruginosa TNP070 transformant harboring pMEXA1 carrying wild type mexA gene | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Tat pathway-mediated translocation of the sec pathway substrate protein MexA, an inner membrane component of the MexAB-OprM xenobiotic extrusion pump in Pseudomonas aeruginosa. |
| AID324311 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. |
| AID285599 | Antimicrobial activity against Pseudomonas aeruginosa 2A2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID533763 | Antibacterial activity against OXA-19 producing Pseudomonas aeruginosa isolate P122 exhibiting PFGE A pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID534305 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA507 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID562737 | Antimicrobial activity against Escherichia coli K-12 transconjugant harboring blaCTX-M-71 gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID519808 | Inhibition of Bocillin FL binding to PBP4 in Pseudomonas aeruginosa PAO1 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID495806 | Antimicrobial activity against Providencia stuartii 6858 strain expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID583653 | Antibacterial activity against Escherichia coli TOP10 | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. |
| AID576283 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17829 by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID585193 | Antimicrobial activity against Escherichia coli DH5[alpha] transformed with pAC-ges1 plasmid encoding Beta-lactamase GES-1 E104, G170 mutant by Etest method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID1373293 | Antimicrobial activity against Escherichia coli expressing beta-lactamase SHV-12 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID522384 | Antimicrobial activity against Aeromonas enteropelogenes ATCC 49803 producing endogenous class C beta-lactamase TRU-1 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes. |
| AID522010 | Antimicrobial activity against Escherichia coli isolate TOP10 harboring pBIC containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID564525 | Antimicrobial activity against Acinetobacter baumannii CIP70.10 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID565280 | Antibacterial activity against Pseudomonas aeruginosa PAO1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. |
| AID1706290 | Oral bioavailability in human | 2020 | European journal of medicinal chemistry, Dec-15, Volume: 208 | β-lactam antibiotics: An overview from a medicinal chemistry perspective. |
| AID519009 | Ratio of Kcat to Km for Beta-lactamase TEM-149 expressed in Escherichia coli HB101 | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID582971 | Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID534492 | Antimicrobial activity against ampN deficient Stenotrophomonas maltophilia KJ by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID521840 | Antibacterial activity against Escherichia coli J53 transconjugated with Klebsiella pneumoniae isolate VA375 containing qnrA1, blaTEM-1, blaSHV-11genes by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID546618 | Antimicrobial activity against Pseudomonas aeruginosa isolate 243-31C expressing beta-lactamase VIM-18 isolated from sputum of patient by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). |
| AID444050 | Fraction unbound in human plasma | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID368721 | Volume of distribution in children | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID425867 | Antimicrobial activity against Carnobacterium divergens BM4490 expressing beta-lactamase CAD1 at 0.5 McFarland inoculum size by E-test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID565508 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-26 harboring T residue at 105 position in PDC- 6 and polymorphic OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID761224 | Inhibition of PBP1b in Pseudomonas aeruginosa ATCC 27853 after 20 mins by fluorescence assay | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID444051 | Total clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID565720 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-25 harboring T residue at 105 position in PDC- 6 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID530327 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pUCP carrying VIM-13 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID583181 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID554390 | Antimicrobial activity against Pseudomonas aeruginosa isolate 615S obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1706291 | Bioavailability in human at 500 mg, IM | 2020 | European journal of medicinal chemistry, Dec-15, Volume: 208 | β-lactam antibiotics: An overview from a medicinal chemistry perspective. |
| AID576308 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 29459 harboring porin OmpK36 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID520983 | Antibacterial activity against Klebsiella pneumoniae GR by Etest method in presence of beta-lactamase inhibitor clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID559689 | Antibacterial activity against ESBL-positive and OmpF and OmpC porin-deficient Escherichia coli HB4 harboring plasmid AT517 | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. |
| AID1395482 | Antibacterial activity against new delhi metallo-beta-lactamase-1 harboring Klebsiella pneumoniae ATCC BAA-2146 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria. |
| AID520807 | Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype A by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID250272 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH25; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID522386 | Antimicrobial activity against Escherichia coli NI540 carrying cloned class C beta-lactamase TRU-1 gene | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes. |
| AID571900 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 14 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID521994 | Antimicrobial activity against Escherichia coli isolate J53 harboring pBb containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID525549 | Antimicrobial activity against ampicillin resistant nontypeable Haemophilus influenzae isolate BB1052 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination. |
| AID535691 | Antimicrobial activity against beta-lactamase CTX-M-15-producing fluoroquinolone-resistant Escherichia coli FMV5825 expressing qnrB2 and aac(6')-Ib-cr and harboring gyrA Ser83Ile and Asp87Asn mutant gene and ParC Ser80Ile and Glu84Val mutant gene obtained | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog. |
| AID560591 | Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ799 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID495512 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4666 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID529458 | Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase TEM-1, CTX-M-15 and Oxa-1 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID1891024 | Antibacterial activity against Escherichia coli 302 producing TEM-10 assessed as inhibition of bacterial growth by CLSI based broth microdilution method | 2022 | Bioorganic & medicinal chemistry, 05-15, Volume: 62 | Broad-spectrum cyclic boronate β-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability. |
| AID587975 | Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 F160T mutant assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID520811 | Antimicrobial activity against CTX-M-59 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype E by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID554402 | Antimicrobial activity against Pseudomonas aeruginosa isolate 3066 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1443399 | Antibacterial activity against extended spectrum beta-lactamase IMP-4 producing multidrug resistant Pseudomonas aeruginosa clinical isolates after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7 | Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections. |
| AID531751 | Antibacterial activity against Pseudomonas aeruginosa 3308 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID444058 | Volume of distribution at steady state in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID574433 | Antimicrobial activity against Escherichia coli isolate 543T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from synovial fluid of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID562811 | Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID649184 | Antibacterial activity against Pseudomonas aeruginosa after 16 to 20 hrs by broth microdilution method | 2012 | Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2 | Potent inhibitors of LpxC for the treatment of Gram-negative infections. |
| AID564528 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-50 plasmid by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID373211 | Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3) relative to benzyl-penicillin | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID565535 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-31 harboring A residue at 105 position in PDC- 9 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID1198149 | Antimicrobial activity against Klebsiella pneumoniae by broth microdilution method | 2015 | Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5 | Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model. |
| AID1278325 | Antibacterial activity against beta-lactamase producing Citrobacter freundii 43864 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID285607 | Antimicrobial activity against Pseudomonas aeruginosa 2A9 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID523513 | Antimicrobial activity against Pseudomonas aeruginosa isolate 3149 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID498085 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of biofilm formation by microtiter plate reader assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID394714 | Antibacterial activity against Pseudomonas aeruginosa clinical isolates assessed as susceptible rate by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID571935 | Antimicrobial activity against Escherichia coli MC4100 harboring promoter hybrid 2 in beta-lactamase GES-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter. |
| AID70619 | In vitro antibacterial activity against ATCC 25922 strain of Escherichia coli | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID555403 | Antimicrobial activity against ampDh2 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID511292 | Ratio of Kcat/Km for Pseudomonas aeruginosa GES-13 beta lactamase assessed as hydrolysis by spectrometry | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. |
| AID405641 | Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 1b | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. |
| AID524389 | Antibacterial activity against Escherichia coli NKE1367 harboring deletion mutation in acrB, mdtABC protein and plasmid expressing nlpE gene | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID531966 | Antibacterial activity against Klebsiella pneumoniae urine isolate A28009 PFGE pattern A expressing KPC-2, TEM-1, SHV-11, CTX-M-2 beta-lactamase by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil. |
| AID534379 | Antibacterial activity against Citrobacter freundii KHM243 clinical isolate by microdilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate. |
| AID572146 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii unique clonal group isolate 40 expressing ampC, ompA, adeB, adeM, aadA1, aacA4, aacC2, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID565709 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-14 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID285261 | Antimicrobial activity against recombinant Escherichia coli DH5-alpha isolate expressing pBK-TEM-36 and IRT by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID285690 | Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA4036 isolate expressing carbapenemase KPC2 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. |
| AID573333 | Antibacterial activity against Enterobacter cloacae isolate El3280 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID519807 | Inhibition of Bocillin FL binding to PBP3 in Pseudomonas aeruginosa PAO1 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID285606 | Antimicrobial activity against Pseudomonas aeruginosa 2A7 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID545146 | Inhibition of Salmonella enterica serotype Newport AM17274 cephalosporinase CMY-31 by UV spectrophotometer in presence of 100 uM of cephalothin | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID498100 | Antibacterial activity against Pseudomonas aeruginosa PA880 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID522352 | Antibacterial activity against mexA deficient Pseudomonas aeruginosa TNP070 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Tat pathway-mediated translocation of the sec pathway substrate protein MexA, an inner membrane component of the MexAB-OprM xenobiotic extrusion pump in Pseudomonas aeruginosa. |
| AID523498 | Antimicrobial activity against Pseudomonas aeruginosa isolate 14169c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID518186 | Antimicrobial activity against Acinetobacter baumannii HPA 327009 harboring beta-lactamase OXA-25 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID559584 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutY::Gm mutant gene by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID573199 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T380C mutant gene selected at 0.5 ug/ml of azithromycin after 2 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID532909 | Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 549 ST 327 expressing beta-lactamase TEM-1 and CTX-M-2 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID567271 | Ratio of Kcat to Ki for Acinetobacter baumannii ADC-33 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID531758 | Antibacterial activity against Pseudomonas aeruginosa 1956 harboring pNF225 carrying nfxB by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID533565 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA399 expressing VIM-2 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID405817 | Antimicrobial activity against Pseudomonas putida 12346 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID558328 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P286 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID285257 | Antimicrobial activity against recombinant Escherichia coli DH5-alpha CL1295 isolate expressing pBK-TEM-151 and CMT by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID531336 | Antibacterial activity against MeXAB-OprM deficient Pseudomonas aeruginosa TNP077 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. |
| AID562340 | Ratio of Kcat to Km for Chryseobacterium indologenes 597 metallo-beta-lactamase IND-2 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. |
| AID534530 | Antimicrobial activity against multidrug-resistant Pseudomonas aeruginosa CCARM 2161 after 18 hrs by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases. |
| AID656365 | Ratio of drug uptake in lung to plasma of mouse at 20 mg/kg, im | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID573195 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 A biofilm harboring deletion mutation at nucleotide 231-244 in nfxB gene selected at 1 ug/ml of azithromycin after 4 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID587964 | Activity of Escherichia coli beta-lactamase Toho-1 D240A mutant assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID1278321 | Antibacterial activity against ESBL negative Escherichia coli 09-20 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID373765 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh13 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID544585 | Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 8133 expressing bla TEM-55 gene by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID565542 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-06 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID203325 | In vitro antibacterial activity against MOR-84-41 strain of Serratia marcescens | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID521834 | Antibacterial activity against Klebsiella pneumoniae isolate VA367 with blaKPC-3, qnrB19, blaTEM-1, blaSHV-11, blaSHV-12, aac(6')-1b genes by CLSI method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. |
| AID565721 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-26 harboring T residue at 105 position in PDC- 6 and polymorphic OprD gene by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID520810 | Antimicrobial activity against SHV-5 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype D by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID761218 | Antibacterial activity against Pseudomonas aeruginosa 1042-06 by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID559590 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutM::Gm mutant gene assessed as doubling time | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID94368 | In vitro antibacterial activity against MOR-84-24 strain of Klebsiella pneumoniae | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID574425 | Antimicrobial activity against Escherichia coli isolate 339 expressing beta-lactamase KPC2, TEM and PFGE cluster 5 isolated from peritoneal fluid of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID521993 | Antimicrobial activity against Klebsiella pneumoniae isolate KpB expressing OXA-48 and CTX-M-15 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID340736 | Activity of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes. |
| AID523518 | Antimicrobial activity against Pseudomonas aeruginosa isolate 17112 from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID565507 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-25 harboring T residue at 105 position in PDC- 6 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID495799 | Ratio of Kcat to Km of KPC-2 using nitrocefin hydrolysis | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France. |
| AID532902 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID559898 | Antimicrobial activity against Klebsiella oxytoca KO281 harboring beta-lactamase OXY-1 and CMY-2 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | First detection of plasmid-encoded blaOXY beta-lactamase. |
| AID285264 | Antimicrobial activity against Escherichia coli DH5-alpha TC1179 isolate expressing TEM-1 by disk diffusion assay | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID498120 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID529661 | Activity of Pseudomonas aeruginosa 9551 beta-lactamase VIM-15 relative to cephaloridine | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID571694 | Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 3 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID678448 | Antibacterial activity against penicillin-resistant, quinolone-sensitive Pseudomonas aeruginosa 1091-05 | 2012 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18 | Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections. |
| AID567307 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2205 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID516139 | Antibacterial activity against Pulsotype F Acinetobacter genomosp. 3 isolate 4 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS18, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID558536 | Antibacterial activity against bla gene-negative and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P854 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID495636 | Ratio of kcat/Km for Pseudomonas luteola LAM Beta-lactamase LUT-1 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. |
| AID521490 | Antibacterial activity against Escherichia coli harboring pCOL plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID521485 | Antibacterial activity against Klebsiella pneumoniae KN2303 by Etest method in presence of beta-lactamase inhibitor clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID540219 | Volume of distribution at steady state in monkey after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID495513 | Antibacterial activity against Acinetobacter baumannii BM4467 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID497694 | Antimicrobial activity against colistin-resistant Klebsiella pneumoniae isolated from bacteremia patient assessed as percentage of resistant isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea. |
| AID511290 | Antibacterial activity against Escherichia coli DH5alpha | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa. |
| AID659486 | Antimicrobial activity against Pseudomonas aeruginosa after 16 to 20 hrs by 2-fold microbroth dilution method | 2012 | Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4 | Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. |
| AID583189 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 5 mM NagZ inhibitor PUGNAc | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID573213 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB T544C mutant gene selected at 4 ug/ml of azithromycin after 1 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID1373324 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-225 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID522021 | Antimicrobial activity against Enterobacter cloacae isolate 2 expressing beta-lactamase OXA-48 and SHV-5 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID1357468 | Antibacterial activity against IMP-4 producing Pseudomonas aeruginosa isolate 207272 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria. |
| AID576314 | Antimicrobial activity against ESBL-negative Klebsiella pneumoniae 299332 harboring porin OmpK36 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID533002 | Antibacterial activity against VEB-1a and OXA-10 producing Pseudomonas aeruginosa isolate P151 exhibiting PFGE I pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID554387 | Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY operon by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID546432 | Ratio of Kcat to Km for Pseudomonas aeruginosa PDC-3 by spectrophotometer | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. |
| AID582976 | Antimicrobial activity against ampD::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID532897 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 ST 340 expressing beta-lactamase TEM-1, SHV-11 and OXA-2 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID518487 | Ratio of Kcat to Km for Escherichia coli ATCC 25922 AmpC | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID428267 | Antimicrobial activity against carbapenemase producing Enterobacteriaceae assessed as susceptible isolates by CLSI breakpoint assay | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. |
| AID565712 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-17 harboring A residue at 105 position in PDC- 3 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID582972 | Antimicrobial activity against ampD::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID530345 | Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID1278323 | Antibacterial activity against ESBL negative Escherichia coli 1515 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID498112 | Antibacterial activity against Pseudomonas aeruginosa PA5043 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID520800 | Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype H by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID517982 | Antimicrobial activity against Stenotrophomonas maltophilia B715 harboring beta-lactamase L1and L2 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID520796 | Antimicrobial activity against SHV-5 producing Klebsiella pneumoniae with PFGE pulsotype D by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID582969 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID532899 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 588 ST 340 expressing beta-lactamase TEM-1 and SHV-11 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID520803 | Antimicrobial activity against Escherichia coli str. K-12 substr. DH10B harboring plasmid CTX-M-2 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID495657 | Antimicrobial activity against Escherichia coli TOP10 expressing recombinant beta-lactamase BEL-1 by solid agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID564019 | Antibacterial activity against Pseudomonas aeruginosa isolated from lung biopsy specimen of patient by Etest | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain. |
| AID583096 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 W87F mutant beta-lactamase by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding. |
| AID368710 | Volume of distribution during elimination phase in healthy human at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID531682 | Antimicrobial activity against Acinetobacter baumannii Ab290 containing plasmid harboring OXA-58-4 by broth dilution test | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii. |
| AID1357450 | Antibacterial activity against KPC-2 producing Klebsiella pneumoniae isolate 212232 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria. |
| AID495838 | Hydrolytic activity of Escherichia coli BL21 DE3 beta-lactamase VIM-19 by microacidimetric method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID250258 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH02; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID558331 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P338 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID555197 | Antimicrobial activity against nagZ gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID529656 | Ratio of Kcat to Km for Pseudomonas aeruginosa 9551 beta-lactamase VIM-15 | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID571218 | Antimicrobial activity against Pseudomonas aeruginosa isolate TX292 obtained from patient with non-cystic fibrosis by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID1733059 | Antibacterial activity against Pseudomonas aeruginosa clinical isolate. assessed as reduction in bacterial growth by CLSI based broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 39 | Synthesis and antibacterial evaluation of new monobactams. |
| AID285612 | Antimicrobial activity against Pseudomonas aeruginosa 65.68-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID520979 | Antibacterial activity against Pseudomonas aeruginosa KG2505 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID576305 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 287942 harboring porin OmpK36 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID283220 | Antimicrobial activity against Pseudomonas aeruginosa PA0905 | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. |
| AID394686 | Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID522009 | Antimicrobial activity against Klebsiella pneumoniae isolate KpBIC expressing beta-lactamase OXA-48 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID564544 | Ratio of Kcat to Ki for Acinetobacter baumannii ADC-33 beta-lactamase to Kcat to Ki for Acinetobacter baumannii ADC-11 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID563966 | Antibacterial activity against Klebsiella pneumoniae 05-560 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID422494 | Antimicrobial activity against Escherichia coli BL21 (DE3) by E-test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID498115 | Antibacterial activity against Pseudomonas aeruginosa PA1036 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID520879 | Antibacterial activity against Achromobacter xylosoxidans DUC by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. |
| AID554394 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2715 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID279940 | Antibiotic susceptibility by resistance against MDR Pseudomonas aeruginosa from samples collected from patients | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. |
| AID576293 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 11932 harboring porin OmpK36 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID532905 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 525 ST 376 expressing beta-lactamase SHV-1 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID250284 | Susceptibility testing against Pseudomonas aeruginosa ATCC 27853; S=Susceptible | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID368711 | AUC in human cystic fibrosis patient at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID528601 | Antimicrobial activity against Escherichia coli TOP10 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID405086 | Ratio of Kcat to Km of Citrobacter freundii PER2 beta lactamase relative to cephalothin | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Biochemical characterization of PER-2 and genetic environment of blaPER-2. |
| AID584847 | Ratio of Kcat to Km for Aeromonas allosaccharophila AL-1 beta-lactamase PER6 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila. |
| AID573530 | Antibacterial activity against Citrobacter youngae isolate CyB38 harboring blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID565530 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-05 harboring A residue at 105 position in PDC- 2 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID497693 | Antimicrobial activity against colistin-susceptible Klebsiella pneumoniae isolated from bacteremia patient assessed as percentage of resistant isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea. |
| AID429062 | Antimicrobial activity against Proteus mirabilis JIE273 expressing 16S rRNA methyltransferase RmtC | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | RmtC 16S rRNA methyltransferase in Australia. |
| AID533762 | Antibacterial activity against OXA-2 and OXA-19 producing Pseudomonas aeruginosa isolate P66 exhibiting PFGE C pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID587727 | Antimicrobial activity against Escherichia coli DH5alpha carrying Pseudomonas aeruginosa strain PS 297 IMP-18-pLBII after 18 hrs by microdilution broth method | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States. |
| AID555676 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring phagemid pBK-CMV by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. |
| AID531680 | Antimicrobial activity against Acinetobacter baumannii Ab290 harboring TVICU53 plasmid by broth dilution test | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii. |
| AID565547 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-11 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID529457 | Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone B expressing beta-lactamase Oxa-48, TEM-1, CTX-M-15 and Oxa-1 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID285440 | Antimicrobial activity against Escherichia coli DH10B expressing GIL1 after 18 hrs by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii. |
| AID520715 | Antibacterial activity against Acinetobacter baumannii CIP7010 by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97. |
| AID571934 | Antimicrobial activity against Escherichia coli MC4100 harboring promoter hybrid 1 in beta-lactamase GES-1 by Etest | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter. |
| AID534306 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA509 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID558338 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P1730 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID583098 | Antimicrobial activity against Escherichia coli XL1-Blue harboring pLBII-VIM-2 plasmid expressing VIM-2 beta-lactamase by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding. |
| AID444052 | Hepatic clearance in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID495909 | Antimicrobial activity in Escherichia coli J53 transconjugate with Escherichia coli DIH-1 expressing natural plasmid containing beta-lactamase VIM-19 | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID285575 | Antimicrobial activity against Pseudomonas aeruginosa 65.18-2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID532412 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate PV-05X-07 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID576074 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18260 harboring pSHA2-encoded porin OmpK36 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID374362 | Ratio of Kcat to Km of Aeromonas caviae A324R metallo-beta-lactamase IMP-19 expressed in Escherichia coli DH5alpha by computerized microacidimetric method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France. |
| AID1278308 | Antibacterial activity against NDM-1 positive Klebsiella pneumoniae BAA-2146 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID522381 | Antimicrobial activity against blaKPC-possessing Klebsiella pneumoniae isolates assessed as susceptible isolates by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniae isolates. |
| AID1357444 | Antibacterial activity against KPC-2 producing Klebsiella pneumoniae isolate 209632 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria. |
| AID522025 | Antimicrobial activity against Escherichia coli isolate A expressing beta-lactamase OXA-48 and TEM-150 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID534288 | Antimicrobial activity against Stenotrophomonas maltophilia KJ harboring pRK415 plasmid by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID373763 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh9 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID532901 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 365 ST 376 expressing beta-lactamase SHV-27, CTX-M-15 and OXA-4 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID573399 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID560277 | Bactericidal activity against Pseudomonas aeruginosa NH57388A infected in Swiss neutropenic mouse assessed as reduction in lung bacterial load at 400 mg/kg BID administered 24 hrs post infection through aerosol | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. |
| AID583652 | Antibacterial activity against Escherichia coli TOP10 expressing metallo-beta-lactamase NDM-1 | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. |
| AID495633 | Antimicrobial activity against Escherichia coli DH10B transfected with pBK-L3 expressing blaLUT-1 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. |
| AID1209733 | Binding affinity to mouse OAT3 expressed in CHO cells at 10 to 1000 uM measured over 20 mins | 2013 | Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4 | Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics. |
| AID761214 | Antibacterial activity against Acinetobacter baumannii AB-3167 by broth microdilution method | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID518494 | Ratio of Kcat to Km for Escherichia coli Penicillin-binding protein 3 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID279183 | Antibacterial activity against Escherichia coli DH10B expressing recombinant beta lactamase LAP1 | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Novel Ambler class A beta-lactamase LAP-1 and its association with the plasmid-mediated quinolone resistance determinant QnrS1. |
| AID555644 | Antimicrobial activity against ampDh2 gene-deficient Pseudomonas aeruginosa PAO1 using 30 ug/disk by agar diffusion method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID571906 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 17 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID565509 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-27 harboring A residue at 105 position in PDC- 7 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID1325282 | Induction of defects in chromosomal segregation in Escherichia coli SH3210 assessed as generation of anucleate cells at MIC after 2.5 hrs using beta-galactosidase substrate DDAOG by fluorescence assay | 2016 | Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22 | 5-Alkyloxytryptamines are membrane-targeting, broad-spectrum antibiotics. |
| AID322323 | Antibacterial activity against Escherichia coli DH5 alpha-URA5905 isolates expressing CTX-M-15 and TEM-1B enzymes by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID567280 | Activity of Acinetobacter baumannii ADC-11 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID574439 | Antimicrobial activity against Escherichia coli DH10B by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID495808 | Antimicrobial activity against Escherichia coli DH5alpha 2878 transformant expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID520981 | Antibacterial activity against Escherichia coli harboring pNYC plasmid expressing blaKPC gene by Etest method in presence of beta-lactamase inhibitor clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID1476617 | Antibacterial activity against Citrobacter freundii ATCC 29063 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID523501 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1352c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID564533 | Antimicrobial activity against Escherichia coli TOP10 harboring pADC-11 plasmid carrying entire blaAmpC gene with alanine residue insertion at 215 position by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID341596 | Antibacterial activity against carbapenem-resistant blaKPC-encoding plasmid harboring Klebsiella pneumoniae 490 isolate producing KPC3 and TEM1 carbapenemases | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. |
| AID1395491 | Antibacterial activity against new delhi metallo-beta-lactamase-1 harboring Klebsiella pneumoniae 13-1 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria. |
| AID518501 | Inhibition of Escherichia coli ATCC 25922 AmpC | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID520775 | Antibacterial activity against beta-lactamase KPC-2 producing Klebsiella pneumoniae isolate K1 to K9 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID532911 | Antimicrobial activity against KPC-3 producing Klebsiella pneumoniae 557 ST 327 expressing beta-lactamase TEM-1 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID1474167 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID322324 | Antibacterial activity against Escherichia coli INSRA5924 isolates expressing CTX-M-32 and TEM-1B enzymes by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID372626 | Ratio of Kcat/Km for Escherichia coli DH5alpha beta-lactamase TEM-12 to Kcat/Km for Escherichia coli DH5alpha beta-lactamase TEM-158 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID340731 | Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase SHV-ES by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID326267 | Antibacterial activity against Escherichia coli DH5-alpha carrying pSCO1 encoding SCO1 by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli. |
| AID1476610 | Antibacterial activity against Pseudomonas aeruginosa ARC 3506 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID531765 | Antimicrobial activity against Pseudomonas aeruginosa blood isolate 4667 containing PFGE clone A expressing beta-lactamase IMP-15 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. |
| AID524388 | Antibacterial activity against Escherichia coli NKE1366 harboring deletion mutation in acrB and vector expressing mdtABC gene | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID559807 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system mutY mutant gene complemented with wild type DNA oxidative repair system mutY gene | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID555227 | Activity of Acinetobacter genomosp. 3 isolate 195 ADC-18 | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Genetic variability among ampC genes from acinetobacter genomic species 3. |
| AID522355 | Antibacterial activity against mexA deficient Pseudomonas aeruginosa TNP070 transformant harboring pPlcMexA carrying chimeric mexA gene with plcH signal sequence | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Tat pathway-mediated translocation of the sec pathway substrate protein MexA, an inner membrane component of the MexAB-OprM xenobiotic extrusion pump in Pseudomonas aeruginosa. |
| AID519014 | Antimicrobial activity against Enterobacter aerogenes isolate SS-13 by broth macrodilution method | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID250259 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH03; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID373760 | Antibacterial activity against imipenem-intermediate Acinetobacter baumannii ab1297 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID1395492 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 12-11 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria. |
| AID559904 | Antimicrobial activity against Escherichia coli TF-KP278 harboring beta-lactamase OXY-1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | First detection of plasmid-encoded blaOXY beta-lactamase. |
| AID565540 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-04 harboring A residue at 105 position in PDC- 2 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID1373363 | Protein binding in human plasma | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID554388 | Antimicrobial activity against ampicillin- and ticarcillin-resistant Pseudomonas aeruginosa FE60 mutant transformed with pAGH97 carrying mexXY F29S mutant by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID573503 | Antibacterial activity against Escherichia coli isolate Ec9381 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID534525 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3696 after 18 hrs by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases. |
| AID529582 | Ratio of Kcat to Km for Bradyrhizobium japonicum beta-Lactamase BJP-1 | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID571040 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA113 obtained from patient with cystic fibrosis by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID521996 | Antimicrobial activity against Escherichia coli isolate J53 harboring p3A containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID394688 | Antibacterial activity against beta-lactams resistant OprD-deficient Pseudomonas aeruginosa isolate by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID532398 | Antibacterial activity against VIM-1 producing Pseudomonas aeruginosa clone D1 isolate VA-06X-63 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID574432 | Antimicrobial activity against Escherichia coli isolate 543 expressing beta-lactamase KPC2, CTX-M-15, TEM and PFGE cluster 4 isolated from synovial fluid of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID495803 | Antimicrobial activity against Escherichia coli 2603 strain expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID555185 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox delta ampDh3::lox and wild type nagZ gene after 18 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID587974 | Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 C69A mutant assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID203318 | In vitro antibacterial activity against IO-83-63 strain of Serratia marcescens | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID498097 | Antibacterial activity against Pseudomonas aeruginosa PA1022 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID562337 | Activity at Chryseobacterium indologenes 597 metallo-beta-lactamase IND-6 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. |
| AID368707 | Volume of distribution at steady state in human cystic fibrosis patient at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID531677 | Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid containing OXA-58-4 by broth dilution test | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii. |
| AID534290 | Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring pRK415 plasmid and ampN with xylE-Gmomega cassette insertion by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID564536 | Antimicrobial activity against Escherichia coli TOP10 harboring pTOPO plasmid by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID582974 | Antimicrobial activity against dacB::lox and nagZ::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID368709 | Volume of distribution during elimination phase in human cystic fibrosis patient at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID519735 | Antibacterial activity against Escherichia coli DH5alpha with deltaampC by agar dilution method in presence of 2 ug/ml clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID571892 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 10 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID523490 | Antimicrobial activity against Pseudomonas aeruginosa AHP Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID373757 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab1308 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID528604 | Antimicrobial activity against Escherichia coli J53 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID565536 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-32 harboring A residue at 105 position in PDC- 10 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID529645 | Antimicrobial activity against Pseudomonas aeruginosa 166301 expressing beta-lactamase VIM-16 obtained from urine of patient by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID498110 | Antibacterial activity against Pseudomonas aeruginosa PA1022 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID565714 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-19 harboring A residue at 105 position in PDC- 3 and wild type OprD gene by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID1373347 | AUC in rat at 10 mg/kg, iv | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID545147 | Inhibition of Klebsiella pneumoniae HP205 cephalosporinase CMY-36 by UV spectrophotometer in presence of 100 uM of cephalothin | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids. |
| AID285271 | Activity of Escherichia coli BL21(DE3) beta-lactamase TEM1 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. |
| AID577648 | Antimicrobial activity against Escherichia coli isolate 157T expressing beta-lactamase KPC2 and PFGE cluster 3 isolated from urine of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID560593 | Antimicrobial activity against rifampin-resistant Pseudomonas aeruginosa ATCC 27853 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates. |
| AID576271 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 18567 harboring porin OmpK36V mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID498122 | Antibacterial activity against Pseudomonas aeruginosa PA899 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID574436 | Antimicrobial activity against Escherichia coli isolate 547T expressing beta-lactamase KPC2 and PFGE cluster 4 isolated from blood of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID558535 | Antibacterial activity against bla gene-negative and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P843 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID558052 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S15 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID1373348 | AUC in dog at 10 mg/kg, iv | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID1592957 | Antibacterial activity against multi-drug resistant Escherichia coli NMI 3548/14 assessed as reduction in microbial growth incubated for 20 hrs | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae. |
| AID522007 | Antimicrobial activity against Escherichia coli isolate J53 harboring pI-1 containing beta-lactamase OXA-48 located within transposon Tn1999.2 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID529660 | Ratio of Kcat to Km for Pseudomonas aeruginosa COL-1 beta-lactamase VIM-2 | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID554410 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2933 expressing inactivated mexB gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID1198150 | Antimicrobial activity against Acinetobacter baumannii by broth microdilution method | 2015 | Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5 | Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model. |
| AID531755 | Antibacterial activity against Pseudomonas aeruginosa 2126 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID558047 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S10 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID560490 | Antibacterial activity against 5 x 10'5 CFU/ml Escherichia coli MC4100 harboring plasmid ACYC184 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase. |
| AID498109 | Antibacterial activity against Pseudomonas aeruginosa PA899 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID573210 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T77C mutant gene selected at 4 ug/ml of azithromycin after 6 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID522387 | Antimicrobial activity against Escherichia coli TOP10 | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Genetic and biochemical characterization of TRU-1, the endogenous class C beta-lactamase from Aeromonas enteropelogenes. |
| AID522020 | Antimicrobial activity against Escherichia coli isolate J53 harboring pEnc1 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID250268 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH21; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID544496 | Ratio of MIC for Escherichia coli TOP10 harboring beta-lactamase KPC-4 to MIC for Escherichia coli TOP10 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. |
| AID372618 | Ratio of Kcat to Km for Escherichia coli CF0042 beta-lactamase TEM-35 | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID532409 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-38 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID563968 | Antibacterial activity against Escherichia coli TOP10 harboring beta-lactamase NDM-1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID558325 | Antibacterial activity against bla gene-negative and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P850 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID565544 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-08 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID576320 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 31750 harboring porin OmpK36 gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID532898 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 523 transformant by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID519011 | Ratio of Kcat to Km for Beta-lactamase TEM-149 T182M mutant expressed in Escherichia coli HB101 | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | E240V substitution increases catalytic efficiency toward ceftazidime in a new natural TEM-type extended-spectrum beta-lactamase, TEM-149, from Enterobacter aerogenes and Serratia marcescens clinical isolates. |
| AID534397 | Ratio of Kcat to Km for Escherichia coli JM109 harboring recombinant pKHM-1 Beta-lactamase KHM-1 assessed as compound hydrolysis at >1 by UV-visible spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate. |
| AID495658 | Antimicrobial activity against Escherichia coli TOP10 by solid agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. |
| AID520968 | Antibacterial activity against Escherichia coli harboring pRYC plasmid expressing blaKPC gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID524263 | Antibacterial activity against Escherichia coli NKE127 harboring deletion mutation in acrB and cpxAR protein | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID495631 | Antimicrobial activity against Pseudomonas luteola LAM expressing blaLUT-1 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola. |
| AID1476621 | Antibacterial activity against Acinetobacter baumannii ATCC BAA 1800 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID519982 | Activity of Klebsiella pneumoniae Beta-Lactamase SHV-55 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae. |
| AID342019 | Antibacterial activity against plasmid pK29 transconjugant Escherichia coli J53 by Etest | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae. |
| AID573502 | Antibacterial activity against Klebsiella pneumoniae isolate Kp38045 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1891022 | Antibacterial activity against Klebsiella pneumoniae 1009 producing class A CTX-M-14 assessed as inhibition of bacterial growth by CLSI based broth microdilution method | 2022 | Bioorganic & medicinal chemistry, 05-15, Volume: 62 | Broad-spectrum cyclic boronate β-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability. |
| AID405634 | Inhibition of bocillin FL binding to Pseudomonas aeruginosa PAO1 penicillin-binding protein 1a | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. |
| AID540221 | Volume of distribution at steady state in human after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID495816 | Antimicrobial activity against Escherichia coli 2603 strain expressing beta-lactamase VIM-19 by microdilution method in presence of 0.4 mM EDTA | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID576062 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 71697 harboring porin OmpK36V mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID561629 | Antimicrobial activity against ampD2-deficient Stenotrophomonas maltophilia KJ by twofold serial agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. |
| AID1373311 | Antimicrobial activity against Escherichia coli expressing beta-lactamase DHA by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID285688 | Antimicrobial susceptibility of carbapenem-resistant Pseudomonas aeruginosa PA2404 isolate expressing carbapenemase KPC2 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. |
| AID322321 | Antibacterial activity against Escherichia coli DH5 alpha-URA5776 isolates expressing CTX-M-14 enzyme by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal. |
| AID1395493 | Antibacterial activity against carbapenem-resistant Klebsiella pneumoniae 12-12 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150 | Synthesis and structure-activity relationship of novel bisindole amidines active against MDR Gram-positive and Gram-negative bacteria. |
| AID497692 | Antimicrobial activity against Klebsiella pneumoniae isolated from bacteremia patient assessed as percentage of resistant isolates by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea. |
| AID1373318 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-40 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID340738 | Ratio of Kcat to Km of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis relative to control | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes. |
| AID522022 | Antimicrobial activity against Escherichia coli isolate J53 harboring pEnc2 containing beta-lactamase OXA-48 located within transposon Tn1999 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID498111 | Antibacterial activity against Pseudomonas aeruginosa PA1042 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID565718 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-23 harboring A residue at 105 position in PDC- 5 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID530349 | Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. |
| AID1373322 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-160 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID761222 | Inhibition of PBP3 in Pseudomonas aeruginosa ATCC 27853 after 20 mins by fluorescence assay | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID1357435 | Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli isolate 209285 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria. |
| AID1278318 | Antibacterial activity against BL positive Pseudomonas aeruginosa 27853 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID560275 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 infected in Swiss neutropenic mouse assessed as mouse survival rate at 400 mg/kg BID administered 24 hrs post infection through aerosol | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. |
| AID498103 | Antibacterial activity against Pseudomonas aeruginosa PA5026 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1139452 | Displacement of fluorescent Bocillin FL from Pseudomonas aeruginosa PBP1b | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Siderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteria. |
| AID520973 | Antibacterial activity against Klebsiella pneumoniae KN2303 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID444055 | Fraction absorbed in human | 2010 | Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3 | Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. |
| AID584837 | Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER1 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila. |
| AID125421 | In vitro antibacterial activity against MOR-84-45 strain of Morganella morganii | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID529491 | Antimicrobial activity against Enterobacter cloacae isolate 649 containing PFGE genetic clone B expressing qnrB2 and beta-lactamase KPC-2 and SHV-12 gene by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. |
| AID571222 | Antimicrobial activity against Pseudomonas aeruginosa isolate 164CD obtained from patient with non-cystic fibrosis by Etest | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID576068 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 69036 harboring porin OmpK36V mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID519817 | Antimicrobial activity against Pseudomonas aeruginosa 27853 by CLSI protocol based broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID517980 | Antimicrobial activity against Pseudomonas aeruginosa HPA996 harboring beta-lactamase VIM-2 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID1229265 | Antibacterial activity against Pseudomonas aeruginosa | 2015 | ACS medicinal chemistry letters, May-14, Volume: 6, Issue:5 | SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3. |
| AID498101 | Antibacterial activity against Pseudomonas aeruginosa PA881 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID25248 | Pseudo first order rate constant for the alkaline hydrolysis of beta-lactams (35 degree Celsius) was determined at pH 10 | 1987 | Journal of medicinal chemistry, Mar, Volume: 30, Issue:3 | Heteroatom-activated beta-lactam antibiotics: considerations of differences in the biological activity of [[3(S)-(acylamino)-2-oxo-1-azetidinyl]oxy]acetic acids (oxamazins) and the corresponding sulfur analogues (thiamazins). |
| AID520970 | Antibacterial activity against Escherichia coli harboring pNGR plasmid expressing blaKPC gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID1373327 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID565531 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-04 harboring A residue at 105 position in PDC- 2 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID1373355 | Clearance in rat at 10 mg/kg, iv | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID519796 | Inhibition of Bocillin FL binding to PBP1A in Escherichia coli MC4100 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID283322 | Antimicrobial activity against Escherichia coli XL10/pSHV-31 | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands. |
| AID571902 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 15 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID424863 | Antimicrobial activity against carbapenem-resistant Pseudomonas aeruginosa clinical isolate assessed as resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID535710 | Antibacterial activity against Escherichia coli TOP10 expressing AmpC-B2 S287N mutant protein by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1 | Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. |
| AID1278328 | Antibacterial activity against beta-lactamase producing Proteus vulgaris 29905 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID529575 | Activity of Erwinia carotovora subsp. atroseptica DSM 30184 beta-lactamase CAR-1 | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID649186 | Antibacterial activity against Escherichia coli after 16 to 20 hrs by broth microdilution method | 2012 | Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2 | Potent inhibitors of LpxC for the treatment of Gram-negative infections. |
| AID498113 | Antibacterial activity against Pseudomonas aeruginosa PA880 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1373329 | Antimicrobial activity against Pseudomonas aeruginosa expressing nalB/delta-mexXY/delta-mexCDoprJ/delta-ampC by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID1278309 | Antibacterial activity against ESBL negative Klebsiella pneumoniae 09-8 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID565713 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-18 harboring A residue at 105 position in PDC- 3 by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID530814 | Antibacterial activity against Klebsiella pneumoniae 11978 harboring plasmid pA-1carrying beta-lactamase OXA-48 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. |
| AID511580 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAO1 deficient in ampD, ampDh3 and ampDh3 gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID562813 | Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. |
| AID396031 | Antibacterial activity against drug-resistant AcrAB-TolC efflux pump deficient Enterobacter cloacae EcdeltaacrA isolate expressing pACYC184 plasmid by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID521286 | Antimicrobial activity against CTX-M-2 and TEM-1 producing Klebsiella pneumoniae transconjugants/transformants with PFGE pulsotype J by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID520713 | Antibacterial activity against Escherichia coli TOP10 harboring pOXA-97 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97. |
| AID1733052 | Antibacterial activity against Escherichia coli ATCC 8739 assessed as reduction in bacterial growth by CLSI based broth microdilution method | 2021 | Bioorganic & medicinal chemistry letters, 05-01, Volume: 39 | Synthesis and antibacterial evaluation of new monobactams. |
| AID1373302 | Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-47 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID25423 | Half life at pH 10 | 1987 | Journal of medicinal chemistry, Mar, Volume: 30, Issue:3 | Heteroatom-activated beta-lactam antibiotics: considerations of differences in the biological activity of [[3(S)-(acylamino)-2-oxo-1-azetidinyl]oxy]acetic acids (oxamazins) and the corresponding sulfur analogues (thiamazins). |
| AID1357465 | Antibacterial activity against IMP-4 producing Pseudomonas aeruginosa isolate 209321 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria. |
| AID373754 | Antibacterial activity against imipenem-susceptible Acinetobacter baumannii ab8 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID572134 | Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 34 expressing ampC, ompA, adeB, adeM by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID554403 | Antimicrobial activity against Pseudomonas aeruginosa isolate 615R expressing inactivated mexB gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID372605 | Antibacterial activity against Escherichia coli BER1 producing beta-lactamase pI 5.2 and pI 5.4 by microdilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases. |
| AID524260 | Antibacterial activity against Escherichia coli NKE96 harboring deletion mutation in acrB protein | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID587970 | Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 N104D mutant assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID519804 | Inhibition of Bocillin FL binding to PBP1A in Pseudomonas aeruginosa PAO1 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID405638 | Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 4 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. |
| AID520711 | Antibacterial activity against Escherichia coli TOP10 harboring pOXA-58 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97. |
| AID531753 | Antibacterial activity against Pseudomonas aeruginosa 2439 by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID498108 | Antibacterial activity against Pseudomonas aeruginosa PA1054 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.6 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID559902 | Antimicrobial activity against Escherichia coli TF-KO279 harboring beta-lactamase OXY-1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | First detection of plasmid-encoded blaOXY beta-lactamase. |
| AID279814 | Antimicrobial activity against Escherichia coli DH5-alpha with pYW2 expressing KPC2 and TEM1 gene by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. |
| AID523491 | Antimicrobial activity against Pseudomonas aeruginosa Z799/61 by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID565543 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-07 harboring A residue at 105 position in PDC- 2 and insertion of ISPa27 sequence in OprD gene by Etest method in presence of cloxacillin | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID520705 | Antibacterial activity against Acinetobacter baumannii phenotype 1 by disk diffusion method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Carbapenem-resistant Acinetobacter baumannii isolates from Tunisia producing the OXA-58-like carbapenem-hydrolyzing oxacillinase OXA-97. |
| AID560086 | Bactericidal activity against Pseudomonas aeruginosa isolate 956 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID656348 | Antibacterial activity against Pseudomonas aeruginosa isolate 1091-05 | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID573204 | Antimicrobial activity against mutS::lox-deficient Pseudomonas aeruginosa PAOMSB biofilm harboring nfxB T41C mutant gene selected at 4 ug/ml of azithromycin after 3 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID534529 | Antimicrobial activity against Listeria monocytogenes KCTC 19111 after 18 hrs by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Antimicrobial activity of a halocidin-derived peptide resistant to attacks by proteases. |
| AID495514 | Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4668 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID574435 | Antimicrobial activity against Escherichia coli isolate 547 expressing beta-lactamase KPC2, TEM and PFGE cluster 4 isolated from blood of patient by vitek-2 method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. |
| AID560089 | Bactericidal activity against Enterobacter cloacae isolate 4073 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID394692 | Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing AmpC, MexAB-OprM pump by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID522023 | Antimicrobial activity against Citrobacter freundii isolate expressing beta-lactamase OXA-48 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID565517 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-18 harboring A residue at 105 position in PDC- 3 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID518507 | Inhibition of Escherichia coli Penicillin-binding protein 2 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID576286 | Antimicrobial activity against ESBL-positive Klebsiella pneumoniae 17049 harboring porin OmpK36V mutant gene by Etest | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. |
| AID587984 | Antibacterial activity against Escherichia coli AS226 carrying pBSDF160T mutant after 18 hrs by broth microdilution method | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID583182 | Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID429078 | Antibacterial activity against Escherichia coli J53 expressing Klebsiella pneumoniae Greece blaKPC-2 gene by E test method | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece. |
| AID309767 | Effect on Pseudomonas aeruginosa PAM1723 infected pneumonic Sprague-Dawley rat model assessed as survival | 2007 | Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22 | MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate. |
| AID554384 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by twofold macrodilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID534293 | Antimicrobial activity against Stenotrophomonas maltophilia KJN2 harboring pRK-EcG plasmid and ampN with xylE-Gmomega cassette insertion by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID571908 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii beta clonal group isolate 18 expressing ompA, adeB, adeM, aacA4, blaSHV-5 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1373312 | Antimicrobial activity against Escherichia coli expressing beta-lactamase CMY-2 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID558534 | Antibacterial activity against bla gene-positive and nitrocefin reaction-negative beta-lactamase harboring Campylobacter jejuni isolate P1699 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID425866 | Antimicrobial activity against Carnobacterium divergens BM4489 expressing beta-lactamase CAD1 at 3 McFarland inoculum size by E-test | 2008 | Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2 | Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens. |
| AID520776 | Antibacterial activity against beta-lactamase KPC-2 producing Serratia marcescens isolate S1 to S21 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID518508 | Inhibition of Escherichia coli Penicillin-binding protein 3 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID546433 | Ratio of Kcat to Km for Pseudomonas aeruginosa PDC-5 by spectrophotometer | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. |
| AID1373296 | Antimicrobial activity against Escherichia coli expressing beta-lactamase VEB-4 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID394694 | Antibacterial activity against beta-lactams resistant Pseudomonas aeruginosa isolate expressing MexAB-OprM pump, MexXY-OprM pump by macrodilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. |
| AID656349 | Antibacterial activity against Klebsiella pneumoniae 1000-02 | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID368720 | Protein binding in healthy human serum at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID571695 | Antimicrobial activity against Acinetobacter baumannii alpha clonal group isolate 4 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID498084 | Antibacterial activity against Pseudomonas aeruginosa PA5043 assessed as inhibition of biofilm formation by microtiter plate reader assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1592960 | Antibacterial activity against multi-drug resistant Klebsiella pneumoniae NMI 3081/09 assessed as reduction in microbial growth incubated for 20 hrs | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168 | Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae. |
| AID529581 | Ratio of Kcat to Km for Janthinobacterium lividum THIN-B | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora. |
| AID532414 | Antibacterial activity against IMP-13 producing Pseudomonas aeruginosa clone C2 isolate NA-14X-02 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID649189 | Antibacterial activity against Acinetobacter baumannii after 16 to 20 hrs by broth microdilution method | 2012 | Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2 | Potent inhibitors of LpxC for the treatment of Gram-negative infections. |
| AID373050 | Antimicrobial activity against Bacillus clausii NR expressing beta-lactamase BCL1 by agar-dilution technique | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii. |
| AID250269 | Susceptibility testing against Pseudomonas aeruginosa PAE_NUH22; R=Resistant | 2005 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 15, Issue:8 | Structure-activity relationships of bivalent aminoglycosides and evaluation of their microbiological activities. |
| AID495907 | Antimicrobial activity in Escherichia coli TOP10 strain harbouring recombinant plasmid VIM-1 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID560094 | Bactericidal activity against Escherichia coli isolate 5411 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID518184 | Antimicrobial activity against Pseudomonas aeruginosa 18S/H harboring beta-lactamase Class C by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID342020 | Antibacterial activity against Escherichia coli J53 by Etest | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Sequencing and comparative genomic analysis of pK29, a 269-kilobase conjugative plasmid encoding CMY-8 and CTX-M-3 beta-lactamases in Klebsiella pneumoniae. |
| AID572122 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 28 expressing ampC, ompA, adeM, aadB, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID534289 | Antimicrobial activity against Stenotrophomonas maltophilia KJ harboring pRK-NG plasmid by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. |
| AID1357438 | Antibacterial activity against extended-spectrum beta-lactamase producing Escherichia coli isolate 106342 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria. |
| AID562338 | Ratio of Kcat to Km for Chryseobacterium indologenes 597 metallo-beta-lactamase IND-6 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. |
| AID565199 | Antimicrobial activity against Klebsiella pneumoniae isolate T-1780 expressing VIM-1 and KPC-2 genes by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. |
| AID573211 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAA biofilm harboring nfxB C89T mutant gene selected at 0.5 ug/ml of azithromycin after 3 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID163069 | In vitro antibacterial activity against IO-83-21 strain of Proteus rettgeri | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID531318 | Ratio of Kcat to Km for Escherichia coli beta-lactamase VIM-1 by spectrophotometry | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family. |
| AID540213 | Half life in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID559585 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring DNA oxidative repair system deltamutT::Gm mutant gene by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID558333 | Antibacterial activity against bla gene-positive and nitrocefin reaction-positive beta-lactamase harboring Campylobacter jejuni isolate P790 by NCCLS agar doubling dilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni. |
| AID283321 | Antimicrobial activity against Escherichia coli XL10/vector | 2007 | Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3 | Detection of a new SHV-type extended-spectrum beta-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in The Netherlands. |
| AID1373299 | Antimicrobial activity against Escherichia coli expressing beta-lactamase TEM-10 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID498096 | Antibacterial activity against Pseudomonas aeruginosa PA899 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID405639 | Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. |
| AID517974 | Antimicrobial activity against Escherichia coli nmcA harboring beta-lactamase NMCA by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID509867 | Antibacterial activity against Acinetobacter baumannii isolate 2824 isolated from human urine | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Acinetobacter baumannii increases tolerance to antibiotics in response to monovalent cations. |
| AID374364 | Antimicrobial activity against Aeromonas caviae A324R expressing metallo-beta-lactamase IMP-19 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France. |
| AID522383 | Inhibition of Beta-lactamase KPC-2 in Klebsiella pneumoniae isolates assessed as reduction in antimicrobial MIC of beta-lactams by agar dilution method relative to untreated control | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniae isolates. |
| AID571034 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA22 obtained from patient with cystic fibrosis by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID565510 | Antibacterial activity against oprD, mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-28 harboring A residue at 105 position in PDC- 7 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID520793 | Antimicrobial activity against CTX-M-2 producing Klebsiella pneumoniae with PFGE pulsotype A by Etest | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. |
| AID532408 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B2 isolate VA-06X-28 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID396026 | Antibacterial activity against drug-resistant Enterobacter cloacae EcDC64 isolate expressing AcrAB-TolC efflux pump by Etest | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. |
| AID582980 | Antimicrobial activity against ampC::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID340725 | Antimicrobial activity against Enterobacter isolates producing extended-spectrum beta-lactamase CTX-M-1 by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. |
| AID424859 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by E-test | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID1706292 | Drug excretion in human urine assessed as unaltered drug | 2020 | European journal of medicinal chemistry, Dec-15, Volume: 208 | β-lactam antibiotics: An overview from a medicinal chemistry perspective. |
| AID324360 | Antibacterial activity against Acinetobacter johnsonii 7037 expressing SCO1 by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina. |
| AID516145 | Antibacterial activity against Pulsotype I Acinetobacter genomosp. 3 isolate 11 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID540220 | Clearance in human after iv administration | 2005 | Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7 | Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. |
| AID555199 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring deltaampD::lox deltaampDh2::lox delta ampDh3::lox after 18 hrs by Etest | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID562736 | Antimicrobial activity against Klebsiella pneumoniae AH24-270 expressing blaCTX-M-71 gene by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID531678 | Antimicrobial activity against Acinetobacter baumannii TVICU53 by broth dilution test | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii. |
| AID583188 | Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 harboring dacB gene by broth microdilution method in presence of 0.5 mM NagZ inhibitor PUGNAc | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID529643 | Antimicrobial activity against Pseudomonas aeruginosa 9551 expressing beta-lactamase VIM-15 obtained from urine of patient by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID532907 | Antimicrobial activity against carbapenem-resistant KPC-2 producing Klebsiella pneumoniae 526 ST 376 expressing beta-lactamase SHV-1 by agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7 | Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. |
| AID583183 | Antimicrobial activity against dacB::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID285610 | Antimicrobial activity against Pseudomonas aeruginosa 65.68-2 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID324359 | Antibacterial activity against Escherichia coli DH10B by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina. |
| AID573501 | Antibacterial activity against Morganella morganii isolate Mm38009 harboring IncL/M plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1373330 | Antimicrobial activity against Pseudomonas aeruginosa expressing delta-mexB/mexXY/delta-ampDh2/ delta-ampD by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID554409 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2729 expressing inactivated mexB gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID517973 | Antimicrobial activity against Serratia marcescens S6 harboring beta-lactamase SME-1.AmpC by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID323040 | Antimicrobial activity against extended-spectrum-beta-lactamase producing Klebsiella pneumoniae assessed as percent resistant isolates | 2007 | Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6 | Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. |
| AID563970 | Antibacterial activity against Escherichia coli J53 harboring beta-lactamase NDM-1 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID573196 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 A biofilm harboring nfxB T248C mutant gene selected at 4 ug/ml of azithromycin after 4 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID519980 | Ratio of Kcat to Km for Klebsiella pneumoniae Beta-Lactamase SHV-55 | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Biochemical characterization of SHV-55, an extended-spectrum class A beta-lactamase from Klebsiella pneumoniae. |
| AID571888 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii alpha clonal group isolate 8 expressing ampC, ompA, adeB, adeM, aacC1, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID1706289 | Elimination half life in human at 30 mg/kg, iv | 2020 | European journal of medicinal chemistry, Dec-15, Volume: 208 | β-lactam antibiotics: An overview from a medicinal chemistry perspective. |
| AID368703 | Elimination half life in human cystic fibrosis patient at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID285577 | Antimicrobial activity against Pseudomonas aeruginosa 65.18-4 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID531681 | Antimicrobial activity against Acinetobacter baumannii Ab290 containing plasmid harboring OXA-58-3 by broth dilution test | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Acquisition of a plasmid-borne blaOXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii. |
| AID520383 | Antimicrobial activity Escherichia coli DH5alpha expressing metallo-beta-lactamase VIM-11 by agar macrodilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain. |
| AID559687 | Antibacterial activity against ESBL-positive Escherichia coli Top10 harboring plasmid AT517 | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. |
| AID519801 | Inhibition of Bocillin FL binding to PBP5 in Escherichia coli MC4100 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID1229260 | Activity of Pseudomonas aeruginosa PBP3 assessed as acylation rate constant | 2015 | ACS medicinal chemistry letters, May-14, Volume: 6, Issue:5 | SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3. |
| AID516147 | Antibacterial activity against Pulsotype D Acinetobacter genomosp. 3 isolate 18 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, repAcil, IS1008, intI1 genetic elements by broth micro dilution | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan. |
| AID532389 | Antibacterial activity against VIM-1 producing Enterobacter cloacae isolate TO-16X-51 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID495802 | Antimicrobial activity against Escherichia coli 138 expressing beta-lactamase VIM-19 by microdilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria. |
| AID523495 | Antimicrobial activity against Pseudomonas aeruginosa isolate 1693c from fibrosis patient by Etest | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID530816 | Antibacterial activity against Escherichia coli J53 harboring plasmid-encoded beta-lactamase OXA-48 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. |
| AID498303 | Antibacterial activity against Pseudomonas aeruginosa PA1042 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID405821 | Antimicrobial activity against Acinetobacter baumannii 695 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID571045 | Antimicrobial activity against Pseudomonas aeruginosa isolate GB61 obtained from patient with non-cystic fibrosis by Etest | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID1476608 | Antibacterial activity against Pseudomonas aeruginosa KW799/wt after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID368704 | Elimination half life in healthy human at 2000 mg/20 mins infusion | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9 | Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. |
| AID567305 | Antimicrobial activity against SHV-12 ESBL producing Pseudomonas aeruginosa isolate 2203 isolated from burn patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | Acquisition of a transposon encoding extended-spectrum beta-lactamase SHV-12 by Pseudomonas aeruginosa isolates during the clinical course of a burn patient. |
| AID498124 | Antibacterial activity against Pseudomonas aeruginosa PA1042 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID1278320 | Antibacterial activity against ESBL positive Klebsiella pneumoniae 700603 after 18 hrs by agar dilution assay | 2016 | European journal of medicinal chemistry, Mar-03, Volume: 110 | Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria. |
| AID656350 | Antibacterial activity against Acinetobacter baumannii AB-3167 | 2011 | ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5 | Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. |
| AID582979 | Antimicrobial activity against ampR::lox gene-deficient Pseudomonas aeruginosa PAO1 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID1357428 | Antibacterial activity against Escherichia coli isolate 210737 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria. |
| AID563967 | Antibacterial activity against Escherichia coli TOP10 by Etest method | 2009 | Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12 | Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. |
| AID587969 | Ratio of Kcat to Km for Escherichia coli beta-lactamase Toho-1 N104A mutant assessed as compound hydrolysis by spectrophotometry | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID564526 | Antimicrobial activity against Acinetobacter baumannii AYE expressing VEB-1 gene by Etest method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Extended-spectrum cephalosporinase in Acinetobacter baumannii. |
| AID495906 | Antimicrobial activity in Escherichia coli TOP10 hourbouring recombinant plasmid VIM-4 by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID561445 | Antibacterial activity against Escherichia coli DH10B harboring plasmid BCSK carrying beta-lactamase CMY-44 gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7 | Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase. |
| AID560091 | Bactericidal activity against Klebsiella pneumoniae isolate 5427 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID521491 | Antibacterial activity against Pseudomonas aeruginosa KG2505 by Etest method in presence of beta-lactamase inhibitor clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. |
| AID530322 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA-SL2 harboring blaVIM-13 gene by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID649188 | Antibacterial activity against Citrobacter freundii after 16 to 20 hrs by broth microdilution method | 2012 | Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2 | Potent inhibitors of LpxC for the treatment of Gram-negative infections. |
| AID531607 | Ratio of Kcat to Km for Escherichia coli beta-lactamase SHV-11 | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae. |
| AID558044 | Antimicrobial activity against blaKPC-positive Klebsiella pneumoniae S7 by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Genetic organization of transposase regions surrounding blaKPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. |
| AID560488 | Antibacterial activity against 5 x 10'5 CFU/ml CMY-30 producing Escherichia coli MC4100 harboring plasmid AC-cmy30 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8 | Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase. |
| AID394496 | Antimicrobial activity against Escherichia coli MC4100 harboring pB-acc1 plasmid by agar dilution technique | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10 | Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli. |
| AID498132 | Antibacterial activity against Pseudomonas aeruginosa PA5020 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID529665 | Activity of Pseudomonas aeruginosa COL-1 beta-lactamase VIM-2 relative to cephaloridine | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany. |
| AID555642 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by using 30 ug/disk by agar diffusion method | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID529460 | Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase TEM-1, SHV-12 and Oxa-9 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID285578 | Antimicrobial activity against Pseudomonas aeruginosa P21.23 tracheal isolates from mechanically ventilated tuberculosis patient | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. |
| AID555640 | Antimicrobial activity against ampDh2 and ampDh3 gene-deficient Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method in presence of 0.5 mM nagZ inhibitor EtBuPUG | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Inactivation of the glycoside hydrolase NagZ attenuates antipseudomonal beta-lactam resistance in Pseudomonas aeruginosa. |
| AID70629 | In vitro antibacterial activity against CMC-84-50 strain of Escherichia coli | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | N-azamonobactams. 2. Synthesis of some N-iminoacetic acid and N-glycyl analogues. |
| AID587982 | Antibacterial activity against Escherichia coli AS226 carrying pBSDD240A mutant after 18 hrs by broth microdilution method | 2011 | Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1 | Roles of residues Cys69, Asn104, Phe160, Gly232, Ser237, and Asp240 in extended-spectrum beta-lactamase Toho-1. |
| AID405636 | Inhibition of bocillin FL binding to Escherichia coli MC4100 penicillin-binding protein 6 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. |
| AID562334 | Antimicrobial activity against Escherichia coli DH5alpha harboring plasmid pBC-SK after 18 hrs by broth microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. |
| AID530330 | Antimicrobial activity against Escherichia coli XL1-Blue by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain. |
| AID528602 | Antimicrobial activity against blaKPC-2, blaKLUC-2 and blaTEM-1 producing Enterobacter cloacae 7506 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. |
| AID1139453 | Displacement of fluorescent Bocillin FL from Pseudomonas aeruginosa PBP2 | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Siderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteria. |
| AID341969 | Antimicrobial activity against Escherichia coli AJE0508 isolate carrying ISCR1 element related blaCTX-M-14 gene by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Novel complex class 1 integron bearing an ISCR1 element in an Escherichia coli isolate carrying the blaCTX-M-14 gene. |
| AID534298 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA500 expressing VIM-1 beta-lactamase | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID532588 | Antibacterial activity against metallo-beta-lactamase positive Pseudomonas aeruginosa assessed as percent susceptible isolates by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID560087 | Bactericidal activity against Pseudomonas aeruginosa isolate 1019 at 1/4 times MIC after 24 hrs by time kill analysis | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. |
| AID495515 | Antibacterial activity against Acinetobacter baumannii CIP70-10 by antimicrobial susceptibility assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. |
| AID279815 | Antimicrobial activity against Escherichia coli DH5-alpha with pGEM-T EASY expressing TEM1 gene by agar dilution method | 2007 | Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2 | Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. |
| AID531747 | Antibacterial activity against Pseudomonas aeruginosa EryR by twofold serial dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. |
| AID519738 | Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-1 by agar dilution method in presence of 2 ug/ml clavulanic acid | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition. |
| AID534304 | Antimicrobial activity against metallo-beta-lactamase-negative Pseudomonas aeruginosa isolate PA494 | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital. |
| AID554411 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2998 expressing inactivated mexB gene by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID583190 | Antimicrobial activity against ampD::lox gene-deficient Pseudomonas aeruginosa PAO1 by broth microdilution method in presence of 5 mM NagZ inhibitor PUGNAc | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa. |
| AID520384 | Antimicrobial activity Escherichia coli DH5alpha expressing beta lactamase VIM-2 by agar macrodilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Biochemical characterization of metallo-beta-lactamase VIM-11 from a Pseudomonas aeruginosa clinical strain. |
| AID1476619 | Antibacterial activity against Acinetobacter baumannii ATCC BAA 1793 after 18 hrs by broth microdilution method | 2017 | Journal of medicinal chemistry, 11-09, Volume: 60, Issue:21 | Methodology for Monobactam Diversification: Syntheses and Studies of 4-Thiomethyl Substituted β-Lactams with Activity against Gram-Negative Bacteria, Including Carbapenemase Producing Acinetobacter baumannii. |
| AID519627 | Antimicrobial activity against Brachyspira pilosicoli 80.10 without producing beta-lactamase OXA-63 by disc diffusion method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442. |
| AID1373321 | Antimicrobial activity against Escherichia coli expressing beta-lactamase Oxa-146 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID533761 | Antibacterial activity against OXA-28 producing Pseudomonas aeruginosa isolate P174 exhibiting PFGE E pattern by 2-fold agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8 | Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. |
| AID565200 | Antimicrobial activity against Klebsiella pneumoniae isolate A-1760 expressing VIM-1 and KPC-2 genes by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9 | Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. |
| AID544531 | Antimicrobial activity against Escherichia coli DH5[alpha] isolate GC 7668 expressing bla SHV-48 gene by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3 | Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155 |
| AID540211 | Fraction unbound in human after iv administration | 2008 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7 | Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. |
| AID572120 | Antimicrobial activity against Acinetobacter baumannii lambda clonal group isolate 27 expressing ampC, ompA, adeB, adeM, aadB, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID562738 | Antimicrobial activity against Escherichia coli K-12 by agar dilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. |
| AID1373291 | Antimicrobial activity against Escherichia coli expressing beta-lactamase PER-2 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID373772 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh36 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID565523 | Antibacterial activity against mexB, mexY and mexD expressing Pseudomonas aeruginosa isolate Paebeta-12 harboring A residue at 105 position in PDC- 2 and polymorphic OprD gene by Etest method | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. |
| AID572130 | Antimicrobial activity against Acinetobacter baumannii nu clonal group isolate 32 expressing ampC, ompA, adeB, adeM, aadB, aadA2 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID571036 | Antimicrobial activity against Pseudomonas aeruginosa isolate PA367 obtained from patient with cystic fibrosis by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. |
| AID518493 | Ratio of Kcat to Km for Escherichia coli Penicillin-binding protein 2 | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID522187 | Antimicrobial activity against Klebsiella pneumoniae isolate KpL expressing beta-lactamase OXA-48 by Etest method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Spread of OXA-48-encoding plasmid in Turkey and beyond. |
| AID1357441 | Antibacterial activity against KPC-2 producing Klebsiella pneumoniae isolate 212423 after 18 hrs by CLSI broth microdilution method | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria. |
| AID524265 | Antibacterial activity against Escherichia coli NKE159 harboring deletion mutation in acrB, cpxAR protein and plasmid expressing nlpE gene | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID761225 | Inhibition of PBP1a in Pseudomonas aeruginosa ATCC 27853 after 20 mins by fluorescence assay | 2013 | Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13 | Pyridone-conjugated monobactam antibiotics with gram-negative activity. |
| AID495908 | Antimicrobial activity in Escherichia coli TOP10 harbouring recombinant plasmid VIM-1-N215K by Etest | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae. |
| AID373773 | Antibacterial activity against imipenem-resistant Acinetobacter baumannii abh37 by broth dilution method | 2007 | Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11 | An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii. |
| AID511585 | Antimicrobial activity against beta-lactam resistant Pseudomonas aeruginosa PAOD1 harboring oprD spontaneous mutant and deficient in ampD gene selected in vitro after antipseudomonal treatment of intensive care unit patient by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. |
| AID573400 | Antimicrobial activity against mucA::lox, mutS::lox-deficient Pseudomonas aeruginosa PAOMSAB biofilm harboring nfxB T86C mutant gene selected at 4 ug/ml of azithromycin after 2 passages by Etest method | 2009 | Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4 | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. |
| AID405823 | Antimicrobial activity against Acinetobacter baumannii 9043 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-3 | 2007 | Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7 | Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. |
| AID517977 | Antimicrobial activity against Acinetobacter baumannii HPA74510 harboring beta-lactamase IMP-4 by broth dilution method | 2010 | Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6 | In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. |
| AID1198147 | Antimicrobial activity against Pseudomonas aeruginosa by broth microdilution method | 2015 | Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5 | Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model. |
| AID524384 | Antibacterial activity against Escherichia coli NKE126 harboring deletion mutation in acrB and acrD protein | 2010 | Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5 | Effect of NlpE overproduction on multidrug resistance in Escherichia coli. |
| AID1139449 | Antibacterial activity against Klebsiella pneumoniae KP-3700 by CLSI broth microdilution method | 2014 | Journal of medicinal chemistry, May-08, Volume: 57, Issue:9 | Siderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteria. |
| AID548950 | Antimicrobial activity against Acinetobacter baumannii ATCC 19606 after18 to 20 hrs by broth dilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antimicrobial evaluation of some fused heterocyclic [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives. |
| AID585181 | Ratio of Kcat to Km for Beta-lactamase GES-1 E104, G170 mutant | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases. |
| AID424857 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 harboring pV2GY3 with blaVIM-2 and aac(6)'-32 by E-test | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12 | Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. |
| AID519806 | Inhibition of Bocillin FL binding to PBP2 in Pseudomonas aeruginosa PAO1 membranes | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID498098 | Antibacterial activity against Pseudomonas aeruginosa PA1042 assessed as time required for reduction of bacterial load to 3 log CFU/ml at 0.2 mg/ml up to 48 hrs by time-kill assay | 2010 | Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. |
| AID519810 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 by CLSI protocol based broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4 | Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1373280 | Antimicrobial activity against wild type Escherichia coli by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID285441 | Antimicrobial activity against Escherichia coli DH10B after 18 hrs by disk diffusion method | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4 | Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii. |
| AID520780 | Antibacterial activity against Escherichia coli EC600 transconjugant harboring beta-lactamase KPC-2 by agar dilution method | 2008 | Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6 | Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. |
| AID562339 | Ratio of Kcat to Km for Chryseobacterium indologenes 597 metallo-beta-lactamase IND-5 expressed in Escherichia coli DH5alpha by Michaelis-Menten equation | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. |
| AID446144 | Inhibition of protein synthesis in Pseudomonas aeruginosa ATCC 27853 assessed as decrease in incorporation of L-[4,5-3H]leucine at 5 times MIC by liquid scintillation counter relative to control | 2010 | Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1 | Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. |
| AID525547 | Antimicrobial activity against ampicillin resistant nontypeable Haemophilus influenzae isolate BB1050 harboring with plasmid pB1000 bearing beta-lactamase ROB-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4 | Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination. |
| AID548949 | Antimicrobial activity against Citrobacter freundii ATCC 8090 after18 to 20 hrs by broth dilution method | 2010 | European journal of medicinal chemistry, Dec, Volume: 45, Issue:12 | Synthesis and antimicrobial evaluation of some fused heterocyclic [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives. |
| AID573521 | Antibacterial activity against Serratia marcescens isolate Sm211 harboring IncA/C plasmid and blaIMP-4-qacG2-aacA4-catB3 array by Etest method | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | bla(IMP-4) in different genetic contexts in Enterobacteriaceae isolates from Australia. |
| AID1373339 | Volume of distribution in rat at 10 mg/kg, iv | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID529459 | Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase Oxa-48 by Etest | 2008 | Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8 | Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. |
| AID554397 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2729 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID572126 | Antimicrobial activity against ISAba1 linked with the blaOXA-51-type beta-lactamase harboring Acinetobacter baumannii lambda clonal group isolate 30 expressing ampC, ompA, adeB, adeM, aadB, aadA1 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9 | Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. |
| AID554401 | Antimicrobial activity against Pseudomonas aeruginosa isolate 2998 obtained from cystic fibrosis patient by disk diffusion method | 2009 | Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5 | Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. |
| AID532410 | Antibacterial activity against VIM-2 producing Pseudomonas aeruginosa clone B3 isolate CR-04X-14 by Etest method | 2008 | Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11 | First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. |
| AID1373287 | Antimicrobial activity against Escherichia coli expressing beta-lactamase KPC-4 by CLSI broth microdilution method | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4 | Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228. |
| AID559587 | Antimicrobial activity against Pseudomonas aeruginosa PAO1 assessed as microbial doubling time | 2009 | Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6 | Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1752475 | Antimicrobial activity against Enterobacterales producing KPC assessed as reduction in microbial growth measured after 16 to 20 hrs in presence of avibactam by broth microdilution method | 2021 | Bioorganic & medicinal chemistry, 09-15, Volume: 46 | A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships. |
| AID1752482 | Antibacterial activity against Enterobacter cloacae SR36276 producing class C beta lactamase, AmpC assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of avibactam by broth microdilution method | 2021 | Bioorganic & medicinal chemistry, 09-15, Volume: 46 | A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships. |
| AID1752477 | Antimicrobial activity against Enterobacterales producing VIM assessed as reduction in microbial growth measured after 16 to 20 hrs in presence of avibactam by broth microdilution method | 2021 | Bioorganic & medicinal chemistry, 09-15, Volume: 46 | A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships. |
| AID1752476 | Antimicrobial activity against Enterobacterales producing NDM assessed as reduction in microbial growth measured after 16 to 20 hrs in presence of avibactam by broth microdilution method | 2021 | Bioorganic & medicinal chemistry, 09-15, Volume: 46 | A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships. |
| AID1752478 | Antimicrobial activity against Enterobacterales producing OXA-48 assessed as reduction in microbial growth measured after 16 to 20 hrs in presence of avibactam by broth microdilution method | 2021 | Bioorganic & medicinal chemistry, 09-15, Volume: 46 | A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships. |
| AID1752485 | Antibacterial activity against Enterobacter cloacae 1,261,347 producing class A beta lactamase, PER-2 assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of avibactam by broth microdilution method | 2021 | Bioorganic & medicinal chemistry, 09-15, Volume: 46 | A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships. |
| AID1752484 | Antibacterial activity against Klebsiella pneumoniae JMI:211 producing class A beta lactamase, KPC-2 assessed as reduction in microbial, growth incubated for 16 to 20 hrs in presence of avibactam by broth microdilution method | 2021 | Bioorganic & medicinal chemistry, 09-15, Volume: 46 | A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships. |
| AID1752480 | Antibacterial activity against Escherichia coli SR34100 producing class A beta lactamase, CTX-M-15 assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of avibactam by broth microdilution method | 2021 | Bioorganic & medicinal chemistry, 09-15, Volume: 46 | A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships. |
| AID1752481 | Antibacterial activity against Enterobacter cloacae IR32 producing class B beta-lactamase, NDM-1 assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of avibactam by broth microdilution method | 2021 | Bioorganic & medicinal chemistry, 09-15, Volume: 46 | A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships. |
| AID1752479 | Antibacterial activity against Escherichia coli NIHJ JC-2 strain assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of avibactam by broth microdilution method | 2021 | Bioorganic & medicinal chemistry, 09-15, Volume: 46 | A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships. |
| AID1752483 | Antibacterial activity against Klebsiella pneumoniae PLE producing class D beta lactamase, OXA-48 assessed as reduction in microbial growth incubated for 16 to 20 hrs in presence of avibactam by broth microdilution method | 2021 | Bioorganic & medicinal chemistry, 09-15, Volume: 46 | A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 587 (36.17) | 18.7374 |
| 1990's | 321 (19.78) | 18.2507 |
| 2000's | 250 (15.40) | 29.6817 |
| 2010's | 306 (18.85) | 24.3611 |
| 2020's | 159 (9.80) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (88.18) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Trials | 234 (14.96%) | 5.53% |
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (1.41%) | 6.00% |
| Reviews | 118 (7.54%) | 6.00% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 4 (1.88%) | 4.05% |
| Case Studies | 99 (6.33%) | 4.05% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Observational | 5 (0.32%) | 0.25% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 206 (96.71%) | 84.16% |
| Other | 1,108 (70.84%) | 84.16% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection (cSSSI) [NCT00423657] | Phase 3 | 680 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Efficacy, Safety and Pharmacokinetics Profile of Nebulized Aztreonam Lysine (AZLI) for Prevention of Gram Negative Pneumonia in Heavily Colonized Mechanically Ventilated Patients [NCT03749226] | Phase 2/Phase 3 | 9 participants (Actual) | Interventional | 2019-03-19 | Terminated(stopped due to due to COVID-19 pandemia) | ||
| A Trial of the Safety, Tolerability and Efficacy of 2 Doses of Cayston (Aztreonam Lysine) Compared to Placebo in Participants With Bronchiectasis [NCT03696290] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-10-19 | Recruiting | ||
| Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240] | Early Phase 1 | 11 participants (Actual) | Interventional | 2014-03-06 | Terminated(stopped due to Not enough patient enrollment and lack of staffing) | ||
| Evaluation of Ceftazidime-avibactam Plus Aztreonam in Patients Infected by MBL-producing Enterobacterales and CRISPR/Cas9-based Strategy for Curing Drug-resistant Genes [NCT05850871] | 427 participants (Anticipated) | Interventional | 2023-01-06 | Recruiting | |||
| Aztreonam for Pharyngeal Gonorrhea: A Demonstration Study [NCT03867734] | Phase 2/Phase 3 | 32 participants (Actual) | Interventional | 2019-04-05 | Completed | ||
| A Randomized, Double-blind, Multicenter Study to Establish the Safety and Efficacy of Ceftobiprole Medocaril Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections [NCT03137173] | Phase 3 | 679 participants (Actual) | Interventional | 2018-02-19 | Completed | ||
| A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections or Acute Uncomplicated Pyel [NCT05887908] | Phase 3 | 600 participants (Anticipated) | Interventional | 2023-05-23 | Recruiting | ||
| Expanded Access for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and Are at Risk for Disease Progression [NCT00989807] | 0 participants | Expanded Access | Approved for marketing | ||||
| A Blinded, Multicenter, Randomized, Placebo-Controlled Trial With Aztreonam for Inhalation (AI) in Cystic Fibrosis Patient With Lung Disease Due to P. Aeruginosa Infection [NCT01055847] | Phase 2 | 105 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftaroline Versus Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections [NCT01400867] | Phase 2/Phase 3 | 163 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Randomized, Multicenter, Phase III, Controlled Clinical Trial, to Demonstrate the no Inferiority of Reduced Antibiotic Treatment vs a Broad Spectrum Betalactam Antipseudomonal Treatment in Patients With Bacteremia by Enterobacteriaceae [NCT02795949] | Phase 3 | 344 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam for Inhalation Solution (AZLI) Versus Tobramycin Inhalation Solution (TIS) in an Intermittent Aerosolized Antibiotic Regimen in Subjects With Cystic Fibrosis Followe [NCT00757237] | Phase 3 | 274 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection [NCT00424190] | Phase 3 | 698 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| A PROSPECTIVE, RANDOMIZED,OPEN-LABEL, COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM- AVIBACTAM (ATM-AVI) AND BEST AVAILABLE THERAPY FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO MULTI-DRUG RESISTANT GRAM- NEGATIVE BACTERI [NCT03580044] | Phase 3 | 15 participants (Actual) | Interventional | 2020-12-25 | Terminated(stopped due to Recruitment of patients with serious infections caused by gram-negative bacteria producing MBL has been challenging. Date study terminated: 16-Dec-2022.) | ||
| Phase I Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-Small Cell Lung Cancer [NCT05777603] | Phase 1 | 20 participants (Anticipated) | Interventional | 2024-01-03 | Recruiting | ||
| Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis. An Randomised, Crossover Pilot Study of AZLI Plus Intravenous Colistin® Versus Standard Dual Intravenous Therapy [NCT02894684] | Phase 4 | 16 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects With Cystic Fibrosis (CF) an [NCT03219164] | Phase 3 | 149 participants (Actual) | Interventional | 2017-11-28 | Terminated(stopped due to Study was terminated early by sponsor due to the challenges and risks introduced by Coronavirus disease 2019 (COVID-19) pandemic.) | ||
| AN OPEN-LABEL, PARALLEL-GROUP, PHARMACOKINETIC STUDY OF MULTIPLE INTRAVENOUS DOSES OF AZTREONAM AND AVIBACTAM IN SUBJECTS WITH SEVERE RENAL IMPAIRMENT AND NORMAL RENAL FUNCTION [NCT04486625] | Phase 1 | 11 participants (Actual) | Interventional | 2020-08-10 | Completed | ||
| Expanded Access Program for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and Are at Risk for Disease Progression [NCT00499720] | 0 participants | Expanded Access | Approved for marketing | ||||
| A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections [NCT01811732] | Phase 3 | 660 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| A Multicenter, Randomized, Double-Blind Comparison of the Safety and Efficacy of Tigecycline With Those of Vancomycin With Aztreonam to Treat Complicated Skin and Skin Structure Infections in Hospitalized Patients. [NCT00228410] | Phase 3 | 503 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Urinary Tract Infection, Acute Uncomplicated Pyelonephritis, [NCT05905055] | Phase 3 | 150 participants (Anticipated) | Interventional | 2023-09-22 | Recruiting | ||
| A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MON [NCT05639647] | Phase 2 | 48 participants (Anticipated) | Interventional | 2023-04-18 | Recruiting | ||
| Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease [NCT02730793] | Phase 2 | 5 participants (Actual) | Interventional | 2017-01-31 | Terminated(stopped due to terminated due to an inability to recruit study subjects) | ||
| Evaluation of Directed Antimicrobial Prophylaxis for Transrectal Ultrasound Guided Prostate Biopsy (TRUSP) [NCT01659866] | Phase 4 | 563 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis [NCT01460836] | 0 participants | Observational | 2010-04-30 | Completed | |||
| A-PACT: The Use of Inhaled Aztreonam to Eliminate or Decrease the Bacterial Burden of Pseudomonas Aeruginosa in Children With a Tracheostomy Tube. [NCT03158116] | Phase 4 | 5 participants (Actual) | Interventional | 2017-07-01 | Terminated(stopped due to IRB application expired.) | ||
| A Phase 2, Multicenter, Randomized, Open-label, Comparative Study to Evaluate the Efficacy and Safety of Intramuscular Ceftaroline Versus Intravenous Linezolid in Adult Subjects With Complicated Skin and Skin Structure Infections [NCT00633152] | Phase 2 | 150 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) vs Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissu [NCT02202135] | Phase 3 | 4 participants (Actual) | Interventional | 2014-06-30 | Terminated(stopped due to "Overall study status is changed to Terminated due to low enrollment") | ||
| Open-Label Phase 2 Trial to Evaluate the Safety and Efficacy of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Pediatric Patients With Cystic Fibrosis (CF) and New Onset Lower Respiratory Tract Cultur [NCT01375049] | Phase 2 | 105 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Phase 3, Multicenter, Randomized, Double-blind, Active Controlled Study to Evaluate the Efficacy + Safety of IV + Oral Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) [NCT01984684] | Phase 3 | 850 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation [NCT01469364] | Phase 4 | 30 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| A PHASE I, SINGLE CENTER, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM ADMINISTERED AS SINGLE AND REPEATED INTRAVENOUS DOSES IN HEALTHY CHINESE PARTICIPANTS [NCT04973826] | Phase 1 | 12 participants (Actual) | Interventional | 2021-08-20 | Completed | ||
| A Phase I, Randomised, Double-blind, 3-Part Study in Healthy Young and Elderly Subjects to Assess the Safety and Tolerability, and Investigate the Pharmacokinetics of Aztreonam and Avibactam Given Alone and in Combination (ATM-AVI) [NCT01689207] | Phase 1 | 222 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft T [NCT01499277] | Phase 3 | 802 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Phase 3 Study of IV to Oral 6-Day Tedizolid Phosphate Compared With 10-day Comparator in Subjects 12 to < 18 Years With cSSTI. [NCT02276482] | Phase 3 | 120 participants (Actual) | Interventional | 2015-03-25 | Completed | ||
| A Single-center, Multi-arm, Open-label, Randomized, 3-period, Crossover, Phase 1 Study to Evaluate the DDI, PK, Safety, and Tolerability of Single Doses of SPR741 Co-administered With Three Different Antibiotics in Healthy Volunteers [NCT03376529] | Phase 1 | 27 participants (Actual) | Interventional | 2017-11-10 | Completed | ||
| Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis (CRO-OSTEOMYELITIS) [NCT02168816] | Phase 2 | 30 participants (Actual) | Interventional | 2014-03-19 | Terminated(stopped due to The study was stopped for feasibility (i.e., low recruitment)) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||